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Resumen 
El objetivo global de la presente memoria experimental ha sido investigar el 
potencial de las nanocápsulas de quitosano como nuevos vehículos para la 
administración de péptidos a través de la mucosa nasal e intestinal. Estas 
nanoestrucutras, constituidas por un núcleo oleoso y una cubierta de quitosano con 
distintas propiedades (peso molecular, tipo de sal y grado de peguilación del 
polímero), se prepararon mediante la técnica de desplazamiento del disolvente. 
Todas las formulaciones presentaron un tamaño de partícula en rango nanométrico, 
una carga superficial positiva y la capacidad para encapsular eficazmente el péptido 
modelo calcitonina. Las nanocápsulas de quitosano mostraron una estabilidad 
adecuada en fluido gástrico. Asimismo, la peguilación del quitosano permitió 
obtener un sistema estable en los fluidos gastrointestinales. Los estudios llevados a 
cabo en cultivo celular Caco-2 revelaron que las distintas nanocápsulas de quitosano 
presentan una baja citotoxicidad, la cual se redujo como consecuencia de la 
peguilación del quitosano. Además, tras evaluar la interacción de las nanocápsulas 
de quitosano con un co-cultivo constituido por células Caco-2 y células secretoras de 
mucus, se observó una asociación muy importante del sistema a las células 
secretoras de mucus, resultado que constata las propiedades mucoadhesivas de 
dichas nanoestructuras. Finalmente, la evaluación in vivo de las nanocápsulas de 
quitosano permitió observar un importante efecto farmacológico tanto tras su 
administración por vía nasal como por vía oral. Además se observó que modulando 
el grado de peguilación del quitosano es posible obtener un sistema estable en los 
fluidos gastrointestinales, de toxicidad muy reducida y con capacidad para promover 
la absorción oral de péptidos. En definitiva, el trabajo en su conjunto permite 
pronosticar el interés de las nanocápsulas de quitosano para mejorar la absorción 
nasal e intestinal de péptidos. 
 
 
Abstract 
The main goal of the present work has been to investigate the potential of 
chitosan nanocapsules as new carriers for nasal and oral administration of peptides. 
These nanostructures, composed of an oily core and a chitosan coating with different 
properties (molecular weight, type of salt and pegylation degree of chitosan), were 
prepared by the solvent displacement technique. All the formulations presented a 
particle size in nanometer range, a positive zeta potential and the ability to 
encapsulate salmon calcitonin as a model peptide. The nanocapsules were stable in 
the gastric fluid. In addition, the pegylation of chitosan improved the stability of the 
nanocapsules in the gastrointestinal fluids. The studies performed in Caco-2 cells 
revealed that chitosan nanocapsules have a low citotoxicity, which could be further 
reduced as a consequence of the chitosan pegylation. Moreover, the evaluation of 
the interaction of chitosan nanocapsules with the co-culture Caco-2:HT29-M6 
(enterocytes and mucus-secreting cells), evidenced an important association of the 
system with mucus-secreting cells, thus corroborating the mucoadhesive properties 
of these nanocapsules. Finally, the studies performed in vivo indicated that chitosan 
nanocapsules are able to elicit a pharmacological effect after nasal or oral 
administration to rats. Additionally, it was observed that modulating the pegylation 
degree of chitosan it was possible to achieve a stable carrier with a very low toxicity 
and the ability to promote the oral absorption of peptides. Briefly, altogether these 
results allowed us to suggest the interest of chitosan nanocapsules for improving the 
nasal and intestinal absorption of peptides. 
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Introducción 
 
Los avances logrados en el campo de la biotecnología y de la ingeniería 
genética han permitido el creciente desarrollo de macromoléculas activas de 
naturaleza peptídica y proteica. A pesar del interesante potencial terapéutico de estas 
macromoléculas, su aplicación en la práctica clínica se ve notablemente restringida 
debido a la necesidad de ser administradas por vía parenteral. Esta necesidad deriva 
de la alta susceptibilidad de estas macromoléculas frente a la degradación y a su 
dificultad para atravesar barreras biológicas. Como consecuencia, en la actualidad, 
uno de los principales retos en el campo de los nuevos sistemas de liberación de 
fármacos, lo constituye el diseño de estrategias dirigidas a la administración de estas 
macromoléculas por vías alternativas a la parenteral, como son la vía nasal y la vía 
oral. 
 
Interés de la vía nasal para la administración de péptidos 
Tradicionalmente, la vía nasal se ha utilizado para el tratamiento local de 
distintas enfermedades como son la congestión nasal, infecciones o alergias nasales. 
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Sin embargo, el progreso en el conocimiento de las características fisiológicas 
cavidad nasal, ha hecho posible la explotación de esta vía para la administración de 
fármacos con fines sistémicos. Así, fármacos polares de pequeño peso molecular, 
como son los antimigrañosos, y distintos péptidos, entre ellos, la calcitonina1, la 
oxitocina1, la desmopresina2, la buserelina3 y la nafarelina4, se administra 
actualmente por vía nasal. Además de estos fármacos, en estos momentos varias 
formulaciones destinadas a la administración nasal de insulina, hormona de 
crecimiento, paratohormona y leuprolide, entre otros, que se encuentran en distintas 
fases de investigación clínica5. No obstante, a pesar de los grandes avances 
realizados en la administración de estos fármacos por vía nasal, en ocasiones la 
biodisponibilidad es baja y muy variable debido principalmente a tres factores: (a) la 
escasa superficie para la absorción que representa el epitelio respiratorio, (b) el 
aclaramiento mucociliar que lleva consigo una regeneración del mucus que recubre 
el epitelio nasal cada 15-20 minutos6, 7 y (c) la degradación proteolítica ocasionada 
por los enzimas presentes en la cavidad nasal8. Estas limitaciones han estimulado la 
búsqueda de nuevos vehículos con el fin de mejorar la biodisponibilidad nasal de 
dichas macromoléculas. Entre las estrategias orientadas a tal fin, destacan 
fundamentalmente: la administración junto con el fármaco de promotores de la 
absorción9, 10, 11, así como, la asociación del fármaco a un transportador. 
                                                 
1 www.novartis.com
2 www.ferring.com
3 www.aventis.com
4 http://home.intekom.com/pharm/searle/synarel.html
5 Davis S.S., Illum L. Absorption enhancers for nasal drug delivery. Clinical 
Pharmacokinetics (2003) 42: 1107-1128. 
6 Gizurarson S. Animal models for intranasal drug delivery studies. Acta. Pharm. Nord. 
(1990) 2: 105-122. 
7 Marttin E., Schipper N.G.M., Verhoef J.C., Merkus F.W.H.M. Nasal mucociliary clearance 
as a factor in nasal drug delivery. Adv. Drug Deliv. Rev. (1998) 29: 13-38. 
8 Lee V.H. Enzymatic barriers to peptide and protein absorption. Crit. Rev. Ther. Drug Carrier 
Systems (1988) 5: 69-97. 
9 Merkus F.W.H.M., Verhoef J.C., Marttin E., Romeijn S.G., van der Kuy P.H.M., Hermens 
W.A.J.J., Schipper N.G.M. Cyclodextrins in nasal drug delivery. Adv. Drug Deliv. Rev. 
(1999) 36: 41-57. 
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Lamentablemente, utilización de promotores ha resultado en la mayoría de los casos 
inviable debido al hecho de que inducen daños histológicos o inhiben drásticamente 
el movimiento de los cilios12. Sin embargo, el diseño de transportadores coloidales 
se revela en la actualidad como una opción altamente prometedora. Los logros más 
destacados conseguidos con estos nanosistemas se describen a continuación. 
 
Interés de los sistemas coloidales para la administración nasal de péptidos 
El empleo de sistemas coloidales para la administración de péptidos por vía 
nasal resulta una alternativa muy atractiva debido a la capacidad de estos vehículos 
para interaccionar íntimamente con la mucosa y, de esta manera, facilitar el 
transporte del fármaco asociado a través del epitelio nasal. Asimismo, estos sistemas 
ofrecen la posibilidad de proteger al fármaco frente a la degradación en los fluidos 
biológicos. 
Entre los distintos sistemas coloidales empleados para mejorar la 
administración nasal de péptidos se encuentran los liposomas13, las emulsiones14, las 
micelas15 y las nanopartículas16, 17. 
                                                                                                                   
10 Ugwoke M.I., Verbeke N., Kinget R. The biopharmaceutical aspects of nasal mucoadhesive 
drug delivery. J. Pharm. Pharmacol. (2001) 53: 3-22. 
11 Davis S. S., Illum L. Absorption enhancers for nasal drug delivery. Clin. Pharmacokinet. 
(2003) 42: 1107-1128. 
12 Quadir M., Zia H., Needham T.E. Toxicological implications of nasal formulations. Drug 
Delivery (1999) 6: 227-242. 
13 Law S.L., Shih C.L. Characterization of calcitonin-containing liposome formulations for 
intranasal delivery. J. Microencapsulation. (2001) 18: 201-211. 
14 Mitra R., Pezron I., Chuw A., Mitra A.K. Lipid emulsions as vehicles for enhanced nasal 
delivery of insulin. Int. J. Pharm. (2000) 205: 127-134. 
15 Tengamnuay P., Mitra A.K. Bile salt-fatty acid mixed micelles as nasal absorption 
promoters of peptides. II. In vivo nasal absorption of insulin in rats and effects of mixed 
micelles on the morphological integrity of the nasal mucosa. Pharm. Res. (1990) 7: 370-375. 
16 Fernández-Urrusuno R., Calvo P., Remuñán-López C., Vila-Jato J.L., Alonso M.J. 
Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharm. Res. (1999) 
16: 1576-1581. 
17 Tobío M., Gref R,. Sánchez A., Langer R., Alonso M.J. Stealth PLA-PEG nanoparticles as 
protein carriers for nasal administration. Pharm. Res. (1998) 15: 270-275. 
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Además del tamaño coloidal, obviamente la composición del sistema juega 
un papel muy importante. Así pues, en los vehículos de naturaleza lipídica, como 
son las emulsiones o/w, se ha observado que el aceite juega un papel crítico en la 
mejora de la absorción de péptidos, como la insulina, por vía nasal18. Por otro lado, 
en los sistemas políméricos, el tipo de polímero y su interacción con las superficies 
mucosas es también decisivo. Así por ejemplo, el quitosano, debido a sus 
características mucoadhesivas, entre otras, ha resultado ser una alternativa muy 
interesante para la administración nasal de fármacos. Concretamente, en nuestro 
laboratorio se ha observado que, tras la administración por vía nasal de quitosano en 
forma de nanopartículas, se consigue aumentar la absorción de insulina en mayor 
extensión que cuando el polímero se encuentra en solución19, 16 tal y como se refleja 
en la figura 1. 
 
Fig. 1: Niveles de glucosa tras la administración nasal a conejos de: tampón acetato 
(x), solución de insulina en tampón acetato (∆), solución de quitosano conteniendo 
insulina en tampón acetato (▲), insulina encapsulada en nanopartículas de quitosano 
(●). Media±SD; n=6. *Diferencias estadísticamente significativas con respecto a la 
solución de insulina (p<0.05). 
                                                 
18 Mitra R., Pezron I., Chuw A., Mitra A.K. Lipid emulsions as vehicles for enhanced nasal 
delivery of insulin. Int. J. Pharm. (2000) 205: 127-134. 
19 Fernández-Urrusuno y col; 2000. ibid. pag 5. 
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Interés de la vía oral para la administración de péptidos 
Aún conociendo las posibilidades y el amplio mercado que ofrece la 
administración nasal de fármacos de acción sistémica, sin duda la vía de 
administración que ofrece una mayor comodidad para el paciente y que, por tanto, 
lleva asociado un mejor cumplimiento del régimen posológico es la vía oral. A pesar 
de las grandes ventajas que ofrece esta vía, la administración oral de péptidos y 
proteínas todavía no es factible debido a las condiciones fisiológicas presentes a lo 
largo del tracto gastrointestinal20, 21. Ciertamente, las condiciones drásticas del 
tracto gastrointestinal (pH variable, contenido enzimático) y la baja permeabilidad 
del epitelio ocasionan una rápida degradación y una baja absorción de dichas 
macromoléculas tras ser administradas por esta vía. Como consecuencia, la 
biodisponibilidad oral de fármacos peptídicos es prácticamente despreciable.  
En la última década, el esfuerzo realizado en el desarrollo de nuevas 
tecnologías que permitan la administración de péptidos y proteínas por vía oral ha 
dado lugar a resultados muy prometedores. De hecho, en estos momentos existen 
formulaciones comercializadas que permiten la administración oral de péptidos 
como la ciclosporina y la desmopresina. Asimismo, en este momento se encuentran 
en ensayos clínicos diversas formulaciones destinadas a la administración de otros 
péptidos. Estas formulaciones se basan en la coadministración de moléculas 
transportadoras22, en la conjugación del péptido con PEG a través de un grupo 
alquil23 o en la combinación del fármaco peptídico con inhibidores enzimáticos, 
promotores de la absorción y un recubrimiento entérico24. Por otro lado, los 
                                                 
20 Lee V.H.L., Kashi S.D. Grass G.M., Rubas W. Oral route of peptide and protein drug 
delivery. En: Peptide and protein drug delivery. Lee V.H.L. (Ed.) Marcel Dekker, Inc. New 
York, (1991) 16: 691-738. 
21 TenHoor C.N., Dressman J.B. Oral absorption of peptides and proteins. S.T.P. Pharma 
Sciences (1992) 2:(4) 301-312. 
22 Singh B.N., Majuru S. Oral delivery of therapeutic macromolecules: a perspective using the 
eligen TM technology, Drug Del. Technol. (2003) 3: 58-62. 
23 Clement S., Dandona P., Still J.G., Kosutic G. Oral modified insulin (HIM2) in patients 
with type 1 diabetes mellitus: results from a phase I/II clinical trial. Metabolism (2004) 53: 
54-58. 
24 Mehta N.M. Oral delivery and recombinant production of peptide hormones. Part I: Making 
oral delivery possible. BioPharm Int. (2004) 17: 38-43. 
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extraordinarios avances en el conocimiento del comportamiento biológico de los 
nanosistemas permiten vislumbrar una nueva era en cuanto a su aplicación para la 
administración oral de macromoléculas. Los resultados obtenidos para péptidos 
asociados a nanosistemas son de interés intrínseco al desarrollo del trabajo 
experimental que se presenta, por lo que se describen a continuación en detalle. 
 
Nanosistemas destinados a la administración oral de péptidos 
El empleo de sistemas coloidales para la administración oral de 
macromoléculas ha adquirido un gran interés en los últimos años como consecuencia 
de su capacidad para interaccionar íntimamente con superficies biológicas. Estos 
sistemas han sido diseñados con el fin de proteger a la molécula encapsulada del 
ataque enzimático y de promover la absorción del fármaco a través del epitelio. En 
este sentido, juega un papel muy importante, no sólo el tamaño del sistema, sino 
también la composición del mismo. Los distintos nanosistemas y polímeros 
empleados para mejorar la absorción de los péptidos administrados por vía oral 
aparecen reflejados en la tabla 1. En dicha tabla se han omitido los trabajos 
realizados utilizando el quitosano para mejorar la absorción oral de péptidos ya que 
dicha revisión aparece reflejada en el artículo 1 de la presente tesis doctoral, titulado 
“The potential of chitosan of oral drug delivery”. 
Los estudios encaminados a aumentar la biodisponibilidad de la 
ciclosporina por vía oral o disminuir sus efectos adversos se centran en la 
elaboración de nanopartículas o nanocápsulas. Además del potencial de las 
nanopartículas de quitosano para mejorar la absorción oral de la ciclosporina25 
(discutido en el artículo 1) es destacable el interés que para dicho péptido ofrecen las 
nanocápsulas de poli-ε-caprolactona (PECL)26. Sin embargo, los resultados 
                                                 
25 El-Shabouri M.H. Positively charged nanoparticles for improving the oral bioavailability of 
cyclosporin-A. Int. J. Pharm. (2002) 249: 101-108. 
26 Varela M.C., Guzman M., Molpeceres J., Aberturas M.R., Rodriguez-Puyol D., Rodriguez-
Puyol M. Cyclosporine-loaded polycaprolactone nanoparticles: immunosuppression and 
nephrotoxicity in rats. Eur. J. Pharm. Sci. (2001) 12: 471-478. 
Introducción 9 
obtenidos hasta el momento para las nanopartículas lipídicas27, 28 no permiten 
concluir su eficacia como vehículos para la administración oral de ciclosporina. Por 
otro lado, tras la evaluación del potencial de las nanopartículas constituidos por 
polímeros pH-sensibles, se observó que la mejora de la biodisponibilidad oral de la 
ciclosporina era dependiente del tipo de polímero utilizado. Así pues, mientras las 
nanopartículas de Eudragit® S 10029 permiten incrementar la absorción oral del 
péptido, las constituídas de Eudragit® RS 100 y RL 100 y ácidos grasos30, así como 
las de ftalato de hidroxipropil metilcelulosa (HPMCP)31, no dieron lugar a una 
mejora de la biodisponibilidad oral de la ciclosporina. Estas diferencias en el 
comportamiento de los distintos nanosistemas podrían estar en relación con sus 
características de liberación y en su capacidad de interacción con la mucosa 
intestinal. 
En el caso concreto de la insulina, los trabajos más significativos realizados 
hasta el momento se basan en el desarrollo de nanocápsulas de cianoacrilatos, 
nanopartículas de polianhídridos e hidrogeles formados a partir de derivados 
metacrílicos. Así por ejemplo, tras la administración oral de insulina encapsulada en 
nanocápsulas de poli(isobutilcianoacrilato) (PIBCA), se observó un descenso 
marcado del nivel de glucosa en ratas diabéticas a partir del segundo día tras la 
administración y dicho efecto se prolongó hasta 20 días32. Dicho efecto biológico 
prolongado fue atribuido a la capacidad de las nanocápsulas de ser internalizadas en 
                                                 
27 Zhang Q., Yie G., Li Y., Yang Q., Nagai T. Studies on the cyclosporin A loaded stearic 
acid nanoparticles. Int. J. Pharm. (2000) 200: 153-159. 
28 Bekerman T., Golenser J., Domb A. Cyclosporin nanoparticulate lipospheres for oral 
administration. J. Pharm. Sci. (2004) 93: 1264-1270. 
29 Dai J., Nagai T., Wang X., Zhang T., Meng M., Zhang Q. pH-sensitive nanoparticles for 
improving the oral bioavailability of cyclosporine A. Int. J. Pharm. (2004) 280: 229-240. 
30 Ubrich N., Schmidt C., Bodmeier R., Hoffman M., Maincent P. Oral evaluation in rabbits 
of cyclosporin-loaded Eudragit RS or RL nanoparticles. Int. J. Pharm. (2005) 288: 169-175. 
31 Wang X., Dai J., Chen Z., Zhang T., Xia G., Nagai T., Zhang Q. Bioavailability and 
pharmacokinetics of cyclosporine A-loaded pH-sensitive nanoparticles for oral 
administration. J. Control. Release (2004) 97: 421-429. 
32 Damge C., Michel C., Aprahamian M., Couvreur P. New approach for oral administration 
of insulin with poly(alkyl cyanoacrylate) nanocapsules as drug carrier. Diabetes (1988) 37: 
246-251. 
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el epitelio intestinal y de liberar la insulina de forma sostenida33. Por otro lado, las 
nanocápsulas han mostrado poseer un efecto protector del péptido encapsulado 
frente a la degradación enzimática33. Estudios posteriores realizados en perros han 
permitido constatar el potencial de estas formulaciones, si bien los resultados del 
efecto hipoglucémico tanto en intensidad como en extensión han sido menos 
llamativos que los obtenidos en ratas34. 
Dentro de la gama de polímeros acrílicos utilizados para mejorar la 
absorción oral de insulina cabe destacar los interesantes resultados obtenidos para 
las nanopartículas elaboradas a partir de poli(ácido metacrílico-etilén glicol) 
P(MAA-g-EG)35, 36, 37. La eficacia de estos vehículos se debe a su capacidad para 
responder a cambios de pH, lo que permite proteger al péptido atrapado en la matriz 
del entorno gástrico y liberarlo en el fluido intestinal35. Además, se ha demostrado 
que estos vehículos poseen propiedades mucoadhesivas38, así como también la 
facultad de inducir una reducción de la resistencia transepitelial en cultivos Caco-2, 
dando lugar a un aumento en el transporte de la insulina a través de las células39. 
                                                 
33 Damge C., Michel C., Aprahamian M., Couvreur P., Devissaguet J.P. Nanocapsules as 
carriers for oral peptide delivery. J. Control. Release (1990) 13: 233-239. 
34 Damgé C., Hillaire-Buys D., Puech R., Hoeltzel A., Michel C., Ribes G.Effects of orally 
administered insulin nanocapsules in normal and diabetic dogs. Diabetes, Nutrition & 
Metabolism (1995) 8: 3-9. 
35 Lowman A.M., Morishita M., Kajita M., Nagai T., Peppas N.A. Oral delivery of insulin 
using pH-responsive complexation gels. J. Pharm. Sci. (1999) 88: 933-937. 
36 Nakamura K., Murray R.J., Joseph, J.I., Peppas N.A. Morishita, Mariko; Lowman, Anthony 
M. Oral insulin delivery using P(MAA-g-EG) hydrogels: effects of network morphology on 
insulin delivery characteristics. J. Control. Release (2004) 95: 589-599. 
37 Morishita M., Goto T., Peppas N.A., Joseph J.I., Torjman M.C., Munsick C., Nakamura K., 
Yamagata T., Takayama K., Lowman A.M. Mucosal insulin delivery systems based on 
complexation polymer hydrogels: effect of particle size on insulin enteral absorption. J. 
Control. Release (2004) 97: 115-124. 
38 Ascentiis A., deGrazia J.L., Bowman C.N., Colombo P., Peppas N.A. Mucoadhesion of 
poly(2-hydroxyethyl methacrylate) is improved when linear poly(ethylene oxide) chains are 
added to the polymer network. J. Control. Release (1995) 33: 197-201. 
39 Ichikawa H., Peppas N.A. Novel complexation hydrogels for oral peptide delivery: In vitro 
evaluation of their cytocompatibility and insulin-transport enhancing effects using Caco-2 cell 
monolayers. J. Biomed. Mat. Res. Part A (2003) 67: 609-617. 
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Las nanopartículas de poli(ácido láctico-glicólico) (PLGA) en asociación 
con polianhídridos, ácido fumárico y sebácico, también han resultado exitosas para 
mejorar la absorción oral de la insulina40 41. Los autores atribuyen este resultado 
positivo a las propiedades mucoadhesivas de los polianhídridos y a la capacidad de 
las nanopartículas de ser internalizadas. No obstante también señalan la necesidad de 
incorporar PLGA a las nanoestructuras ya que las formulaciones preparadas sólo con 
polianhídridos o con PLGA no resultaron exitosas. 
En cuanto a las formulaciones coloidales destinadas a mejorar la absorción 
intestinal de calcitonina, cabe destacar las nanopartículas de poliestireno recubiertas 
con derivados polivinílicos, las nanopartículas de PLGA conteniendo complejos de 
ácidos grasos y los liposomas de doble capa. 
La asociación de calcitonina a nanopartículas constituidas a base de núcleos 
de poliestireno recubiertos por cadenas de derivados de poli-ácido metacrílico, poli-
acrilamida, poli-vinilamida y poli-vinilacetamida permitió lograr un efecto 
hipocalcémico dependiente de la estructura química del material de recubrimiento42, 
43, 44. Así pues, los mejores resultados se obtuvieron tras la administración de estas 
nanopartículas recubiertas por cadenas hidrofílicas catiónicas (cadenas de poli-N-
isopropilacrilamida copolimerizadas con poli-vinilacetamida). El descenso del nivel 
de calcio observado con estas nanopartículas se atribuyó a sus propiedades 
                                                 
40 Mathiowitz E., Jacob J.S., Jong Y.S., Carino G.P., Chickering D.E., Chaturvedi P., Santos 
C.A., Vijayaraghavan K., Montgomery S., Bassett M., Morrell C. Biologically erodable 
microspheres as potential oral drug delivery systems. Nature (1997) 386: 410-414. 
41 Carino G.P., Jacob J.S., Mathiowitz E. Nanosphere based oral insulin delivery. J. Control. 
Release (2000) 65: 261-269. 
42 Sakuma S., Suzuki N., Kikuchi H., Hiwatari K., Arikawa K., Kishida A., Akashi M. Oral 
peptide delivery using nanoparticles composed of novel graft copolymers having hydrophobic 
backbone and hydrophilic branches. Int. J. Pharm. (1997) 149: 93-106. 
43 Sakuma S., Suzuki N., Kikuchi H., Hiwatari K., Arikawa K., Kishida A., Akashi M. 
Absorption enhancement of orally administered salmon calcitonin by polystyrene 
nanoparticles having poly(N-isopropylacrylamide) branches on their surfaces. Int. J. Pharm. 
(1997) 158: 69-78. 
44 Sakuma S., Suzuki N., Sudo R., Hiwatari K., Kishida A., Akashi M. Optimized chemical 
structure of nanoparticles as carriers for oral delivery of salmon calcitonin. Int. J. Pharm. 
(2002) 239: 185-195. 
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mucoadhesivas45 y a la capacidad de inhibir la degradación enzimática del péptido 
asociado46. 
En cuanto al éxito de las nanopartículas de PLGA para la administración 
oral de calcitonina (en forma de complejo con oleato sódico) cabe destacar un 
aumento importante de la concentración del péptido en sangre47. Este resultado fue 
atribuido al efecto protector de las nanopartículas frente a la actividad enzimática. 
Por otro lado, estudios realizados en el cultivo celular Caco-2 mostraron que las 
nanopartículas poseen capacidad para transportar la calcitonina a través del epitelio 
intestinal mediante transcitosis. 
Por último, los estudios realizados tras la asociación de calcitonina a 
liposomas de doble capa con carga positiva, negativa y neutra mostraron que el 
máximo efecto hipocalcémico ocurría con los liposomas dobles cargados 
positivamente48, 49. Este efecto se atribuyó a la interacción entre el liposoma cargado 
positivamente y la mucosa intestinal. Hipotéticamente, dicha interacción daría lugar 
a un aumento del tiempo de residencia del sistema en el intestino, traduciéndose en 
una mejora en la absorción del péptido. 
En definitiva, el conjunto de los resultados recogidos en la literatura 
relativos a la utilización de nanosistemas para mejorar la absorción de péptidos 
indican que el éxito de los mismos está directamente relacionado con su capacidad 
protectora del péptido encapsulado, así como también con su facilidad para 
                                                 
45 Sakuma S., Sudo R., Suzuki N., Kikuchi H., Akashi M., Ishida Y., Hayashi M. Behavior of 
mucoadhesive nanoparticles having hydrophilic polymeric chains in the intestine. J. Control. 
Release. (2002) 81: 281-290. 
46 Sakuma S., Ishida Y., Sudo R., Suzuki N., Kikuchi H., Hiwatari K., Kishida A., Akashi M., 
Hayashi M. Stabilization of salmon calcitonin by polystyrene nanoparticles having surface 
hydrophilic polymeric chains, against enzymatic degradation. Int. J. Pharm. (1997) 159: 181-
189. 
47 Yoo H.S., Park T.G. Biodegradable nanoparticles containing protein-fatty acid complexes 
for oral delivery of salmon calcitonin. J. Pharm. Sci. (2004) 93: 488-495. 
48 Ebato Y., Kato Y., Onishi H., Nagai T., Machida Y. In vivo efficacy a novel double form of 
salmon calcitonin. Drug Dev. Res. (2003) 58: 253-257. 
49 Yamabe K., Kato Y., Onishi H., Machida Y. Potentiality of double liposomes containing 
salmon calcitonin as an oral dosage form. J. Control. Release (2003) 89: 429-436. 
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interaccionar con la mucosa intestinal. Asimismo, en algunos casos, se señala el 
efecto de los polímeros constitutivos de los nanosistemas en las uniones estrechas 
intercelulares. No obstante, además de estos factores, un aspecto determinante, 
aunque no suficientemente discutido, de la eficacia de los nanosistemas reside en su 
estabilidad en los fluidos gastrointestinales y en su capacidad de control de la 
liberación. En efecto, estos nanosistemas no han de liberar el péptido asociado de 
forma prematura en los fluidos gastrointestinales; sin embargo han de procurar su 
liberación una vez en contacto con la mucosa intestinal. Por tanto, se podría concluir 
resaltando el interesante potencial de los nanosistemas a la vez que llamando la 
atención acerca de la necesidad de su optimización de forma individualizada, en 
función de las características del péptido a asociar. 
Tabla 1: Estudios basados en la administración oral de péptidos encapsulados en 
nanoestructuras. 
Sistema Composición Fármaco Parámetro analizado Ref. 
Nanopartículas PECL Ciclosporina Biodisponibilidad 50
Nanopartículas Ácido esteárico Ciclosporina Biodisponibilidad 51
Nanopartículas Lipídicas Ciclosporina Biodisponibilidad 52
Nanopartículas Eudragit® Ciclosporina Biodisponibilidad 53
Nanopartículas Eudragit® y ácidos grasos Ciclosporina Biodisponibilidad. 
54
Nanopartículas HPMCP Ciclosporina Biodisponibilidad 55
Nanocápsulas PIBCA Insulina Respuesta farmacológica 56, 57, 58
Nanocápsulas PIBCA Insulina Biodisponibilidad 59
Nanopartículas PIBCA Insulina Respuesta farmacológica 60, 61
Nanopartículas PECA Insulina Respuesta farmacológica 62
Hidrogeles P(MAA-g-EG) Insulina Respuesta farmacológica Biodisponibilidad 
63, , 64 65
Nanopartículas P(FA:SA) Insulina Respuesta farmacológica 66
Nanopartículas FAO:PLGA Insulina Respuesta farmacológica 67
Nanopartículas 
PS-g-PNIPAA/ 
PS-g-PNIPAA-
g-PVA 
Calcitonina Respuesta farmacológica 68, , 69 70
Nanopartículas PLGA/ ácidos grasos  Calcitonina Biodisponibilidad 
71
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carriers for oral peptide delivery. J. Control. Release (1990) 13: 233-239. 
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Abreviaturas 
 
DMPC: Dimiristoil- fosfatidilcolina 
DPPC: dipalmitoil-fosfatidilcolina 
FAO:PLGA: Oligómeros de ácido fumárico: ácido poliláctico 
HPMCP: Ftalato de hidroxipropil metilcelulosa 
P(FA:SA): poli(ácido fumárico y sebácico) 
P(MAA-g-EG): poli(ácido metacrílico-etilén glicol) 
PECA: poli(etilcianoacrilato) 
PECL: poli-ε-caprolactona 
PIBCA: poli(isobutilcianoacrilato) 
PIHCA: poli(isohexilcianoacrilato) 
PLGA: poli(ácido láctico-glicólico) 
PS-g-PNIPAA: poliestireno-poli-N-isopropilacrilamida 
PS-g-PNIPAA-g-PVA: poliestireno-poli-N-isopropilacrilamida-g-polivinilamina 
SA: estearilamina 
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Abstract 
Over the last years, a major challenge in drug delivery has been the design 
of appropriate vehicles for the oral administration of macromolecular drugs 
(peptides and proteins). Indeed, despite the increasing market value of these 
complex molecules, their clinical use has been highly limited by their reduced oral 
bioavailability. Among the different delivery approaches explored so far, those 
based upon the use of the polysaccharide chitosan have opened promising 
alternatives towards this ambitious goal. This is due to the interesting 
physicochemical and biopharmaceutical properties of this polymer. This article 
describes the advances that have been made in the design of chitosan-based systems 
specially adapted for the oral administration of peptides. These systems include: 
solutions, microspheres, nanoparticles, nanocapsules and liposomes. More 
specifically, the article discusses the efficacy of the different delivery approaches for 
improving the absorption of peptides, and analyzes the various mechanisms that 
have been proposed for the understanding of their efficacy. 
 
Keywords: chitosan, oral administration, delivery systems, 
peptides/proteins. 

Artículo 1: The potential of chitosan for oral… 25 
Introduction 
Chitosan is a natural polymer synthesized by alkaline deacetylation of 
chitin, which is the second polysaccharide most abundant in nature after cellulose. 
This polymer can be found in the exoskeleton of crustacean, insects and some fungi. 
The main difference in the chemical structure between chitin and chitosan [α (1→4) 
2-amino 2-deoxy β-D glucan] is related to the number of acetyl groups (Fig. 1). This 
small difference makes chitin insoluble in water or in the most common organic 
solvents, whereas chitosan base is soluble in acidic solutions. 
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Figure 1: Chemical structure of chitin and chitosan. R: N-acetyl group (acetylation 
percentage usually < 50%). 
 
Chitosan was discovered in 1859 by Rouget [1], however, most of the 
reports on its biological and pharmaceutical applications have been published in the 
last couple of decades. Biomedical and biological applications of chitosan include its 
use as a dietary supplement for weight loss and as a hypocholesterolemic [2], 
antimicrobial [3] and wound healing [4] agent. On the other hand, properties such as 
good biocompatibility, low toxicity [5, 6], biodegradation by lysozyme [5, 7] make 
of chitosan a new promising biomaterial. 
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From a pharmaceutical perspective, chitosan has also attracted significant 
attention for a variety of applications and modalities of administration. One area in 
which interest is growing is related to the use of chitosan as a material for 
transmucosal drug delivery. This is justified by some interesting characteristics of 
chitosan, such as bioadhesiveness and absorption promoting characteristics. These 
two properties have been exploited for achieving either, local or systemic drug 
delivery. For example, chitosan has become particularly well known because of its 
ability to increase the systemic absorption of drugs and vaccines administered 
intranasally [8-13]. A clear proof of its efficacy and acceptability is the fact that 
there are several formulations in different stages of clinical trials. For example, at 
this moment a chitosan-based liquid formulation is in clinical evaluation for nasal 
administration of several drugs and vaccines [14, 15]. Chitosan has also shown 
interesting potential as an ocular drug delivery agent [16]. For this specific modality 
of administration, the interest relies on the ability of chitosan-based systems to 
enhance the intensity and time of retention of topically applied drugs [17-19]. A 
wide range of applications have also been identified for the use of chitosan in oral 
drug delivery. A simple one would be its use as a hydrophilic excipient to increase 
the solubility of poorly soluble drugs [20]. Chitosan can also be presented in the 
form of microspheres (cross-linked or reacetylated) which have the ability to control 
the release of therapeutic agents along the intestinal tract [21, 22] or to deliver drugs, 
i.e. antibiotics, locally to the gastric wall [23]. Finally, a number of chitosan 
derivatives and chitosan-based carriers have been proposed to increase the systemic 
absorption of peptides by providing the polymer with a better solubility at the 
absorption intestinal pH or an enhanced mucoadhesive and permeation enhancing 
properties [24-26]. 
There are already several general reviews on the general potential of 
chitosan in the field of drug delivery [26-28] as well as specific reviews covering the 
application of chitosan for nasal [29] and ocular drug delivery [16]. Therefore, in 
this article we aimed to review a specific application of chitosan with a great market 
potential: the enhancement of the oral absorption of peptides. This is with no doubt 
one of the greatest challenges confronted by the pharmaceutical scientists in the last 
decade. A challenge that, on the other hand, is clearly justified by the increasing 
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number of macromolecular drugs approved and which have to be administered 
parenterally. Keeping this goal in mind, we will first describe the physicochemical 
and the biopharmaceutical properties of chitosan that are critical for the oral 
application of chitosan. Then, in the second part, we will present the features and 
efficacy of the different chitosan delivery systems evaluated so far for oral peptide 
delivery, making the distinction between solutions, microspheres and 
nanostructures. Finally, we will analyze the mechanisms suggested until now in 
order to explain the way these systems are able to enhance the bioavailability of 
orally administered peptides. 
 
Chitosan properties 
Bearing in mind that this review is focused on the use of chitosan as a 
material for oral peptide delivery, in the next paragraphs we will discuss about some 
physicochemical and biological properties which may affect this specific application 
of chitosan. In this sense, it is important to keep in mind that chitosan comprises a 
series of polymers, which vary in the percentage of N-acetyl groups, the degree of 
deacetylation, and in the molecular weight. Both characteristics are critical, not only 
from a physicochemical point of view, but also from a biological perspective. 
 
Solubility properties 
A property that affects greatly the solubility of chitosan is its deacetylation 
degree. Highly deacetylated chitosans (85%) are readily soluble up to a pH value of 
6.5. However, their solubility decreases significantly with the deacetylation degree 
[30]. Consequently, most of the studies regarding the pharmaceutical use of chitosan 
have been performed with highly deacetylated chitosan. 
Highly deacetylated and purified chitosans are commercially available, in a 
broad range of molecular weights, in the form of a base and also as a salt. The 
chitosan base form is soluble in acidic solutions such as hydrochloric, glutamic, 
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acetic and lactic acid solutions, in which the amino groups of chitosan become 
protonated leading to a positively charged polymer. Obviously, chitosan salts do not 
require the use of acids and are readily soluble in water. However, irrespective of the 
initial form, the solubility of chitosan decreases significantly when raising the pH to 
neutral or basic values. In addition to the pH, the ionic strength affects the solubility 
of chitosan. The higher the ionic strength is, the lower the solubility. In fact, a higher 
electrolyte concentration results in a salting-out effect which leads to the 
precipitation of the polymer [31]. 
This solubility behaviour is important from the perspective of the use of 
chitosan for oral administration. Indeed, chitosans administered orally in the form of 
an aqueous solution are expected to precipitate upon reaching the intestinal region 
due to the increase in the pH up to values in the range 6.5-7.5. On the other hand, 
chitosans administered as powders are supposed to dissolve in the acidic pH of the 
gastric cavity and, then, precipitate in the intestinal compartment. Consequently, the 
behaviour of classical solutions and powders justifies the search of optimized 
presentations of chitosan, either in the form of a chemical derivative that is soluble 
at the intestinal pH or, in the form of a device (nanoparticles/ microspheres) that is 
stable in the physiological conditions of the gastrointestinal tract. 
 
Penetration enhancement properties 
It is well known that chitosan can enhance the permeability of different 
compounds through the intestinal monolayer. This has been very clearly shown 
using the Caco-2 cell line for a variety of compounds such as buserelin, inulin, 
mannitol, and horseradish peroxidase [32-36]. The increase in the permeability has 
been generally related to a decrease in the transepithelial electric resistance (TEER) 
which was attributed to a partial disruption of the tight junctions. Moreover, the 
results of these studies have shown that the increase in the permeability of the 
monolayer and, hence, on the transport of drugs is dependent on a number of factors, 
such as the chitosan dose as well as the chitosan molecular weight and deacetylation 
degree [33-35]. More specifically, Schipper et al. [34] observed, using mannitol as a 
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model molecule, that chitosans with low acetylation degree (1-15%) showed a clear 
effect on the transport of the molecule, regardless the molecular weight. In contrast, 
for high acetylation degree of chitosan (>35%), a permeability enhancement of 
mannitol across the monolayers was only achieved with high molecular weight 
chitosans. 
Despite the evidence of the penetration enhancement ability of chitosan, the 
mechanism of action remains unclear. Studies performed at the beginning nineties 
concluded that the exposure of the cell surface to chitosan solutions induces clear 
changes in the F-actin distribution [32]. Some years later, it was observed that 
chitosan induces not only a redistribution of F-actin but also that of the tight junction 
proteins zona occludens 1 (ZO-1) [33, 35]. In addition, it was found that the content 
of ZO-1 and occludin in the cytoskeleton increase, revealing the ability of chitosan 
to disrupt the epithelial cell tight junctions involving the translocation of the proteins 
ZO-1 and occludin from the membrane to the cytoskeleton [35]. Very recently, the 
same authors found that chitosan acts, at least in part, via an activation of protein 
kinase C (PKC). [37] Interestingly, the results of the previous studies [33-35] also 
indicated that the effect of chitosan on the Caco-2 cell monolayer is reversible and, 
hence, that the opening of the cellular barrier is transient. This specific behavior 
makes a great difference, in terms of toxicity, between chitosan and the classical 
penetration enhancers which are known to cause irreversible epithelial damage. 
Within the context of this review article, we found it important to analyze 
this mechanism of action of chitosan with regard to its ability to enhance the 
absorption of peptides. However, as will be discussed later, the relevance of this 
mechanism on the efficacy of a specific chitosan-based oral drug delivery system 
will be obviously dependent on the characteristics of the device and, obviously, on 
the physical state of chitosan. 
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Mucoadhesive properties 
One of the limitations of the oral route is the rapid transit that reduces the 
chances for the drug to interact with the absorptive epithelium. One of the 
approaches to deal with this limitation has been based upon the use of materials 
which favour the interaction of the drug with the mucus layer that covers the 
intestinal epithelium. Chitosan belongs to the category of these so-called 
mucoadhesive materials. Indeed, due to its positive charge, chitosan is able to 
interact with the negatively charged mucus components [38, 39]. This property has 
attracted significant attention to the use of chitosan for transmucosal drug delivery 
and, in particular, for nasal drug delivery. For example, in this case, the chitosan-
mucus interaction leads to the formation of a viscous gel that reduces the 
mucociliary clearance and increases the residence time of the drug in the absorptive 
mucosa [29]. However, while the advantage of this property is clear for nasal 
application, its contribution to the potential of chitosan for oral drug delivery is 
uncertain. This is due to the fact that the mucus covering the intestinal wall 
undergoes a rapid turnover and, consequently, the mucoadhesion of chitosan does 
not necessarily imply a more intense and prolonged contact of the co-administered 
drug with the absorptive epithelium. Therefore, a critical point in the design of a 
chitosan-based mucoadhesive delivery device would be to achieve, first, a facilitated 
interaction with the mucus and, second, an adequate diffusion through the mucus 
layer towards the underlying epithelium. In addition, as mentioned above, classical 
chitosan solutions and powders are expected to precipitate upon reaching the 
intestinal tract and this uncontrolled precipitation may logically affect the inherent 
mucoadhesive properties of chitosan. 
Irrespective of the importance of the role of mucoadhesion in the efficacy 
of chitosan-based delivery systems, there are some characteristics of chitosan that 
have been found to affect the intensity of the mucoadhesion phenomenon. Logically, 
as expected from the mechanism of mucoadhesion, the mucoadhesive character of 
chitosan is dependent on its acetylation degree. Indeed, a higher deacetylation 
degree of chitosan leads to a more important number of positive charges and, hence, 
to a more marked adhesiveness [39]. 
Artículo 1: The potential of chitosan for oral… 31 
On the other hand, the molecular weight of chitosan has also been regarded 
as a parameter that affects the mucoadhesive properties of chitosan. For example, 
Kawashima et al. [40] observed, using a rat everted intestinal sac, that the 
mucoadhesion of chitosan increased with the molecular weight. The same 
conclusion was derived from a rheological study aimed at predicting the 
mucoadhesive properties of chitosan. The results of this study indicated that the 
mucoadhesion forces could be modulated by adjusting the chitosan molecular 
weight and concentration [41]. 
As in the case of the permeability enhancing property, it is worthwhile to 
mention that, despite the evidence of the chitosan inherent properties on its 
mucoadhesive character, the consequence that these properties may have on the 
behavior of chitosan-based delivery devices will obviously be highly dependent on 
the specific characteristics of the device. 
 
Chitosan toxicity issues and regulatory status 
The safety of chitosan has been investigated, showing its low toxicity and 
biocompatibility [5, 6, 42]. In fact, the oral LD50 of chitosan in rodents has been 
reported to be over 16 g/kg [42], showing that chitosan is safe following oral 
administration. On the other hand, the results in humans indicate that it is necessary 
to consume several grams of chitosan a day in order to observe signs of constipation 
or diarrhea [43, 44]. These amounts are far beyond those needed in pharmaceutical 
formulations and, consequently, it is accepted that the risk of side effects following 
oral administration of chitosan formulations is negligible. 
With regard to the regulatory aspects, there is a monograph of chitosan 
hydrochloride in the European Pharmacopoeia (EP1774). In addition, The American 
Society for Testing and Materials (ASTM) has published a guideline (ASTM F 
2103) for the characterization of chitosans for use in Tissue Engineered Medical 
Products (TEMPs). Finally, according to the information provided by the company 
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Novamatrix, a Drug Master File covering the chitosan salts and bases have been 
submitted to the US FDA in July 2004. 
 
Chitosan-based systems for oral peptide delivery  
Over the last years, a number of chitosan-based formulations (i.e. solutions, 
microspheres and nanostructures) have been developed for improving the oral 
administration of peptides and proteins. In this section we describe the performance 
of these vehicles in terms of their ability to enhance the intestinal absorption as well 
as the mechanistic details. The pharmacological efficacy obtained for the two model 
peptides, insulin and calcitonin, that have received the greatest attention as 
candidates for these chitosan-based carriers are summarized in Tables 1 and 2. 
 
Table 1: Pharmacological efficacy obtained after oral administration to rats of 
insulin encapsulated in chitosan-based carriers. 
 
Chitosan-
based carrier Drug 
Dose 
(IU/kg) 
R maxa 
(%) 
tmaxb  
(h) 
Duration of 
effect Reference 
Chitosan 
nanoparticlesc
Insulin  7, 14, 
and 21 
60 10 From 8 until 
24 h 
Pan et al., 
2002 [68] 
Chitosan 
nanoparticlesc
Insulin  50 and 
100 
50 19 From 13 h 
until 24 hours 
Ma et al., 
2001 [69] 
Chitosan/glu- 
comannan 
nanoparticles 
Insulin  50 50 14 From 14h 
until 24 h 
Alonso-
Sande et al., 
2004 [73] 
Chitosan-
coated 
liposomes 
Insulin 100 30 3 From 30 min 
until 12 h 
Takeuchi et 
al., 1996 
[82] 
a: Maximum pharmacological effect. 
b: Time of the maximum pharmacological effect. 
c: In vivo study performed in diabetic rats. 
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Table 2: Pharmacological efficacy obtained after oral administration to rats of 
calcitonin encapsulated in chitosan-based carriers. 
 
Chitosan-based 
carrier Drug 
Dose 
(IU/kg) 
R maxa 
(%) 
tmaxb  
(h) 
Duration 
of effect Reference 
Enteric-coated 
chitosan-based 
microspheres 
Calcitonin 500c 15 10 From 8 h 
until 12 h 
Lamprecht 
et al., 2004 
[59] 
Chitosan 
nanocapsules 
Calcitonin 500 30 1 More than 
24 h 
Prego et 
al., 2005 
[76] 
Chitosan-coated 
solid 
nanoparticles 
Calcitonin 500 30 1 More than 
24 h 
Garcia-
Fuentes et 
al., 2005 
[82] 
Chitosan-coated 
PLGA 
nanoparticles 
Calcitonin 125, 250 
and 500 
25 8 36 h Kawashi- 
ma et al., 
2000 [40] 
Chitosan-coated 
liposomes 
Calcitonin 500 22 2 8 h Takeuchi et 
al., 2003 
[84] 
a: Maximum pharmacological effect. 
b: Time of the maximum pharmacological effect. 
c: Expressed by the authors in mg/kg and converted to IU taking the relation 1mg=5000IU. 
 
Chitosan solutions 
Most of the studies intended to evaluate the ability of chitosan solutions to 
improve the absorption of drugs across the intestinal epithelium were performed in 
vitro, either in cell culture [45] or in rat intestinal [46]. The in vivo evaluation of the 
effectiveness of chitosan solutions for oral peptide delivery is limited. This is 
understandable if we take into account that, as indicated above, chitosan precipitates 
at the pH of the intestinal tract (~6.5-7.5). In fact, from our literature search, we only 
found one study reporting the in vivo absorption enhancing effects of chitosan 
hydrochloride [47]. More concretely, the results showed an increase in the 
bioavailability of a nonapeptide following intraduodenal injection to rats. This 
positive result was attributed to the inherent capacity of chitosan to open the 
intercellular junctions. 
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The problem associated to the low solubility of chitosan at neutral and high 
pH values could be overcome by chemical modification of the chitosan molecule. 
For example, the derivative, N-trimethyl chitosan, was found to be readily soluble at 
neutral and basic pH values [48]. Unfortunately, the studies performed in Caco-2 
cells showed that the mucoadhesive [49] and the promoting enhancing [46] 
properties of trimethylated chitosan were not as remarkable as those of the parent 
chitosan molecule. According to the authors [46, 49], this phenomenon could be 
related to a change in the conformation of the trimethylated chitosan that reduces the 
flexibility of the polymer molecules and, therefore, the interpenetration into the 
mucus layer. This reduced mucoadhesion could also be due to a decrease in the 
density of amino groups available for protonation subsequent to the chemical 
modification. Nevertheless, despite the reduced mucoadhesion of the chemically 
modified polymers in the in vitro cell line, the in vivo studies performed in rats or 
pigs revealed that trimethylated chitosan was significantly more efficient than 
chitosan hydrochloride at increasing the absorption of the peptide octreotide [50, 
51]. This greater efficacy was attributed to the more important absorption enhancing 
effect of trimethylated chitosan at neutral pH values as compared to chitosan 
hydrochloride [52]. 
A quite successful approach has been the chemical modification of chitosan 
by the introduction of a thiol group [53]. Thiolated chitosans exhibited improved 
mucoadhesive properties in vitro [54] as well as an enhancement in the epithelial 
drug permeability [55]. Their in vitro behavior correlated well with their ability to 
increase the absorption of calcitonin or insulin following oral administration to rats 
[53, 56]. It should be, however, clarified that, in these studies, chitosan was 
presented in the form of a solid matrix (1.5 mm minitablets). 
 
Chitosan-based microspheres 
A different strategy towards increasing the systemic absorption of peptides 
administered orally has been designed specifically to deliver drugs in the colonic 
region. The strategy was proposed to take advantage of two critical facts: the limited 
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peptide enzymatic activity, as compared to that of the small intestine, and the 
markedly slower rate of colonic transit. Chitosan-based microspheres were chosen as 
candidate vehicles to achieve this goal due to the specific degradation of chitosan in 
the colonic microflora [57, 58], and to its mucoadhesive/absorption enhancing 
effects. Indeed, if conveniently designed, chitosan-based microspheres can travel 
intact along the gastrointestinal tract and reach the colonic region. Once in this 
region, the polymer matrix degrades and releases the peptide which, at this level, is 
free to cross the colonic mucosa. 
The technological approach, adopted to prevent the alteration of chitosan-
based microspheres during their gastrointestinal transit, was their entrapment or 
coating with pH-sensitive polymers (acrylic or cellulosic) [59-61]. Using fluorescent 
markers, i.e. carboxyfluorescein, or the peptide insulin, it has been shown that the 
pH-sensitive microspheres containing chitosan exhibit a pH-dependent release 
behavior. More specifically, when exposed to a pH-gradient they provide a 
negligible release until the colonic pH was reached (~6.5-7), and then, a continuous 
and controlled drug release [59-61]. 
Unfortunately, the limited number of in vivo studies intended to evidence 
the efficacy of these pH-sensitive chitosan systems do not permit us to extract clear 
conclusions regarding the efficacy of this approach. For example in the study 
performed by Lamprecht et al. [59], aimed at evaluating the performance of enteric-
coated chitosan-based microspheres containing calcitonin, it was observed that the 
pharmacological response was not affected by the presence of chitosan. 
Consequently, the authors concluded that the success of the formulation was due to 
the enteric coating and that the role of chitosan was negligible in this type of 
formulation. These results differ from those observed by Tozaki et al. [62] who 
studied the efficacy of a large chitosan capsule, administered orally to rats. The 
chitosan capsule had an enteric polymer coating and contained insulin in association 
with an absorption enhancer and an enzyme inhibitor. A hypoglycemic response was 
noted at 6 hours post-administration, when the capsule reached the colon, giving an 
insulin bioavailability of 5.73%. The authors justified the success of this formulation 
to the specific disintegration of the capsules in the colonic region and to the 
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absorption enhancing properties of chitosan. In addition, they found that the positive 
effect of chitosan could be reinforced by the co-administration of other absorption 
enhancers. 
Therefore, while this colonic delivery approach offers some potential, it is 
quite possible that the performance of a pH sensitive chitosan delivery system will 
be dependent on the type of peptide as well as on the specific composition of the 
final formulation. 
 
Chitosan nanostructures 
Over the last decade, a number of nanostructures based on chitosan and 
chitosan derivatives have been proposed for the oral administration of peptides. 
These nanostructures can be classified into three categories: chitosan-based self-
assembling structures, chitosan-based nanoparticles and chitosan-coated 
nanosystems. Self-assembling nanostructures can be formed using specific chemical 
derivatives of chitosan. Chitosan-based nanoparticles can be composed of simply 
cross-linked chitosan or chitosan in combination with other hydrophilic polymers. 
Chitosan-coated nanosystems include chitosan-coated solid hydrophobic 
nanoparticles, chitosan-coated liposomes and chitosan-coated oily nanodroplets, also 
called nanocapsules. 
 
Chitosan-based self assembling nanostructures 
Recently, a number of authors have reported the chemical modification of 
chitosan with hydrophobic groups like palmitoyl, or linolenic or deoxycholic acid. 
The attachment of the hydrophobic moiety led the polymer to self-assemble forming 
a micelle-like nanostructure [63-65]. Moreover these systems have shown a capacity 
to entrap peptide molecules such as bovine serum albumin [65]. 
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A different type of nanostructure was described by Ohya et al. [66]. 
According to these authors, the grafting of hydrophilic polymers such as PEG to the 
chitosan backbone provides the polymer with the ability to self-aggregate in aqueous 
media due to the formation of intermolecular hydrogen bridges. Moreover, these 
nanostructures could associate insulin and release it in a controlled fashion 
depending on the degree of PEGylation of chitosan. 
Unfortunately, although these self-assembling nanostructures have been 
proposed as promising carriers for the delivery of labile molecules like peptides and 
proteins, so far there is no evidence of their performance following in vivo 
administration. 
 
Chitosan-based nanoparticles 
Chitosan has the ability to gel upon contact with specific polyanions. 
Taking advantage of this specific property, a few years ago, we developed 
nanoparticles made of solely chitosan or chitosan in combination with other 
hydrophilic polymers such as poly(ethyleneglycol) (PEG) [67]. These nanoparticles 
are formed immediately upon mixing two aqueous phases (one containing chitosan 
and the other one containing sodium tripolyphosphate) through inter and 
intramolecular linkages created between phosphates and chitosan amino groups. 
Besides the advantage of being produced under extremely mild conditions, these 
nanoparticles have shown a great capacity for the association of peptides and 
proteins like bovine serum albumin, tetanus toxoid and insulin [11, 12, 67]. The 
physical appearance of these nanoparticles as seen by transmission electronic 
microscopy is shown in figure 2A and compared to that of chitosan-coated systems, 
which will be described later. 
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Figure 2: Transmission electron micrographs of: A) chitosan nanoparticles, B) 
chitosan nanocapsules and C) chitosan-coated tripalmitin nanoparticles*.* Figure 
from Garcia-Fuentes et al. [79]. 
 
More recently, these ionically cross-linked nanoparticles were tested for 
their efficacy as carriers for oral peptide administration [68]. The results obtained 
following oral administration of insulin-loaded chitosan nanoparticles to diabetic 
rats revealed their efficacy at improving the hypoglycemic response of insulin. More 
specifically, they observed a reduction of the blood glucose levels at 8 hours post-
administration and this response was prolonged for up to 24 hours. In contrast, 
chitosan solution, used as a control, was totally inefficient at increasing the intestinal 
absorption of insulin. This report was coincident with that of Ma et al., [69] who 
evaluated the efficacy of the same type of nanoparticles after oral administration to 
normal and diabetic rats. They observed that, while no significant hypoglycemic 
response was registered in normal rats, a marked hypoglycemic effect was observed 
in similarly dosed diabetic rats. The onset of action occurred at 10 hours post-
administration and the effect was maintained for a few hours. 
With respect to the mechanism by which chitosan nanoparticles are able to 
increase the hypoglycemic response of orally administered insulin, the authors [68, 
69] have speculated about several possible effects: the protection of the peptide from 
degradation in the gastrointestinal tract, and the potential mucoadhesive and 
absorption enhancing properties of chitosan. Furthermore, the authors argued that 
the long-term response could be associated with the uptake of the nanoparticles by 
the M cells overlaying the Peyer’s patches. Despite the advances made in this sense, 
the mechanism of action of these nanoparticles has not been fully elucidated. For 
example, using the Caco-2 model cell line we could observe that some chitosan 
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nanoparticles were able to enter into the cells and that this interaction with the 
monolayer was more important in the case of the mucus secreting cells (MTX-E12) 
[70]. Consequently, we concluded that the presence of mucus favoured the 
interaction of the particles with the underlying epithelium. Unfortunately, we can not 
directly translate this interpretation to the in vivo situation. However, we can 
reasonably accept that the nanoparticles may protect the peptide molecules from 
degradation and facilitate their interaction with the absorptive mucosa. 
More recently, we have produced a different type of nanoparticles made of 
chitosan in association with the polysaccharide glucomannan, using the same 
principle of ionic cross-linking [71]. The rational for the design of this novel 
colloidal carrier was that glucomannan would improve the stability of nanoparticles 
in the gastrointestinal fluids and also facilitate the interaction of nanoparticles with 
mannose receptors present in the epithelial cells [72]. In order to validate this 
hypothesis we chose insulin as a model peptide and tested the efficacy of the carrier 
following oral administration to normal rats [73]. Interestingly, 
chitosan/glucomannan nanoparticles were able to elicit a delayed hypoglycemic 
response at 14 hours post-administration and this response was maintained for at 
least 10 hours. However, under the experimental conditions of this study, we could 
not observe a significant response for the insulin associated to chitosan 
nanoparticles, used as a control. The success of chitosan/glucomannan nanoparticles 
as compared to those made of chitosan could be related to the observed stabilizing 
effect of glucomannan [73]. In fact, very recently, we have observed a similar 
response for chitosan nanoparticles stabilized with poloxamer (non-published 
results). While the stabilization effect of glucomannan has been verified, its ability 
to improve the uptake of nanoparticles remains to be investigated.  
Chitosan nanoparticles have also been explored for their efficacy to 
increase the systemic absorption of hydrophobic peptides such as cyclosporin-A 
[74]. In this study chitosan nanoparticles were administered orally to beagle dogs, 
and the currently available cyclosporin-A microemulsion (Neoral®) was used as a 
control. The results indicated that chitosan nanoparticles provided an improved 
absorption and, hence, a greater bioavailability of cyclosporine A, as compared to 
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the control microemulsion. The authors understood that this positive behaviour was 
due to a combination of the mucoadhesion and the ability to open the tight junctions 
of epithelial cells, inherent properties of chitosan. However, no mechanistic studies 
were undertaken in order to verify this proposed mechanism. 
 
Chitosan-coated nanostructures 
Chitosan has also been used as a coating material in order to change the 
surface properties of colloidal drug carriers. As indicated above, different types of 
nanosystems, oily nanodroplets, solid nanoparticles and liposomes have been 
selected as cores for the coating process. The purpose while designing these systems 
was to improve the interaction of the cores with mucosal surfaces. Obviously, the 
nature of the core is expected to affect the drug encapsulation and release properties 
of the system. 
 
Chitosan nanocapsules
A few years ago, we developed chitosan-coated oily nanodroplets, also 
called nanocapsules [75]. The formation of these nanosystems was possible using 
the solvent displacement technique, but introducing an important modification: the 
incorporation of chitosan to the aqueous phase. The physical appearance of the 
coated systems is the one presented in figure 2B. Recently, we have investigated the 
efficacy of chitosan nanocapsules as carriers for oral peptide delivery using salmon 
calcitonin as a model peptide [76, 77]. We have monitored the reduction of serum 
calcium levels after oral administration of calcitonin-loaded chitosan nanocapsules 
and used an aqueous solution and a nanoemulsion containing calcitonin as controls. 
Interestingly, as shown in figure 3, a marked hypocalcemic response was noted 
when the peptide was associated to the nanocapsules, whereas no significant effect 
was observed after administration of the solution or the uncoated nanoemulsion. 
Therefore, a conclusion from these data was the chitosan coating was critical for the 
performance of the formulation. Moreover, the percentage of reduction of the serum 
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calcium levels achieved following administration of chitosan nanocapsules was 
maintained for, at least, 24 hours [76]. This pronounced and long-lasting 
hypocalcemic effect led us to speculate about the adhesion of the carrier and a 
sustained release of the associated peptide from the absorptive epithelium towards 
the blood stream. 
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Figure 3: Hypocalcemic effect after oral administration in rats of chitosan 
nanocapsules as well as the control nanoemulsion and the aqueous solution of 
salmon calcitonin (mean ± s.e.; n=6).* Statistically significant differences from 
salmon calcitonin solution (p<0.05). Data from Prego et al. [76]. 
 
In order to obtain some evidence on the mechanism of action of chitosan 
nanocapsules we have performed some studies in the Caco-2 model cell line [76]. 
Two main conclusions were extracted from these experiments: (i) chitosan 
nanocapsules were able to reduce the TEER of the Caco-2 cell monolayer in a dose-
dependent manner; however, the important concentration required to detect a 
significant change in permeability, led us to conclude that this phenomenon can not 
be taken as an explanation for the success of the formulation following in vivo 
administration; (ii) confocal experiments performed with rhodamine-labeled 
chitosan nanocapsules, suggested that both, the nanocapsules and the corresponding 
control emulsions, were able to enter Caco-2 cells monolayer; however, the level of 
internalization was very low and similar for coated and uncoated carriers and, 
consequently, these results do not justify the in vivo success of the chitosan-coated 
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systems. More recently, we tested chitosan nanocapsules using a co-culture of Caco-
2 cells and mucus secreting cells (HT29-M6) and observed the fluorescence signals 
by confocal microscopy [78]. The images indicated that the level of interaction of 
chitosan nanocapsules was greatly enhanced by the presence of the mucus secreting 
cells. In addition, no transport of the particles across the monolayer was observed 
[78]. Therefore, overall, these results led us to suggest that the expected 
mucoadhesion of the chitosan-coated system could be responsible for the facilitated 
access of the drug to the underlying epithelium, and, hence for the pronounced and 
long-lasting hypocalcemic effect. An illustration of this mechanism is presented in 
figure 4. 
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Figure 4: Schematic illustration of the interaction of chitosan-based nanostructures 
with the intestinal mucosa and the transport of the associated peptide 
 
Chitosan-coated solid nanoparticles 
In order to investigate the importance of the nature of the lipid core in the 
performance of chitosan-coated lipid systems, in our laboratory, we have also 
produced chitosan-coated tripalmitin nanoparticles [79]. First, calcitonin-loaded 
tripalmitin nanoparticles were prepared by the double emulsion-solvent 
emulsification method [80] and, then, coated with chitosan by simple incubation in a 
chitosan aqueous solution (Fig. 2C). After oral administration of calcitonin-loaded 
chitosan-coated tripalmitin nanoparticles to rats, the hypocalcemic effect was 
Artículo 1: The potential of chitosan for oral… 43 
evaluated. A great and long-lasting reduction of the serum calcium levels was 
obtained [81, 82]. This response was similar to the one observed for calcitonin-
containing chitosan nanocapsules [76]. However, as in the case of non-coated 
nanoemulsion, tripalmitin cores were inefficient at reducing the serum calcium 
levels. An obvious conclusion from these observations was that the chitosan coating 
was critical for the success of the formulation. As in the case of the chitosan 
nanocapsules, our interpretation was that the presence of chitosan could facilitate the 
interaction with the overlying mucus layer leading to a prolonged site-specific 
delivery of calcitonin and, thus, an extended pharmacological response. 
These results agree with those previously reported for chitosan-coated 
poly(lactic acid/glycolic acid) (PLGA) nanoparticles [40]. In this study, elcatonin-
loaded PLGA nanoparticles were prepared by the emulsion solvent diffusion 
method. Then, the nanoparticles were isolated and incubated with a chitosan 
solution, forming chitosan-coated PLGA nanoparticles. The effectiveness of 
chitosan-coated PLGA nanoparticles was assayed in rats, showing a reduction of the 
serum calcium levels as compared to the peptide solution and the uncoated 
nanoparticles. As in the case of the chitosan-coated lipid nanoparticles, this positive 
in vivo behavior was attributed to the mucoadhesive character of the carrier and its 
intimate contact with the intestine. This explanation was justified by the observed 
mucoadhesion of the carrier using the everted intestinal sac model. 
 
Chitosan-coated liposomes 
Liposomes have been considered as candidate vehicles for oral peptide 
delivery due to their capacity to encapsulate peptides and to protect them from 
enzymatic degradation. One of approaches to improve their interaction with the 
intestinal mucosa and, hence, to increase the absorption of the associated peptide has 
been their coating with mucoadhesive polymers such as chitosan. For example, 
Takeuchi et al. prepared multillamelar liposomes coated with chitosan by hydration 
the lipid film with an aqueous solution of the polymer [83, 84]. As expected, these 
chitosan-coated liposomes exhibited a mucoadhesive character whose degree was 
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dependent on the amount of chitosan attached to their surface [83]. The efficacy of 
the coated liposomes as carriers for oral peptide delivery was tested in vivo for two 
model peptides, insulin and salmon calcitonin [83-85]. The results of these studies 
indicated that the chitosan-coated liposomes were more effective than the uncoated 
ones in terms of improving the pharmacological effect of the peptides administered 
orally to rats. This improved response was related to the mucoadhesive properties of 
the chitosan-coated liposomes. Moreover, the same authors tested the performance 
of the chitosan solutions for improving the absorption of calcitonin and observed 
that the simple presence of chitosan in solution did not help the absorption of this 
peptide. As a consequence, they concluded that the protection of the peptide in the 
liposomal core as well as their coating with the mucoadhesive polymer were critical 
for the success of the formulation. 
Overall, the results obtained from chitosan-coated nanostructures underline 
the efficacy of this type of colloidal carrier. In general, the chitosan coating around 
the carriers showed a positive effect at improving the pharmacological response of 
the peptide, which was mainly attributed to the mucoadhesive properties of the 
polymer. However, the differences in the core material could also influence the level 
of protection of the associated peptide and also in its release from the carrier. As a 
consequence, these differences could have an impact on the intensity and duration of 
the pharmacological response. 
 
Conclusion 
Different chitosan-based drug delivery systems were revealed as promising 
peptide carriers. Among them, those based on chemically modified chitosan and also 
nanoparticulate carriers (nanoparticles and nanocapsules) have been particularly 
successful. Moreover, there is a clear evidence of the greater performance of 
nanoparticulate chitosan carriers, as compared to the solutions of non-modified 
chitosan, in terms of enhancing the absorption of peptides such as insulin and 
salmon calcitonin. The explanation to this phenomenon is that the particulate 
carriers are able not only to increase the peptide absorption due to the mucoadhesive 
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properties of chitosan, but also to offer protection from enzymatic degradation. 
Furthermore, while more work is needed to fully understanding the mechanism of 
action and the efficacy of these carriers, we can certainly conclude that chitosan-
based systems have a promising future in oral drug delivery. 
 
Expert opinion 
At present, only the hydrophobic peptide cyclosporine A can be 
administered orally in the form of a microemulsion (Neoral®). However, the 
progress made over the last years, towards making feasible the oral administration of 
peptides, offers an optimistic perspective. Indeed, the Eligen® technology (based on 
using a low molecular weight delivery agent) has reached phase II-clinical trials for 
insulin and salmon calcitonin [86, 87]. Similarly, hexyl –insulin monoconjugate 2 
(HIM2), a modified insulin conjugated to an amphiphilic polymer [88], as well as 
oral formulations of calcitonin and parathyroid hormone consisting of a combination 
of enzyme inhibitors, absorption enhancers, and enteric coating, have been evaluated 
in humans [89]. On the other hand, a number of particulate polymer and bioadhesive 
systems have given evidence of their effectiveness in large scale animals [90, 91]. 
Therefore, these delivery-based strategies are opening the way for future great 
developments, preferably based on nanosystems and polymers. This article presents 
the value of a more immature, but promising, strategy based upon the use of the 
bioadhesive polysaccharide chitosan. Chitosan as such (in solution or powder) can 
not be used because it is soluble in the gastric fluids but precipitates at the intestinal 
pH. However, a number of delivery approaches based on chitosan have shown a 
degree of success in small scale animals: (i) the use of chemically modified chitosan 
which is soluble at the intestinal pH; (ii) the use of nanosystems that protect the 
peptide and facilitate its interaction with the absorptive epithelium; and (iii) the 
design of devices that specifically deliver the peptide together with chitosan in the 
colonic region. Despite the difficulties to compare the results of these approaches, 
the specific characteristics of the nanosystems and the documented information 
about their efficacy lead us to the consideration of their special potential for oral 
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peptide administration. More detailed studies about their mechanism of action will 
help designing the way to proceed for their further optimization. 
 
Five-year view 
At present, there is the proof of concept that chitosan-based nanocarriers 
can enhance the absorption of model peptides such as insulin and salmon calcitonin 
in small scale animal models. It could be anticipated that these initial results will 
stimulate the optimization of oral peptide formulations based on chitosan delivery 
nanosystems. Further, this accumulated information is expected to lead to the 
evaluation of the efficacy of these nanosystems in large-scale animals in fed and 
fasting conditions. These results together with those of the efficacy of these 
nanosystems upon storage and also upon presentation in a solid dosage, will give 
very soon an indication of the potential of these nanosystems for clinical use. 
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Antecedentes 
 
1. La encapsulación de insulina en nanocápsulas constituidas por un 
núcleo oleoso y una cubierta polimérica permite mejorar la absorción 
sistémica de dicho péptido tras su administración por vía oral. Esta 
mejora se ha atribuido a la capacidad del núcleo oleoso para proteger la 
integridad del péptido en el tracto gastrointestinal1, 2. 
2. La utilización de sistemas coloidales que llevan en su composición el 
polisacárido quitosano ha permitido mejorar la absorción sistémica de 
fármacos peptídicos a través de la mucosa nasal e intestinal3, 4. 
                                                 
1 Lowe P.J., Temple C.S. Calcitonin and insulin in Isobutylcyanoacrylate nanocapsules: 
Protection against proteases and effect on intestinal absorption in rats. J. Pharm. Pharmacol. 
(1994) 46: 547-552. 
2 Damgé C., Michel C., Aprahamian M., Couvreur P., Devissaguet J.P. Nanocapsules as 
carriers for oral peptide delivery. J.Control. Release (1990) 13: 233-239. 
3 Fernández-Urrusuno R., Calvo P., Remuñán-López C., Vila-Jato J.L., Alonso M.J. 
Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharm. Res. (1999) 
16: 1576-1581. 
4 Kawashima Y., Yamamoto H., Takeuchi H., Kuno Y. Mucoadhesive DL-lactide/glycolide 
copolymer nanospheres coated with chitosan to improve oral delivery of elcatonin. Pharm. 
Dev. Technol. (2000) 5: 77-85. 
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3. La modificación de la superficie de los sistemas coloidales con PEG ha 
permitido mejorar la estabilidad de los vehículos en los fluidos 
biológicos5, 6 y la absorción sistémica de las proteínas asociadas a los 
mismos, tras su administración por vía nasal y oral 5, 7. 
 
Hipótesis 
 
1.  Nanocápsulas constituidas por un núcleo oleoso y una cubierta de 
quitosano, pueden proteger el fármaco encapsulado de su degradación en 
fluidos biológicos así como, mejorar la absorción del fármaco a través de 
la mucosa nasal e intestinal. 
2. La modificación de la cubierta polimérica mediante la peguilación del 
quitosano puede mejorar la estabilidad de los vehículos en los fluidos 
biológicos y, posiblemente, la absorción sistémica del péptido asociado. 
 
Objetivos 
 
Teniendo en cuenta lo previamente expuesto, el objetivo global del trabajo 
se ha dirigido a la evaluación del potencial que ofrecen las nanocápsulas de 
quitosano como sistemas para la administración de péptidos a través de la mucosa 
                                                 
5 Tobío M., Sánchez A., Vila A., Soriano I., Evora C., Vila-Jato J.L., Alonso M.J. The role of 
PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following 
oral administration. Colloids and Surfaces. (2000) 18: 315-323. 
6 Garcia-Fuentes M., Torres D., Alonso M.J. Design of lipid nanoparticles for the oral 
delivery of hydrophilic macromolecules. Colloids and Surfaces, B: Biointerfaces (2003) 27: 
159-168. 
7 Tobío M., Gref R,. Sánchez A., Langer R., Alonso M.J. Stealth PLA-PEG nanoparticles as 
protein carriers for nasal administration. Pharm. Res. (1998) 15: 270-275. 
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nasal e intestinal. A fin de facilitar el seguimiento de esta memoria, hemos 
desglosado este objetivo global en los siguientes objetivos parciales: 
 
Desarrollo y evaluación del comportamiento in vitro de nanocápsulas 
de quitosano para la administración de péptidos por vía nasal 
Este objetivo ha consistido en la optimización del proceso de preparación 
de las nanocápsulas de quitosano, evaluando la influencia de distintas variables 
tecnológicas sobre las características finales de los sistemas desarrollados. 
Asimismo, el objetivo se ha centrado en la incorporación de un péptido modelo, la 
calcitonina, a las nanocápsulas de quitosano para, posteriormente, explorar el 
potencial de dichos vehículos con el fin de mejorar la biodisponibilidad de la 
calcitonina por vía nasal. 
Los resultados del trabajo correspondiente a este objetivo se recogen el 
artículo 2 titulado: “Chitosan nanocapsules: a new carrier for nasal peptide 
delivery” (sometido a evaluación). 
 
Evaluación del potencial de las nanocápsulas de quitosano como 
sistemas para la administración oral de péptidos 
Este objetivo ha consistido en evaluar si las nanocápsulas de quitosano 
pueden o no favorecer la absorción sistémica de calcitonina administrada por vía 
oral. Para ello se analizó la influencia de distintas variables como son el tipo de sal 
de quitosano y su peso molecular. 
Los resultados correspondientes a este objetivo aparecen recogidos en los 
artículos titulados: 
“Transmucosal macromolecular drug delivery”; Journal of Controlled 
Release 101 (2005) 151–162. 
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“Chitosan nanocapsules as carriers for oral peptide delivery: Effect of 
chitosan molecular weight and type of salt on their in vitro behaviour and in vivo 
effectiveness” (sometido a evaluación). 
“Efficacy and mechanism of action of chitosan nanocapsules for oral 
peptide delivery” (sometido a evaluación). 
 
Evaluación del potencial de las nanocápsulas de quitosano-PEG como 
sistemas de administración de péptidos por vía oral 
El objetivo de esta etapa de trabajo ha sido el de evaluar si la peguilación 
del quitosano podría mejorar la estabilidad de las nanocápsulas en los fluidos 
gastrointestinales y, como consecuencia, su eficacia desde el punto de vista de 
mejorar la absorción intestinal de la calcitonina. Asimismo, se ha considerado como 
objetivo adicional la evaluación de la toxicidad y del mecanismo de interacción de 
las nanocápsulas de quitosano-PEG con la línea celular Caco-2. 
Los resultados del trabajo correspondiente a este objetivo se recogen el 
artículo 5 titulado: “Chitosan-PEG nanocapsules as new carriers for oral peptide 
delivery. Effect of chitosan pegylation degree” (sometido a evaluación). 
 
Estudio del mecanismo de interacción de las nanocápsulas de quitosano 
con células Caco-2 y con células goblet (HT29-M6) 
El objetivo de este estudio ha sido el de investigar el papel del 
recubrimiento con quitosano en la interacción con la línea celular Caco-2 y con el 
cocultivo Caco-2:HT29-M6. Para ello se analizó el efecto de las nanocápsulas en la 
viabilidad celular, en la modificación de las uniones intercelulares, así como, en la 
interacción de las nanocápsulas con las células. Finalmente, con la finalidad de 
conocer la influencia de la presencia de mucus en la interacción de los sistemas con 
las células, se evaluó el comportamiento de las nanocápsulas de quitosano en el 
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cocultivo Caco-2:HT29-M6, constituido por enterocitos (Caco-2) y células 
secretoras de mucus (HT29-M6). 
Los resultados correspondientes a este objetivo aparecen recogidos en los 
artículos ya mencionados: 
“Chitosan nanocapsules as carriers for oral peptide delivery: Effect of 
chitosan molecular weight and type of salt on their in vitro behaviour and in vivo 
effectiveness” (sometido a evaluación). 
“Efficacy and mechanism of action of chitosan nanocapsules for oral 
peptide delivery” (sometido a evaluación). 
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Abstract 
This work describes the preparation and characterization of chitosan (CS)-
coated oil nanodroplets (CS nanocapsules) as well as the evaluation of their potential 
for enhancing the nasal absorption of peptide drugs. For this purpose, salmon 
calcitonin (sCT) was chosen as the model peptide. CS nanocapsules were obtained 
by the solvent displacement technique which involves mixing an organic polar phase 
with and aqueous phase. The coating of the oily nanodroplets was feasible due to the 
interaction between negatively charged phospholipid, lecithin, and the positively 
charged CS, which allowed the stabilization of the system. For the formation of this 
coating, CS was added to the aqueous phase either before or after the mixing with 
the organic phase. In both cases, the influence of lecithin and CS concentration on 
the physicochemical properties of the nanocapsules was evaluated. CS nanocapsules 
displayed a mean particle size in the nanometer range, between 200 and 570 nm, 
depending on the formulation variables. The presence of the CS coating was noted 
by transmission electron microscopy and confirmed by the increase in size and the 
inversion in the zeta potential of the nanocapsules, as compared with the respective 
values observed for the uncoated nanoemulsions. The association efficiency of sCT 
to the nanocapsules was high and affected by the presence of the CS coating. The 
effectiveness of CS nanocapsules for nasal delivery of sCT was evaluated by 
measuring the plasma calcium levels in rats. The hypocalcemic effect observed 
following nasal administration of sCT-loaded CS nanocapsules was significantly 
enhanced and prolonged in comparison to that corresponding to the uncoated sCT-
loaded nanoemulsion or to the sCT aqueous solutions containing CS. Furthermore, 
the area above the hypocalcemic effect-time curve (AAC0-12h) obtained for CS 
nanocapsules and the control nanoemulsion was 2 and 1.3 times, respectively, higher 
than the one corresponding to the aqueous solution of sCT. Consequently, the results 
highlight the critical role of the CS coating in enhancing the transport of the 
associated peptide and, hence, the potential utility of CS nanocapsules for nasal 
peptide delivery. 
Keywords: Nasal administration, peptide delivery, nanocapsules, 
chitosan 
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Introduction 
Despite the advances made in the last decade, the use of a non-parenteral 
route is still, in most cases, a non viable or deficient option for peptide 
administration. The most important biopharmaceutical problems inherent to these 
macromolecules are their instability in the biological environment and their low 
permeability across biological barriers. Within this frame, most of the studies have 
been directed towards making the delivery of these macromolecules across mucosal 
surfaces feasible (1-4). Among these, the intranasal delivery is an attractive non-
invasive route which offers several unique advantages for peptide drugs, such as the 
ease of administration, the looseness of the epithelium and the avoidance of the 
hepatic first-pass metabolism. In fact, currently there are a few peptide formulations 
being administered by this route, such as buserelin, desmopresin, oxitocin, calcitonin 
and nafarelin. However, despite these promising results, we must admit that while 
the permeability of the nasal mucosa is acceptable for small molecules, 
unfortunately, it falls off sharply with the increase of the molecular weight of the 
drug (5). Indeed, the bioavailability of peptides such as salmon calcitonin (sCT) 
(3200 Da), has been reported to be very limited (only 1.6% with respect to the 
intramuscular administration) (6). 
Several strategies have been explored so far to enhance the absorption 
efficacy of peptides by the nasal route. A frequently chosen option has been the use 
of penetration enhancers (7, 8). However, a major limitation of the majority of the 
enhancers is related to their ability to induce morphological damage on the nasal 
mucosa and/or inhibition of the ciliary movement (9, 10). Among the penetration 
enhancers, a special case is represented by the polysaccharide chitosan (CS). Even 
though this polysaccharide may cause a reduction of the ciliary movement, when 
applied as a solution, it has been reported that the penetration enhancing effect of CS 
is reversible and, hence, does not compromise the integrity and functionality of 
epithelia (11, 12). In addition to this property, CS is known as a mucoadhesive 
material. The efficacy of this material in terms of increasing the nasal absorption of 
peptides has already been illustrated for insulin, salmon calcitonin, leuprolide, 
parathyroid hormone (12-14). 
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Another strategy for improving nasal peptide absorption has been based 
upon the use of colloidal systems such as liposomes, micelles, nanoemulsions and 
nanoparticles (15-18). The absorption enhancement ability of these nanosystems has 
been attributed to different mechanisms, which include (i) the facilitated interaction 
of the peptide-containing nanosystem with the mucosa (ii) the transport of the 
peptide-containing nanosystem across the nasal mucosa (iii) the enhancement of the 
mucosal permeability caused by some of components of the nanocarrier, i.e. lipids, 
CS. For example, we have shown that the presentation of CS in the form of 
nanoparticles leads to a significant enhancement in the nasal absorption of insulin 
(18). Moreover, we have recently reported that low molecular weight CS 
nanoparticles enhance the nasal transport of large proteins, such as tetanus toxoid, 
leading to enhanced and long-lasting immune responses (19). 
Here we present a new alternative nanocarrier for nasal peptide delivery, 
called CS nanocapsules, which could offer some potential advantages as compared 
to those previously reported. CS nanocapsules are composed of an oily core 
surrounded by a CS coating. The selection of the coating was justified by the 
positive behavior reported for CS solution which, in our understanding, could be 
reinforced by the presentation of the polymer in the form of a nanostructure. On the 
other hand, it was our hypothesis that the presence of an oily core could offer some 
beneficial effects in terms of stabilizing the associated peptide and enhancing its 
absorption (20, 21). Thus, the main objective of the present study was to develop 
and evaluate the potential of CS nanocapsules as a new colloidal system for nasal 
peptide delivery. sCT was selected as a model peptide in order to test the in vivo 
efficacy of the proposed system. 
 
 
 
 
 
Artículo 2: Chitosan nanocapsules: a new carrier… 73 
Materials and Methods 
Materials 
CS, in the form of hydrochloride salt (Protasan® Cl 110, Mw= 140 kDa, 
deacetylation degree: 86%) was purchased from Pronova Biopolymer, A.S., 
(Norway). 
Miglyol 812® (caprylic/capric triglycerides) was supplied by Lemmel 
(Spain). The surfactant soybean L-α-lecithin and poloxamer 188 (Pluronic F-68®) 
were provided by Sigma-Aldrich (Spain). Salmon calcitonin (sCT) was kindly 
donated by Almirall Prodesfarma, S.A. (Spain). 
 
Preparation of CS and sCT-loaded CS nanocapsules 
CS nanocapsules were prepared by the solvent displacement technique (22) 
as follows. A variable amount of lecithin (0.4, 0.8 and 1.2% w/v) and 0.125 ml of 
Miglyol 812® were dissolved in 10 ml of acetone. This organic phase was, then, 
poured under moderate agitation into 20 ml of an aqueous phase containing 
poloxamer 188 (0.25% w/v) and different amounts of CS (0, 0.1, 0.2 and 0.3%). The 
mixture turned milky immediately as a result of the formation of CS nanocapsules. 
Finally, the solvent was evaporated and the suspension concentrated to 10 ml under 
vacuum. Alternatively, CS was added to the external aqueous medium upon mixing 
the organic phase with the aqueous phase containing poloxamer 188 (0.25% w/v) 
followed by the solvent evaporation. 
The variables investigated in the development of CS nanocapsules were: 
lecithin concentration in the organic phase (0.4, 0.8 and 1.2% w/v), CS 
concentration in the aqueous phase (0, 0.1, 0.2 and 0.3% w/v) and the way of CS 
incorporation, either during the nanocapsules preparation step or by addition to the 
previously formed nanoemulsion followed by incubation for 1 hour at room 
temperature. The nanocapsules were isolated by ultracentrifugation at 120,000 xg 
for 1 hour. 
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The formulations variables investigated for the association of sCT to CS 
nanocapsules were: the concentration of lecithin (0.4 and 1.2% w/v) and the 
concentration of CS (0 and 0.1% w/v). 
 
Characterization of CS nanocapsules 
The particle size and polydispersion index of the nanocapsules were 
determined by photon correlation spectroscopy (PCS). Samples were diluted to the 
appropriate concentration with filtered ultrapure water. Each analysis was performed 
at 25ºC with an angle detection of 90º. The zeta potential was calculated from the 
mean electrophoretic mobility values, which were determined by laser Doppler 
anemometry (LDA). Samples were diluted with KCl 1mM and placed in the 
electrophoretic cell where a potential of ±150 mV was established. The PCS and 
LDA analysis were performed using a Zetasizer® 3000 HS (Malvern Instruments, 
Malvern, UK). Each batch was analyzed in triplicate. 
The morphological examination of CS nanocapsules and nanoemulsions 
was performed using a transmission electron microscopy (TEM), (Philips CM12, 
Eindhoven, Netherlands), following staining with a 2% w/v phosphotungstic acid 
solution.  
 
sCT encapsulation efficiency 
Due to the important affinity of sCT for the lipids, the attempts directed to 
extract or separate the encapsulated sCT from the nanocapsules and nanoemulsions 
were unsuccessful. Consequently, the encapsulation efficiency of sCT in the 
nanocapsules was calculated by the difference between the total amount of sCT used 
in the encapsulation process and the amount of free sCT that remained in the 
aqueous suspending medium. The amount of free sCT was determined in the 
supernatant following separation of nanocapsules from the aqueous medium by a 
combined ultrafiltration-centrifugation technique (Centricon YM-100, Millipore, 
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USA) at 1000 x g for 1h. The supernatant was diluted with pH=4 acetate buffer and 
assayed for sCT content by HPLC at 220 nm (Agilent Technologies, Germany) as 
described in the British Pharmacopoeia, 1998 (column: Vidac 218TP). A calibration 
curve was made with solutions of sCT in pH=4 acetate buffer at concentrations 
ranging from 5 to 100 μg/ml. Each sample was assayed in triplicate. 
 
In vitro release of sCT from CS nanocapsules 
In vitro release studies of sCT from CS nanocapsules and control 
nanoemulsions were performed by incubating the formulations in acetate buffer 
(pH= 4.0) in a shaking water bath at 37°C. At appropriate time intervals, individual 
samples were ultrafiltered at 1,000x g for 1 h. The amount of sCT released at each 
time point was determined by HPLC. 
 
Nasal administration of sCT-loaded CS nanocapsules 
Male Sprague-Dawley rats (225-275 g), from the Central Animals House of 
the University of Santiago de Compostela (Spain), were fasted for 12 h before 
experiments, but allowed water ad libitum. Animals were kept conscious during the 
experiments. These experiments were approved by the Ethical Committee of the 
University of Santiago de Compostela. The following formulations were instilled 
intranasally to rats by means of a micropipette inserted into the nostrils: (1) isolated 
sCT-loaded CS nanocapsules and (2) non-isolated sCT-loaded CS nanocapsules (3) 
sCT-loaded nanoemulsion, (4) sCT aqueous solution and (5) sCT aqueous solution 
containing CS. The dose of sCT administered was, in all cases, 15 UI/kg in a volume 
of 20 µl (10µl in each nostril). Blood samples were collected from the tail vein 30 
min prior to the nasal administration, in order to establish the baseline calcium 
levels, and at different times after dosing. The serum was separated by 
centrifugation at 3,000x g for 5 min. Hypocalcemic effects were determined in 
serum samples by a colorimetric method at 570 nm (Kit OR-cresolphtalein v/v, 
Spinreact, Spain). The area above the hypocalcemic effect-time curve (AAC0-12h) 
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was calculated by means of the trapezoidal method. Results are shown as the mean 
values of serum calcium levels (± s.e.) of 6 animals. 
 
Statistical analysis 
Particle size and zeta potential were statistically analyzed by the analysis of 
variance (ANOVA) combined with a lineal regression using the program SPSS 11.5. 
Differences were considered to be significant at a level of p <0.01. 
The mean serum calcium levels determined in samples collected before 
sCT administration were taken as the baseline levels. Using these values, the 
statistical comparison of the percentages of calcium reduction at each time was 
performed by the ANOVA test followed by the Student-Newman-Keuls test for 
multiple comparisons between treatments. Differences were considered to be 
significant at a level of p <0.05. 
 
Results and discussion 
The main goal of the present work was to investigate some formulation 
factors involved in the preparation of CS-coated oily nanodroplets and to evaluate 
their potential for the association and delivery of peptides following nasal 
administration. With this purpose in mind, sCT was selected as a model peptide. The 
rational behind this work was that the combination of an oily core with a CS coating, 
in the form of a colloidal system, would help protect the associated peptide from 
degradation while favoring its interaction with the nasal mucosa. 
 
Development and characterization of CS nanocapsules 
The supporting hypothesis for the preparation of CS nanocapsules was that 
the ultradispersion of a lipid solution in a CS aqueous solution would facilitate the 
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ionic interaction between the negatively charged lipids and the positively charged 
CS molecules. This hypothesis was verified a number of years ago (22). In the 
present work, we aimed to elucidate the factors that were determinant in the 
formation of these CS nanocapsules. Hence, the variables evaluated were: the 
concentration of lecithin in the organic phase, the concentration of CS in the 
aqueous phase and the way CS was incorporated into the aqueous phase, either 
before or after mixing the organic and the aqueous phase. The analysis of the 
particle size by PCS indicated that all formulations displayed a size in the nanometer 
range, between 200 and 570 nm, depending on the values of the variables selected 
(Figure 1 and 2). In addition, the results indicated that, irrespective of the way CS 
was incorporated, both lecithin and CS concentration had a statistically significant 
influence on the particle size, the presence of CS being the main factor affecting the 
particle size. More specifically, figure 1 depicts the surface response showing the 
simultaneous influence of the variables selected on the size of CS nanocapsules 
formed by incorporating CS prior to the oil-in-water mixing process. It can be noted 
that the addition of a small amount of CS to the external aqueous phase (0.1-0.2%) 
did not significantly change the size of the oily droplets, however, a further increase 
in the CS concentration (0.3%), led to a significant enlargement in the particle size 
(from 200 to 570 nm). On the other hand, in figure 1 it can also be noted that the 
influence of the lecithin concentration was determined by the CS concentration. 
Concretely, for the lowest CS concentration, an increase in the lecithin concentration 
did not lead to a significant change in the particle size. However, for the upper limit 
of the CS concentration, the particle size decreased significantly when the lecithin 
concentration increased. This size decrease was attributed to the presence of a 
population of CS-lecithin nanocomplexes that accompanied the formation of the 
nanocapsules. In order to corroborate this hypothesis, these high lecithin-content 
formulations were ultracentrifuged at 120,000 x g for 1 hour. The result of this 
process was a three-phase system consisting of a foam caused by the association of 
nanocapsules, a precipitate attributed to the formation of complexes between lecithin 
and CS and the aqueous suspending medium. In contrast, for the low lecithin content 
formulations only a-two phase system consisting of a foam and aqueous suspending 
medium was observed. Consequently, these results indicate that there is a critical 
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value for the parameters investigated, lecithin and CS concentration, in order to 
obtain a unique population of CS nanocapsules. 
 
Figure 1: Response surface showing the effect of lecithin and CS concentrations on 
the particle size of CS nanocapsules obtained by adding CS to the external aqueous 
medium prior to the mixing with the organic solution of the lipids. 
Mean particle size = 211.231 + 181.462 X1 – 1426.453 X2 + 9581.111 X2
2 – 
1269.295 X1X2; r = 0.966. 
X1 = Lecithin concentration in the organic phase. 
X2 = CS concentration in the aqueous phase. 
 
Figure 2 shows the influence of the concentration of both CS and lecithin, 
on the size of CS nanocapsules formed by incorporating CS after the dispersion of 
the lipids in the aqueous medium. The size of the nanosystems was affected by the 
variables investigated, CS and lecithin concentration, although to a different extent. 
As observed in the previous method, the increase in the CS concentration led to a 
significant enlargement in the particle size. In both cases, this effect, which was 
slightly affected by the concentration of lecithin, was attributed to the deposition of 
increasing amounts of CS around the oily nanodroplets. In fact, as shown in figure 3, 
the size enlargement occurred simultaneously with a progressive inversion in the 
zeta potential. A similar effect was previously observed when increasing either the 
amount of CS or its molecular weight (22, 23). In contrast, the lecithin concentration 
had an opposite effect on the size as compared to that observed in the previous 
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method: for the highest CS concentration, the size became larger as the lecithin 
concentration increased. This could be simply attributed to a more important 
deposition of CS onto the lipid cores. However, as occurred with the previous 
method, the presence of lecithin-CS complexes was detected upon 
ultracentrifugation of the formulations prepared with the highest lecithin 
concentration. Consequently, the increase in the size could be attributed not only to 
the more important deposition of CS but also probably to some lecithin-CS 
complexes attached to the nanoemulsion during the incubation step. 
 
Figure 2: Response surface showing the effect of lecithin and CS concentration on 
the particle size of CS nanocapsules prepared by adding CS to the external aqueous 
medium after the formation of the submicron emulsion. 
Mean particle size = 122.624 + 173.027 X1 + 217.725 X2 – 60.299 X12 + 420.139 
X22 + 5.163 X1 X2; r = 0.994. 
X1 = Lecithin concentration in the organic phase. 
X2 = CS concentration in the aqueous phase. 
 
Finally, irrespective of the moment of addition of CS, the particle size 
distributions were close to a monomodal distribution for the lowest CS 
concentration (polydispersion index < 0.2), however for higher CS concentration 
values, a less homogeneous population was obtained, as confirmed by the 
polydispersion index values which evolved to a value of 0.4. The increase in the 
polydispersion index could also be related to the presence of different populations 
corresponding to the nanocapsules and the nanocomplexes. 
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The appearance of CS nanocapsules and the corresponding control 
nanoemulsion is presented in figure 3. In the case of the nanoemulsion, we could 
only appreciate a spherical morphology. However, for CS nanocapsules we 
visualised the presence of an oily core surrounded by a CS coating, regardless the 
concentration of lecithin. 
A B C
 
Figure 3: Transmission electron micrographs of: (A) uncoated nanoemulsion, (B) 
CS nanocapsules prepared with 0.4% w/v of lecithin and (C) CS nanocapsules 
prepared with 1.2% w/v of lecithin. 
 
In addition to the results of the particle size analysis, the evidence of the CS 
coating around the oily nanodroplets was corroborated by the measurement of the 
zeta potential of the nanocapsules. As shown in figure 4, the uncoated 
nanoemulsions (0% CS) exhibited a high negative charge that was inverted upon 
coating with CS. Moreover, it can be noted that the concentration of CS was the 
most relevant factor on the evolution of the surface charge of the nanocapsules. This 
inversion from highly negatives values (about -60 mV) to highly positive values 
(about +50 mV) was certainly due to the presence of the cationic polymer on the 
surface of the nanodroplets. On the other hand, the lecithin concentration did not 
have a significant effect on the surface charge. As observed in a previous study (22), 
a minimum amount of lecithin is enough to facilitate the formation of the CS 
coating, and thus to confer the nanocapsules with a positive charge. After the 
inversion of the charge, neither the lecithin concentration, nor the CS concentration 
produced significant changes on the surface charge. 
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Figure 4: Response surface showing the effect of lecithin and CS concentration on 
the zeta potential of CS nanocapsules prepared by adding CS to the external aqueous 
medium after the formation of the submicron emulsion. 
ζ Potential = -54.340 + 923.767 X2 – 1981.667 X22; r = 0.977. 
X2 = Chitosan concentration in the aqueous phase. 
 
Characterization of sCT-loaded CS nanocapsules  
An important goal of this work was to associate the peptide sCT to CS 
nanocapsules. To achieve this goal the peptide was dissolved in 50 µl of water and 
then added to the organic phase containing the lipids. Using this approach, it was 
thought that the interaction between the peptide and the lipids would be facilitated 
due to the positive charge of sCT at the selected pH (pKa= 10.4). As describe in the 
Materials and Methods section, these peptide-loaded formulations were prepared by 
the method involving the addition of CS upon mixture of the oily and water phases. 
The results presented in table 1 indicate that more than 90% of sCT was 
associated to the control nanoemulsion, regardless of the lecithin concentration. The 
reason for this high association could be related to the strong electrostatic interaction 
between the negatively charged lecithin and the positively charged sCT, as 
previously described for other lipid systems containing sCT (24, 25). Moreover, sCT 
has some hydrophobic regions in their structure enabling them to interact with 
lipidic structures by means of some specific interactions (26). On the other hand, as 
can be noted in table 1 that the association of sCT to the nanocapsules was reduced 
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by the presence of CS and that this reduction was affected by the lecithin 
concentration (values of encapsulation efficiency between 44 and 52%). This effect 
was ascribed to the positive character of both sCT and CS, which may be a result of 
a competition between the polymer and the peptide for the anionic binding sites in 
the oily core. Theoretically, this displacement effect should affect the sCT molecules 
which are associated to the surface of the oily droplets, since the attachment of CS 
occurred upon encapsulation of sCT in the lipid droplets. In order to verify the 
displacement of sCT molecules due to the presence of CS, some control experiments 
were performed. The experiment involved the incubation sCT-loaded nanoemulsions 
in the presence of a cation (0.1% w/v calcium chloride) and the evaluation of the 
sCT displacement. The results indicated that, as in the case of CS, calcium competed 
with sCT leading to its displacement from the surface of the oily nanodroplets. An 
additional control experiment consisted of incubating an uncoated nanoemulsion 
with sCT and subsequently with CS (0.1% w/v). The results showed that sCT was 
greatly adsorbed onto the nanoemulsion and further displaced following incubation 
with CS. Therefore, overall these results indicate that the surface association of the 
cationic peptide is reduced upon coating of the system with CS. These results agree 
well with those previously reported by Kawashima et al. (27) who observed that the 
coating of PLGA nanospheres with CS reduced the elcatonin encapsulation. 
Nevertheless, despite the above mentioned displacement effect, it must be noted that 
the association efficiency of sCT to the nanocapsules remains sufficiently important.  
 
Table 1: Physicochemical properties and encapsulation efficiency of chitosan 
nanocapsules and uncoated nanoemulsions containing sCT (mean ± s.d.; n=3). 
 
% Lecithin 
(w/v) 
% Chitosan 
(w/v) 
Particle Size 
(nm) 
ζ Potential 
(mV) 
Encapsulation 
efficiency (%) 
0 193.3±1.2 -52.0±1.1 > 90 
0.4 
0.1 224.7±0.6 +20.2±0.4 44.1±3.2 
0 243.7±2.1 -59.9±2.0 > 90 
1.2 
0.1 333.0±6.1 +28.3±2.1 51.9±1.9 
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With regard to the physicochemical properties (size and zeta potential) of 
the sCT-loaded systems, the results in table 1 show that, as expected, the coating 
with CS increased the particle size of the oily nanodroplets and led to an inversion of 
the surface charge. These changes were more pronounced for the highest lecithin 
concentration. 
 
In vitro release of sCT from CS nanocapsules 
Figure 5 displays the release profiles of sCT from CS nanocapsules 
prepared with different lecithin concentration (0.4 and 1.2% w/v). These profiles 
indicate that a certain amount of sCT was rapidly released in the first 30 minutes and 
then, no further release was observed in the 6 hours of the study. The initial release 
was attributed to the surface-associated peptide whereas the second slow phase 
would correspond to the release of the well entrapped peptide molecules showing a 
high affinity for the oily core. Interestingly, the initial burst effect observed for CS 
nanocapsules was higher for those prepared with 1.2% lecithin compared to those 
prepared with 0.4% lecithin (15% vs 50%). This difference may be related to the 
presence of complexes lecithin-CS in those prepared with the highest concentration 
of lecithin. Indeed, some sCT molecules could be associated to these complexes and 
be rapidly released upon incubation in the release medium. In contrast, the release of 
sCT from lecithin nanoemulsions was negligible irrespective of the lecithin 
concentration, probably due to the peptide binding affinity to the lipid. Similarly, the 
leakage of calcitonin from positively liposomes was greater than for negative or 
neutral ones, suggesting that the charge repulsion played an important role in the 
leakage of calcitonin from positive liposomes (24). 
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Figure 5: In vitro release profiles of sCT from CS nanocapsules prepared with 
different lecithin concentrations, 0.4% w/v (♦) and 1.2% w/v (■) (mean ± s.d.; n=3). 
 
Nasal administration of sCT-loaded CS nanocapsules 
The reduction in the serum calcium levels obtained after intranasal 
administration to rats of sCT included in CS nanocapsules (0.4% w/v lecithin), as 
well as in the uncoated nanoemulsion, and in an aqueous solution (with or without 
CS) are shown in figure 6. The results show that the hypocalcemic effect observed 
after administration of the colloidal systems, (uncoated nanoemulsion and CS 
nanocapsules) was significantly greater than that obtained with the sCT aqueous 
solutions containing CS or not. In fact, the presence of CS in the sCT solution with a 
similar amount to that incorporated in the nanocapsules did not have any effect on 
the response of sCT. The significant decrease in the calcium levels observed for the 
uncoated nanoemulsion might be related to the lipids stabilizing and/or absorption-
enhancing effects. Indeed, Mitra et al. 2000 (17) reported that the insulin absorption 
could be enhanced by its incorporation into an o/w emulsion. They found that the 
presence of a small fraction of oil droplets along with the peptide in the aqueous 
phase appeared to play an important role in the nasal absorption enhancement 
mechanism. Similarly, this potential absorption promoting effect of the lipid 
vehicles has been extensively studied by Muranishi (21). On the other hand, it has 
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also been shown that lipids are able to protect peptide drugs from protease 
degradation, especially upon contact with gastrointestinal fluids (20, 28). 
Nevertheless, besides the possible absorption-enhancing and/or protective 
effects of the nanoemulsion, the results of the present study clearly show that the 
coating of the oily nanodroplets with CS markedly improved the hypocalcemic 
effect of sCT. Consequently, these results confirm the importance of the CS coating 
at promoting the interaction of the colloidal system with the nasal mucosa, thus 
leading to a further enhancement of the sCT transport. This interpretation agrees 
well with the results reported for other CS-based nanocarriers (18, 19, 24). Indeed, 
CS nanoparticles have been shown to increase the nasal absorption of insulin and 
also the immune response of tetanus toxoid administered intranasally (18, 19). 
Similarly, CS-coated liposomes have displayed a capacity of enhancing the 
absorption of salmon calcitonin (24). 
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Figure 6: Serum calcium levels in rats after nasal administration of sCT (dose: 15 
UI/kg) in aqueous solution (with or without CS) or encapsulated in the control 
nanoemulsion (NE) or in non- isolated CS nanocapsules (CS NC); (mean ± s.e.; 
n=6).  
* Significantly different from sCT solutions (p< 0.05). 
# Significantly different from nanoemulsion (p< 0.05). 
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An additional observation from figure 6 is the lack of effect observed for 
CS solutions. Even though this observation could be considered in disagreement 
with the previously observed positive effect of CS in the nasal absorption of insulin 
and salmon calcitonin (12, 13), it does correlate well with the negligible effect that 
we have previously observed for the CS solutions containing insulin (18). These 
differences in the efficacy of CS solutions could be related to the different 
experimental conditions of the different reports (different animal model and 
different CS dose) but they could also be related to the different molecular weight of 
the polymer used in the various experiments. 
Interestingly, a similar decrease in the serum calcium levels was observed 
following administration of both types of nanocapsules, isolated or not (Figure 7). 
The differences between both types of administrations are related to the presence of 
free sCT, free CS, and Poloxamer 188. Consequently, the similarity of the behaviour 
could be attributed to the crucial role of the CS nanocapsules at facilitating the 
absorption of the free peptide. 
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Figure 7: Serum calcium levels in rats after nasal administration of sCT (dose: 15 
UI/kg) encapsulated in isolated or in non-isolated CS nanocapsules (CS NC) and 
sCT in CS aqueous solution; (mean ± s.e.; n=6) 
* Significantly different from sCT solution (p< 0.05). 
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Finally, the comparison of areas above the hypocalcemic effect curve (AAC 
0-12h) obtained following administration of the different formulations (Figure 8) 
confirms the significantly greater pharmacological effect elicited by CS 
nanocapsules in comparison to those corresponding to the sCT solution containing 
CS or not and the uncoated nanoemulsion. In fact, the AAC 0-12h of the serum 
calcium levels-time curve after nasal administration of CS nanocapsules (isolated or 
not) was significantly higher than that of sCT control solution with or without CS. 
Additionally, this hypocalcemic effect was maintained within 12 hours post-
administration. In the case of CS nanocapsules, the AAC 0-12h was increased by 
about 1.5, 1.7 and 2 fold when compared with the uncoated nanoemulsion, the CS 
solution containing sCT and the sCT aqueous solution, respectively. Overall, these 
results highlight the crucial role of the combination of CS and lipids in the form of a 
nanocarrier in terms of improving the nasal absorption of sCT. 
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Figure 8: Area above hypocalcemic effect curve (AAC 0-12 hr) after nasal 
administration to rats of sCT (dose: 15 UI/kg) incorporated in different 
formulations: aqueous solution (sol sCT), CS aqueous solution (sol sCT+ CS), 
uncoated nanoemulsion (NE) and isolated and non- isolated CS nanocapsules (CS 
NC). 
* Significantly different from sCT solutions and uncoated nanoemulsion (p < 0.05). 
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Conclusions 
CS nanocapsules consisting of a hydrophobic core (oily nanodroplets) and a 
hydrophilic coating have shown an excellent capacity for enhancing the absorption 
of sCT across the nasal mucosa. This was confirmed by the significant and 
prolonged reduction in the serum calcium levels which was obtained with these 
nanocarriers compared to the sCT control solutions or uncoated nanoemulsion. 
Therefore, this innovative system could be considered as a promising carrier for 
improving the nasal absorption of peptide drugs, such as sCT. 
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Abstract 
Mucosal surfaces are the most common and convenient routes for 
delivering drugs to the body. However, macromolecular drugs such as peptides and 
proteins are unable to overcome the mucosal barriers and/or are degraded before 
reaching the blood stream. Among the approaches explored so far in order to 
optimize the transport of these macromolecules across mucosal barriers, the use of 
nanoparticulate carriers represents a challenging but promising strategy. The present 
paper aims to compare the characteristics and potential of nanostructures based on 
the mucoadhesive polysaccharide chitosan (CS). These are CS nanoparticles, CS-
coated oil nanodroplets (nanocapsules) and CS-coated lipid nanoparticles. The 
characteristics and behaviour of CS nanoparticles and CS-coated lipid nanoparticles 
already reported [A. Vila, A. Sanchez, M. Tobio, P. Calvo, M.J. Alonso, Design of 
biodegradable particles for protein delivery, J. Control. Release 78 (2002) 15–24; R. 
Fernandez-Urrusuno, P. Calvo, C. Remuñan-Lopez, J.L. Vila-Jato, M.J. Alonso, 
Enhancement of nasal absorption of insulin using chitosan nanoparticles, Pharm. 
Res. 16 (1999) 1576–1581; M. Garcia-Fuentes, D. Torres, M.J. Alonso, New 
surface-modified lipid nanoparticles as delivery vehicles for salmon calcitonin 
(submitted for publication).] are compared with those of CS nanocapsules originally 
reported here. The three types of systems have a size in the nanometer range and a 
positive zeta potential that was attributed to the presence of CS on their surface. 
They showed an important capacity for the association of peptides such as insulin, 
salmon calcitonin and proteins, such as tetanus toxoid. Their mechanism of 
interaction with epithelia was investigated using the Caco-2 model cell line. The 
results showed that CS-coated systems caused a concentration-dependent reduction 
in the transepithelial resistance of the cell monolayer. Moreover, within the range of 
concentrations investigated, these systems were internalized in the monolayer in a 
concentration-dependent manner. This uptake was slightly enhanced by the presence 
of the CS coating but, as compared with previously published results [M. Garcia-
Fuentes, C. Prego, D. Torres, M.J. Alonso, Triglyceride-chitosan nanostructures for 
oral calcitonin delivery: evaluation in the Caco-2 cell model and in vivo (submitted 
for publication)], highly dependent on the nature of the lipid core. Nevertheless, 
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these differences in the uptake of the CS-coated systems (solid lipid core or oily 
core) by the Caco-2 cells did not have a consequence in the in vivo behaviour. 
Indeed, both CS-coated systems (nanocapsules and CS-coated nanoparticles) 
showed an important capacity to enhance the intestinal absorption of the model 
peptide, salmon calcitonin, as shown by the important and long-lasting decrease in 
the calcemia levels observed in rats. 
 
Keywords: chitosan; nanoparticles; nanocapsules; transmucosal 
transport; peptide/protein carriers. 
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Introduction 
Over the last decades significant efforts have been dedicated to explore new 
routes, alternative to injection, for the administration of macromolecules such as 
peptides and proteins. Among them, the transmucosal routes such as the nasal, 
pulmonary and oral routes, are those which have received the most important deal of 
attention [1–5]. As a consequence of this activity, the pulmonary administration of 
the peptide insulin has recently become a reality in clinical practice [5]. In addition, 
the number of peptides that are being administered intranasally increases year by 
year. However, the possibility to administer large macromolecules by the oral route 
needs still further investigations. The harsh conditions of the gastrointestinal tract 
and the limited permeability of the intestinal barrier make the situation very 
complex, and the solution to these problems a great challenge [6]. Nevertheless, 
despite the past pessimistic view, the knowledge accumulated during recent years 
regarding the mechanisms of interaction between nanostructured biomaterials and 
biological surfaces, as well as the discovery of new nanotechnologies and 
characterization approaches, has led to a new promising perspective on the use of 
nanocarriers for transmucosal macromolecular drug delivery [7–9]. The hypothesis 
behind this strategy has been that nanosystems, due to their colloidal size, are able to 
cross and, hence, transport the associated drug through the mucosal barrier, thus 
acting as transmucosal macromolecular nanocarriers. Indeed, at present, there is no 
doubt on the fact that the size is a critical parameter for the nanosystems to cross 
biological barriers [10,11]. However, the question that remains to be answered is 
how the ability of these systems to overcome these barriers can be optimized. 
By accepting the premise that not only the size but also the surface 
properties and composition of the nanocarriers may affect their stability in biological 
fluids and their interaction with mucosal surfaces, we have focused our activity to 
the design of new types of nanocarriers especially adapted for transmucosal drug 
delivery [12–16]. The first relevant conclusion from this work was that a hydrophilic 
polyethylene glycol (PEG) coating around the nanosystem has a very positive effect 
on its in vivo success as a macromolecular drug carrier. More specifically, using 
tetanus toxoid as a model of a large protein, we showed that its transport across the 
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nasal and intestinal barriers was greatly improved following its nanoencapsulation 
into PEG-coated poly(lactic acid) (PLA) nanoparticles [12,13]. More importantly, 
we observed that the positive behaviour of the nanoparticles was mainly due to the 
presence of a PEG coating around them. The efficacy of these PEG-coated 
nanoparticles as nasal protein and DNA carriers was further corroborated by 
studying the immune response generated by the nanoencapsulated protein and 
plasmid DNA [14–16]. The positive effect of the hydrophilic coating around the 
nanosystems was not exclusive of PEG. In fact, another early discovery from our 
work was that a coating consisting of the hydrophilic polysaccharide CS 
significantly improved the ability of polyester nanocapsules to transport drugs across 
the corneal epithelium [17]. More recently, we have compared the effect of a CS vs. 
a PEG coating on the transport of these nanocapsules across the corneal epithelium 
[18]. While the mechanistic details need to be further investigated, the results 
indicated that both types of coatings affected significantly the interaction of these 
nanosystems with the ocular mucosa. Therefore, despite the different nature of the 
two hydrophilic coatings, PEG and CS, these initial studies led us to the overall 
conclusion that an adequate selection of the biomaterials and a specialized design of 
the nanosystems are required in order to optimize the capacity of nanocarriers to 
transport drugs across mucosal surfaces. 
The purpose of the present report was to compare the characteristics and 
potential of different nanostructures having as a common material the Mucoadhesive 
polysaccharide CS. These nanosystems are CS nanoparticles, CS-coated oil 
nanodroplets (nanocapsules) and CS-coated lipid nanoparticles. By comparing these 
systems, the idea was to evaluate the role of the CS alone or in combination with 
lipids, and also the importance of the structural organization of these materials, in 
their behaviour as transmucosal drug carriers. 
The selection of CS was based on its excellent properties including 
biocompatibility, mucoadhesion [19] and ability to reversibly alter the tight 
junctions [20]. On the other hand, for the selection of the lipid cores we have taken 
into account the promising results obtained for solid lipid nanoparticles [21] as well 
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as for oily polyisobutylcyanoacrylates nanocapsules with regard to their use as 
transmucosal drug carriers [22]. 
 
Materials and methods 
Chemicals and animals 
The materials and methods used for the preparation and evaluation of CS 
nanoparticles have been described in Refs. [14,23]. Similarly, the materials and 
methods used for the preparation and evaluation of CS-coated lipid nanoparticles 
have been described in Refs. [24–26]. The chemicals and animals used for the 
preparation and evaluation of the CS-coated oil nanodroplets are reported below. 
CS with 85% degree of deacetylation and a viscosity of 16 mPa was 
purchased from FMC Biopolymer/ Novamatrix, (Norway). Miglyol 812®, a 
triglyceride formed from medium chain fatty acids was supplied by Lemmel (Spain). 
The surfactant soybean l-α-lecithin and Poloxamer 188 (Pluronic F- 64®) were 
supplied from Sigma-Aldrich (Spain). Salmon calcitonin (sCT) was kindly donated 
by Almirall Prodesfarma (Spain). Rhodamine was purchased from Sigma (Spain). 
The Caco-2 cell line was obtained from the European Collection of Cell 
Cultures (ECACC, UK). Minimum Eagle Medium (MEM), fetal bovine serum 
(FBS), non-essential amino acids, l-glutamine, 100 UI/ml Penicillin/100 μg/ml 
Streptomycin solution, 0.05% Trypsin/0.02% EDTA solution, Dulbecco’s phosphate 
buffered saline (DPBS) and Hank’s basal salt solution (HBSS) were purchased from 
Sigma (Spain). 
Male Sprague–Dawley rats (225–275 g), from the Central Animals House 
of the University of Santiago de Compostela (Spain) were used. They were kept in a 
12-h light–dark cycle and at a temperature of 20±2ºC. The animals were allowed 
access to food and water ad libitum. 
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Preparation of CS nanocapsules 
CS-coated oily nanodroplets (here called CS nanocapsules) were prepared 
according to the procedure previously described by our group, in two steps. More 
specifically, firstly, we prepared a nanoemulsion using a solvent displacement 
technique [27]. For this purpose, 125 μl of Miglyol 812 were added to an organic 
phase composed of 40 mg of lecithin dissolved in 0.5 ml of ethanol and 9.5 ml of 
acetone. This organic phase was added to an aqueous phase containing Poloxamer 
188 (0.25% w/v). The mixture immediately turned milky due to the formation of the 
nanoemulsion. Then, the solvents were evaporated under vacuum. Secondly, this 
nanoemulsion was coated with CS by simple incubation in the polymer solution 
[28,29]. More specifically, 5 ml of the control nanoemulsion were incubated with 1 
ml of CS aqueous solution (0.5% w/v) for 1 h, leading to the formation of CS 
nanocapsules.  
 
Physicochemical characterization of CS-coated systems 
The different colloidal carriers were characterized with regard to 
morphology, particle size, zeta potential and encapsulation efficiency. The 
association efficiency of sCT to the nanosystems was calculated from the 
concentration of the non-encapsulated peptide. The separation of the nanocapsules 
from the non-encapsulated peptide was performed by ultrafiltration (Centricom® 
YM-100, Millipore, Spain) for CS nanocapsules. The concentration of sCT was 
determined by HPLC as described (BP 1998). 
 
Cell culture experiments 
Caco-2 cells were cultivated in 80 cm2 flasks (Nunc, Denmark) using MEM 
supplemented with 10% FBS, 1% l-glutamine, 1% nonessential amino acids and 
Penicillin/Streptomycin solution. Cells were maintained in a controlled atmosphere 
at 37ºC with 95% of relative humidity and 5% CO2. The culture medium was 
Artículo 3: Transmucosal macromolecular drug… 103 
changed every two days for approximately 5–6 days until cells reached 
approximately 80–90% confluency. After the passage operation, cells were seeded 
approximately at 2.5x105 cells per flask. For the experiments, cells with passage 
numbers between 30 and 35 were used. 
 
Cytotoxicity studies 
The effect of the different nanosystems on their in vitro biocompatibility 
was investigated at different concentrations using Caco-2 cell cultures. Cells were 
seeded on 96 well plates with a cell density of 104 cells/cm2 for 7 days until cell 
monolayer was obtained. After 7 days, the medium was replaced by the nanocapsule 
suspensions at concentrations between 0.01 and 2 mg/ml in an appropriate volume 
to obtain a density of nanocapsules between 6 and 1212 μg/cm2. As a positive 
control we used HBSS and as a negative control 2% sodium dodecyl sulphate 
(SDS). Nanocapsules and the controls were in contact with the monolayers for 90 
min, at 37ºC and 5% CO2. After this time, the nanocapsule suspensions were 
removed. The cell viability was determined using a colorimetric method (MTS, 
Promega), which determines the intracellular dehydrogenase activity. The 
absorbance was measured at 490 nm. 
 
Measurement of the transepithelial electrical resistance 
The measurement of the transepithelial electrical resistance (TEER) was 
performed on Transwell® plates with a cell density of 5.5x104 cells 21 days post-
seeding. The integrity of the monolayers was checked on the 21st day in MEM. The 
TEER measurements were performed with a Millicell®ERS connected to a pair of 
chopstick electrodes (Millipore, Spain). After these measurements, the medium was 
changed by HBSS (HBSS pH 6 in the apical side in the case of CS nanocapsules) in 
order to perform the experiments in buffer. After 1 hour of equilibrium, the apical 
solutions were replaced by the nanocapsule suspensions and the respective controls 
(HBSS or HBSS pH 6). The concentration of nanocapsules was 250 μg/ml in two 
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different cell growing areas, 1.1 and 4.5 cm2 leading to a nanocapsule dose of 204.5 
and 80 μg/cm2, respectively. Nanocapsule suspensions were incubated for 100 min 
and TEER measurements were performed every 25 min. After this time, the 
solutions were removed and replaced by MEM in order to check the recuperation of 
the TEER values at 24 h. 
 
Quantitative uptake studies 
Caco-2 cells were seeded with a density of 5.5x104 cells/cm2 on 12-well 
plates with an area of 3.5 cm2 and left to grow until full differentiation (19–21 days). 
The culture medium was replaced by rhodamine-loaded nanostructures in HBSS (or 
HBSS pH 6) at concentrations of 0, 250, 500 and 1000 μg/ ml (the corresponding 
dose per surface area values were: 0, 71.43, 142.86 and 286.71 μg/cm2, 
respectively). The suspensions were incubated for 1 h. After incubation, the 
nanocapsule suspensions were removed and the monolayers washed five times with 
ice-cold DPBS. Monolayers were finally incubated for 15 min with 5 mM EDTA in 
DPBS adjusted to pH=5 (“acid wash”), a medium intended to detach the 
nanocapsules associated to the monolayer surface. Caco-2 monolayers were dried 
overnight and dissolved in a 2% SDS/50 mM EDTA/ DPBS at pH=6 (“lysis 
medium”). The nanocapsules-associated fluorescence internalized by the 
monolayers was quantified by fluorimetry. The calculation of the amount of 
fluorescent carriers taken up by the cells was performed using the corresponding 
calibration curves (different concentrations of fluorescence nanocapsules incubated 
in the lysis medium). The fluorescence of monolayers without nanocapsules (0 
mg/ml samples) in lysis medium was substracted from the experimental values.  
 
In vivo studies 
Male Sprague–Dawley rats (225–275 g) were fasted for 12 h before 
experiments, but allowed water ad libitum. Animals were kept conscious during the 
experiments. 
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The following formulations were administered intragastrically to rats: (1) 
sCT aqueous solution, (2) nanoemulsion, and (3) CS nanocapsules. The dose at sCT 
administered was 500 IU/kg in a volume of 0.5 ml. Blood samples were collected 
from the tail vein 30 min prior to the oral administration to establish the baseline 
calcium levels and at different times after dosing. The serum was separated by 
centrifugation at 3000xg for 5 min. Hypocalcemic effects were determined in serum 
samples by a colorimetric method at 570 nm (Kit OR-cresolphtalein v/v, Spinreact, 
Spain). 
 
Statistical analysis  
The statistical significance of the differences between parameters of the 
oily-based nanosystems was tested by the analysis of variance (ANOVA) together 
with the multiple comparison Student–Newman– Keuls method. 
The mean serum calcium levels determined in samples collected before 
sCT administration was taken as the baseline levels. Using these values, the 
statistical comparison of the percentage of calcium reduction at each time after 
dosing was performed by the one-way analysis of variance (ANOVA) followed by 
the Student–Newman–Keuls test for multiple comparisons between treatments. 
Differences were considered to be significant at a level of p<0.05. 
 
Results and discussion 
The main goal of the present report was to provide an overview of the 
potential of different nanosystems consisting of solely CS or CS in combination with 
solid and liquid lipids as carriers for the transmucosal (nasal and oral) transport of 
macromolecules. The common feature of these nanosystems is the presence of CS in 
their composition. As illustrated in Fig. 1, the key differences between these systems 
are the following: (i) CS is in the form of solid nanoparticles (nanogel network) or as 
a soluble coating around lipid cores, (ii) the lipid core of the CS-coated systems is 
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either an oil (Miglyol® 812) or a solid lipid (tripalmitin). Here, we describe the 
physicochemical properties of these systems (size and zeta potential) as well as their 
ability to associate and release macromolecules. In addition, we provide information 
about the in vitro viability of Caco-2 cells exposed to CS nanocapsules and about 
their mechanism of interaction with this cell model and compared with that reported 
for CS-coated lipid nanoparticles and CS nanoparticles. Finally, we present the 
efficacy of the CS-based systems as transmucosal macromolecular drug carriers.  
ChitosanChitosan corona
Oil core
Chitosan corona
Solid lipid core
Chitosan 
Nanocapsules
Chitosan-coated
Lipid Nanoparticles
Chitosan 
Nanoparticles  
Figure 1: Illustration of the different chitosan-based nanosystems described in the 
present report. 
 
Preparation and physicochemical characterization of the CS-based 
nanosystems  
We have previously reported [14,27–30] the optimal conditions for the 
formation of CS nanoparticles and CS nanocapsules. The formation of the 
nanoparticles was achieved according to an ionic gelation process of CS upon 
contact with a counter anion, i.e. sodium tripolyphosphate. On the other hand, the 
formation of CS-coated oily droplets (nanocapsules) was achieved by means of an 
ionic complexation process between the negatively charged lecithin and the 
positively charged CS. This polymer layer was found to be responsible for the 
stabilization of the oily core of the nanoemulsions [27,28]. The same approach was 
recently applied to the formation of CS coated-lipid nanoparticles [25,26]. In this 
latter case, the coating was formed by simple incubation of the lipid nanoparticles 
with an aqueous solution of CS. The attachment of CS was due to its interaction 
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with lecithin and probably with other negative lipids that are present in the core lipid 
nanoparticles. 
Table 1 shows the physicochemical properties (size and zeta potential) of 
the different systems we have designed and those of the corresponding control 
nanoemulsion. In addition, the table presents some macromolecules that have been 
associated to the systems and the modality of administration for which we have 
tested them as carriers for transmucosal macromolecular drugs. These results 
indicate that, despite their different composition, all CS-based systems have a 
colloidal size and a positive zeta potential. Moreover, it can be noted that the zeta 
potential was inverted from highly negative values for the uncoated nanoemulsion 
(about -52 mV) to highly positive values for CS nanocapsules (about +34 mV). The 
positive zeta potential can be logically explained by the presence of the cationic 
polysaccharide CS on the surface of these nanosystems. Simultaneously to the 
inversion of the zeta potential, we observed an increase in the size that was 
attributed to the presence of a CS coating. 
 
Table 1: Physicochemical properties and encapsulation efficiency of different 
macromolecules into a nanoemulsion, chitosan-coated lipid nanoparticles chitosan 
nanocapsules and chitosan nanoparticles as well as the route of administration of the 
nanosystems (mean ± s.d.; n=3). 
 
Carrier Size (nm) ζ Potential (mV) 
Encapsulated 
peptide 
Administration 
route 
Encapsulation 
efficiency (%) 
Nanoemulsion 195.8±1.1 -52.0±1.1 Salmon calcitonin 
Oral 
Nasal >98 
Chitosan 
nanocapsules 266.6±7.6 +34.8±0.6 
Salmon 
calcitonin 
Oral 
Nasal 44.1±3.2 
Chitosan-
coated lipid 
nanoparticles* 
537±16 +29.2±6.2 Salmon calcitonin Oral 30.7±2.3 
Chitosan 
nanoparticles** 337±14 +36.9±0.3 Insulin Nasal 94.7±2.1 
* Data from Garcia-Fuentes et al, (ref. 26, 33). 
** Insulin/chitosan ratio (w/w): 0.4. Data from Urrusuno et al, 1999 (ref. 23). 
 
The presence of this coating could also be visualized by transmission 
electron microscopy (Fig. 2). It can be seen that both, the control nanoemulsion and 
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CS nanocapsules, have a spherical shape. However, the nanocapsules show a corona 
that was attributed to the CS molecules attached to the surface of the oily droplets. 
Interestingly, besides the potential mucoadhesive characteristics that CS confers to 
the nanosystems, it was recently observed that this CS corona enhanced the stability 
of the oily nanodroplets in the gastric fluids [31]. 
A B
 
Figure 2: Transmission electron micrographs of (A) the control nanoemulsion and 
(B) chitosan nanocapsules. 
 
The three CS-based systems showed a great capacity to associate 
macromolecules. For example, CS nanoparticles have a high loading capacity for 
acidic proteins such as insulin (I.P.=5.4) and tetanus toxoid (I.P.=4.4–5.9), reaching 
association efficiencies as high as 97% and 55%, respectively [14,23]. The reason 
for this high association was related to the affinity of these negatively charged 
molecules with the positively charged CS molecules. The association of other types 
of macromolecules such as the lipophilic peptide cyclosporin A has also been 
possible through the adjustment of the formulation conditions. On the other hand, 
the CS-coated lipid systems have also shown an ability to associate insulin as well as 
the cationic peptide sCT (I.P.=10.4) [25,26,29]. The association of insulin was 
attributed to its affinity for lipid materials and also for CS, whereas the association 
of sCT was facilitated by the lipids but slightly inhibited by CS. This inhibition of 
sCT association was ascribed to the positive character of both sCT and CS, that may 
compete for the anionic binding sites of the lipid cores. Overall, these results 
indicated that a variety of macromolecules, either hydrophilic or lipophilic, can be 
efficiently associated to these CS-based nanosystems. 
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With respect to the in vitro release behaviour, our previous work on CS 
nanoparticles led us to the conclusion that the chemical structure of the protein, and 
its interaction with CS in the release medium conditions, were major factors 
governing the release process. For example, in the case of insulin, we observed a fast 
release that was associated to its easy detachment from CS in buffered conditions 
[23]. In contrast, in the case of tetanus toxoid-loaded CS nanoparticles, we noted an 
initial burst of release followed by a slow release that was dependent on the CS 
molecular weight [32]. This slow release was justified by the affinity of the toxoid 
for CS and the characteristics of the release medium. Similarly, the release of the 
peptide sCT from the CS-coated lipid systems followed a biphasic pattern consisting 
of an initial burst followed by a continuous and slow release [26,29]. The burst of 
release was attributed to the surface-associated peptide whereas the second slow 
phase corresponds to the release of the well-entrapped peptide molecules. These 
results suggest that more studies are needed in order to fully understand the factors 
that govern the release from the different nanostructures. However, we must keep in 
mind that the physiological conditions under which these nanosystems release their 
content in vivo are expected to be quite different from those in vitro and, 
consequently, in vitro–in vivo correlations should not be expected. 
Cytotoxicity of CS-based nanosystems in Caco-2 cells 
In order to investigate the cytotoxicity of CS associated to a nanosystem, 
we determined the intracellular dehydrogenase activity in Caco-2 cells exposed to 
different concentrations of CS nanocapsules and to the control nanoemulsion. Fig. 3 
shows that, as it was the case for the lipid nanoparticles [33], the control 
nanoemulsion did not affect cell viability in the range of concentrations assayed. On 
the other hand, following exposure of Caco-2 cells to CS nanocapsules, we observed 
a dose-dependent cell viability [34]. More specifically, the cellular viability 
decreased when the concentration varied between 250 μg/ml (152 μg/cm2) and 1000 
μg/ml (606 μg/cm2), being the media lethal concentration (LC50) around 1000 
μg/ml of nanocapsules suspension (606 μg/cm2), a value that corresponds to 
approximately 80 μg of chitosan/ml (48.49 μg/cm2). A similar dependence of cell 
viability with CS dose was observed for CS-coated lipid nanoparticles [33] and CS 
110 Nanocápsulas de quitosano: nuevos vehículos… 
 
[35]. A conclusion that can be drawn from this study is that the toxicity values are 
not clearly dependent on the nanocarrier structure (polymer solution, or CS-coated 
nanosystems). This conclusion is also corroborated by a recent study that showed 
similar cellular toxicity for CS nanoparticles and CS solutions [36]. On the other 
hand, from the perspective of the potential in vivo toxicity, it is worthwhile to 
mention that the toxicity of these new formulations is low if we take into account the 
surface area of the intestinal barrier (1 m2 for rats, 200 m2 for humans) [37]. 
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Figure 3: Cytotoxicity profiles of chitosan nanocapsules and the control 
nanoemulsion in Caco-2 cell monolayer (Mean±SD, n=4–8). *Statistically 
significant differences from the nanoemulsion ( p<0.01). 
 
Interaction of CS-based nanosystems with the Caco-2 cells monolayer: 
measurement of the transepithelial electrical resistance (TEER) 
It is well known that CS solutions cause a significant and dose-dependent 
decrease of the TEER of the Caco-2 cell monolayers. The first evidence of this 
phenomenon was reported in the early 1990s [20]. These initial studies intended to 
explore the mechanism of interaction between CS and the intestinal epithelium 
concluded that the loss of tight junction integrity was caused by a reorganization of 
the actin rings [20]. However, a more recent hypothesis points to an interaction 
between chitosan and the tight junction protein ZO-1, leading to its translocation to 
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the cytoskeleton [38]. In addition to these mechanistic details, some studies have 
shown that the ability of CS to modify the TEER of Caco-2 monolayers is dose-
dependent [38,39]. Unfortunately, quantitative comparisons between studies are 
difficult due to the different experimental conditions used and also to the different 
types of CS tested (different deacetylation degrees and molecular weights). For 
example, very marked TEER reductions (up to 80%) were observed for high CS 
concentrations (5 mg/ml) [38]. However, significant reductions in the TEER values 
after prolonged exposure to low CS concentrations 0.5 mg/ml were also reported 
[39]. 
Based on this information, we found it important to evaluate if the 
association of CS to a colloidal carrier would modify its interaction with the 
intestinal epithelial cells. With this purpose in mind, we have measured the TEER of 
the monolayer exposed to different doses of CS nanocapsules and to the 
corresponding controls. In Fig. 4 we can notice that neither the controls (HBSS and 
HBSS pH 6) nor the control nanoemulsion influenced the TEER values after 
incubation for 100 minutes. On the other hand, following exposure of the cells to CS 
nanocapsules, we detected a reduction in the TEER values of the monolayer, 
however, the extent of this decrease was remarkable only for high concentrations of 
CS nanocapsules. More precisely, when the dose of CS nanocapsules was 80 
μg/cm2 the TEER value was slightly reduced (10%), and a decrease of around 35% 
was only observed for a high dose of CS nanocapsules (204.5 μg/cm2). Higher doses 
were not tested since the dose of 204.5 μg/cm2 led to a decrease in cell viability of 
20–30%. An additional observation was that in all the cases, the TEER values 
returned gradually to the normal values (total recuperation after 24 h in MEM). A 
comparable decrease in TEER was observed with similar CS doses in the form of 
CS-coated lipid nanoparticles [33]. Despite the difficulties to compare experiments 
only on the basis of the polymer concentrations, globally CS nanosystems and 
solutions seem to have similar dose- TEER reduction profiles [39]. This indicates 
that CS-coated lipid systems mostly maintain the intrinsic permeabilizing properties 
of the CS polymer solutions. In contrast, preliminary data using CS nanoparticles 
suggested that these nanosystems do not display this permeabilizing property at least 
at concentrations below 250 μg/ml. At this point it is tempting to speculate that the 
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different presentation of CS, in the form of a soluble coating or as solid CS 
nanoparticles, may be responsible from this different behaviour. 
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Figure 4: Transepithelial electric resistance (TEER) of Caco-2 monolayer exposed 
to chitosan nanocapsules with two doses of formulations per surface area, 80 μg/cm2 
(solid black line with open circles, o) and 204.5 μg/cm2 (solid black line with close 
circles, ●), the nanoemulsion (solid grey line, ─), or their respective controls of 
Hank´s balanced salt solution (HBSS) (HBSS pH 7.4; dotted grey line, - - -, and 
HBSS pH 6; dotted black line, - - -). (Mean±SD, n=3). *Statistically significant 
differences from chitosan nanocapsules with the lowest dose per surface area, the 
nanoemulsion and both HBSS (p<0.01). 
 
Interaction of chitosan-based nanosystems with the Caco-2 cells 
monolayer: quantitative uptake studies 
We have previously investigated the mechanism of interaction of CS 
nanoparticles with the Caco-2 cells [40]. The results of this study made clear that CS 
nanoparticles were internalized by the cells and also that this internalization process 
was saturable (30 min approx.) as well as energy and temperature-dependent. 
Moreover, these previous results showed that the presence of mucus in the 
monolayers (MTX-E12cells) strongly increased the association of the nanoparticles. 
In the study reported here, we aimed to investigate the behaviour of CS 
nanocapsules and, hence, to elucidate if the composition of the carrier would affect 
the interaction of CS-based systems with the Caco-2 cells monolayer (Fig. 5). For 
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this purpose, we used fluorescent rhodamine-loaded CS nanocapsules and quantified 
the percentage of internalized fluorescence as a function of the dose per area of 
nanocapsules added to the incubation medium. The results showed a linear dose-
dependent uptake for the range of concentrations between 250 and 1000 μg/ml (71–
286 μg/cm2). It was also noted that the uptake was low and similar for the 
nanocapsules (maximum value of uptake of 7 μg/cm2) than for the corresponding 
nanoemulsion (5 μg/cm2). Interestingly, a much higher association was observed for 
both CS-coated lipid nanoparticles and the corresponding control lipid nanoparticles 
as compared to that observed for the nanocapsules [33]. Consequently, these results 
suggest that, not only the CS coating but mainly the nature of the core (either oil or 
tripalmitin) influences the systems uptake. On the other hand, we observed that the 
low association values of CS nanocapsules to the Caco-2 cells monolayer are also 
comparable to those we have observed for CS nanoparticles [40]. The differences 
observed for the various nanosystems in the Caco-2 cells association profiles, as 
well as the suggested dependence on the structure of the system, underline the 
necessity of additional studies in order to gain a better understanding about the role 
of CS in the interaction of nanosystems with the intestinal epithelium. 
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Figure 5: Percentages of fluorescent nanoemulsions and chitosan nanocapsules 
associated to the Caco-2 monolayer following their incubation for 1 hour at different 
concentrations (Mean±SD, n=3). The dose of the incubated formulations per surface 
area values were: 0, 71.43, 142.86 and 286.71 μg/cm2. *Statistically significant 
differences from the nanoemulsion (p<0.01). 
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In vivo efficacy of CS-based nanosystems as transmucosal macromolecular 
drug carriers 
Bearing in mind that the main goal of our work has been to design new 
transmucosal macromolecular drug carriers, we have tested different CS-based 
nanosystems for their ability to increase the transport of peptides and proteins across 
the nasal and intestinal mucosa. We showed the first evidence of this capacity for CS 
nanoparticles containing insulin. Indeed, these nanoparticles led to a significant 
decrease of the glycemia levels, as compared to a control solution of insulin and CS, 
following intranasal administration to rabbits [23]. Moreover, we observed that this 
increased absorption was maintained after freeze-drying and further resuspension of 
the nanoparticles [41]. Recently, we also showed that chitosan nanoparticles were 
able to increase the nasal transport of antigens, i.e. tetanus toxoid [32]. More 
importantly, the results of the increasing and long-lasting IgG levels generated 
following intranasal administration of tetanus toxoid-loaded CS nanoparticles led us 
to hypothesize that the nanoparticles facilitated the delivery of the antigen to the 
immunocompetent cells. 
As an alternative vehicle for nasal administration, we have also evaluated 
the efficacy of CS nanocapsules for enhancing the systemic absorption of sCT [29]. 
With this purpose in mind, we determined the hypocalcemic effect of sCT in 
aqueous solution or sCT associated to a control nanoemulsion and to CS 
nanocapsules after nasal administration to rats. The results showed a negligible 
response for the controls (either the aqueous sCT solution or the nanoemulsion) but 
a significant reduction in the calcemia levels for the nanocapsules. 
The potential of CS nanoparticles for oral peptide administration has also 
been reported [42]. The results of this previous study, which was performed in rats, 
showed that CS nanoparticles were efficient in improving the response of insulin 
administered orally. The authors speculated that the hypoglycaemic response 
obtained with CS nanoparticles could be attributed to the protection of the peptide 
by the formulation and to the potential mucoadhesive and absorption enhancing 
properties of CS. 
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Very recently, we have evaluated the potential of CS-coated lipid systems 
(CS nanocapsules and CS-coated lipid nanoparticles) for oral administration of sCT, 
using a rat animal model [25,28,33]. In order to elucidate the role of the CS coating 
we have compared the behaviour of the CS-coated systems with that of the control 
formulations (nanoemulsion and lipid nanoparticles). In Fig. 6 it is shown that the 
reduction of the serum calcium levels following oral administration of sCT in the 
form of an aqueous solution or a nanoemulsion was insignificant. However, the 
hypocalcemic response was greatly enhanced for CS nanocapsules. More 
importantly, the percentage of reduction of the serum calcium levels (27% for CS 
nanocapsules reached at 1 h post-administration) was maintained for 24 h. This 
long-lasting hypocalcemic response was similar to the one observed for sCT-
containing CS-coated lipid nanoparticles [25,33]. Given the lack of efficacy of the 
controls (non-coated nanoemulsion and lipid nanoparticles), the important 
hypocalcemic effect elicited by the new formulations was, logically, attributed to the 
presence of the CS corona around the nanosystems. These results agree with those 
previously reported for CS-coated poly(lactic acid/glycolic acid) nanoparticles and 
CS-coated liposomes containing sCT [43,44] and underline the positive effect of a 
CS coating around the colloidal peptide carriers. 
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Figure 6: Hypocalcemic effect observed following oral administration of chitosan 
nanocapsules, a control nanoemulsion and an aqueous solution of sCT to rats 
(mean±s.e.; n=6). The dose of sCT administered was 500 IU/kg. *Statistically 
significant differences from sCT solution ( p<0.05). 
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The overall conclusion from these studies is that CS-based nanosystems are 
efficient vehicles for improving the transmucosal transport of peptides. The 
explanation to this positive effect of CS could be found at different levels: (i) first, 
as suggested by Kawashima et al. [43] this effect could be related to the 
mucoadhesive properties of CS and, hence, to its positive interaction with the 
negatively charged mucosal surfaces; (ii) there is also the possibility that some of 
these nanosystems interact with the underlying epithelium entering the cells and also 
opening the tight junctions; (iii) the peptide, either in a free form or associated to the 
nanosystem, reaches the blood or lymphatic vessels. If we take into account that the 
quantity of particles that enter the Caco-2 cells (with no mucus layer) was low for 
both, uncoated and CS-coated systems, while only those coated with CS were 
effective in vivo, we could speculate that, indeed, the mucoadhesion properties of 
CS might be determinant in the efficacy of these nanosystems. Nevertheless, more 
detailed studies will have to be performed in order to fully understand the in vivo 
behaviour of these novel nanocarriers. 
 
Conclusions 
The present study reports the efficacy of three different CS-based 
nanosystems, i.e., CS nanoparticles, CS nanocapsules and CS-coated lipid 
nanoparticles, as carriers for nasal/oral administration of macromolecules. 
Moreover, it gives some mechanistic details that help to understand the mechanism 
of action of these new systems. The presence of CS on the systems provides a 
modification of the transepithelial resistance and enhances slightly the uptake of the 
nanosystems by the Caco-2 model cell line. However, the great enhancement of the 
in vivo response to a model peptide, sCT, associated to the nanosystems suggests 
that additional mechanisms, which remain to be elucidated, are responsible for this 
positive behaviour. 
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Abstract 
Very recently, we reported preliminary data that showed the efficacy of 
chitosan nanocapsules as carriers for oral peptide delivery. In the present work, our 
aim was to investigate the influence of some chitosan properties, such as molecular 
weight and type of salt, on the in vitro behaviour of these nanocapsules in terms of 
their interaction with the Caco-2 cells and also on their in vivo effectiveness. 
Chitosan nanocapsules were prepared by the solvent displacement 
technique using high (450 kDa) and medium (160 kDa) molecular weight chitosan 
glutamate as well as high molecular weight chitosan hydrochloride (270 kDa). The 
results of their in vitro characterization indicated that the size of the nanocapsules 
was dependent on the chitosan molecular weight, varying between 250 and 344 nm, 
whereas the zeta potential (around +30 mV) and the association efficiency of salmon 
calcitonin (40% approx.) were not affected by the chitosan properties. Upon 
incubation with the Caco-2 cells, chitosan nanocapsules exhibited a dose-dependent 
cellular viability, which was hardly affected by, either the chitosan molecular weight 
or, the type of salt. In addition, it was observed that the transepithelial resistance of 
the Caco-2 monolayer was not significantly modified upon their exposure to a dose 
of chitosan nanocapsules which does not compromise the cellular viability. 
The results of the in vivo response achieved following oral administration to 
rats indicated that chitosan nanocapsules were able to reduce significantly the serum 
calcium levels, in comparison to the uncoated nanoemulsion, and to prolong this 
reduction for at least 24 hours. Moreover, this response was not affected by the type 
of chitosan salt nor by its molecular weight. 
In conclusion, this study corroborates the efficacy of chitosan nanocapsules 
for improving the oral absorption of salmon calcitonin. Moreover, it indicates that 
changes in chitosan properties such as chitosan type of salt and molecular weight did 
not affect either the interaction or the permeability of the Caco-2 monolayer or their 
in vivo efficacy. 
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Introduction 
There is no doubt that the oral route is the more convenient way to deliver 
drugs to the body. Unfortunately, up until now the oral administration of peptides 
and proteins has not been feasible due to their instability in the gastrointestinal tract 
and also to their low permeability across the epithelium. However, the important 
efforts that many researchers have dedicated over the last few years to the design of 
approaches intended to overcome these problems have crystallized in very positive 
results. In fact, nowadays there are a number of peptide formulations in clinical trials 
which hold great promise and open optimistic prospects towards the oral peptide 
administration (1-3). These technologies include the chemical modification of 
peptides, but also the use of carriers that facilitate the transepithelial transport of 
macromolecules (Eligen technology) as well as the use of a combination of enzyme 
inhibitors, absorption enhancers and enteric coating. 
Apart from the technologies undergoing clinical trials, one of the 
approaches that has led to great expectations is one based upon the use of 
nanosystems (4-7). Indeed, in the late 80s it was shown for the first time that 
poly(alkylcyanoacrylate) nanocapsules were able to protect insulin from degradation 
and to facilitate its transport across the intestinal barrier (8). Following this original 
study, a number of reports have made it clear that the size is critical for the 
interaction of the delivery carrier with the absorptive site (9, 10), and also that the 
biological behaviour of the constituent of the carrier is a determining factor for its 
efficacy. More specifically, it has been found that polymers which exhibit 
mucoadhesive properties are very good candidates for the design of a trasmucosal 
drug nanocarrier (11-13). The efficacy of this approach is well illustrated with the 
results reported for the nanosystems based on the polysaccharide chitosan (14, 15). 
Indeed, this hydrophilic and cationic polymer has been presented in the form of 
nanomatrices (16, 17) and also as a coating of different types of nanosystems (12, 
18, 19). In all cases, the nanostructural presentation of chitosan has resulted in a very 
positive behaviour in terms of their application for transmucosal drug delivery and, 
in particular for ocular (20), nasal (21) or intestinal (19, 22) drug delivery. While the 
mechanistic details need to be further investigated, the hypothesis is that the known 
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mucoadhesive and penetration enhancing properties inherent to chitosan may play a 
significant role in their performance (23, 24). 
Chitosan is commercially available in the form of different types of salt and 
with different molecular weights. Some authors have investigated the influence of 
these properties, using chitosan as an aqueous solution, on its in vitro cell toxicity 
and penetration enhancing properties (25-29). Unfortunately, the analysis of these 
results makes it difficult to extract clear conclusions. For example, Schipper et al, 
1996 (25) observed that soluble chitosans are able to promote the drug transport 
across the Caco-2 monolayer, regardless the molecular weight of the polymer 
(ranging between 4.7 and 19 kDa). However, Chae et al, have shown an effect of the 
molecular weight of chitosan on the ability to modify the tight junctions, chitosan 
olygomers being (molecular weigh <10 kDa) those that produced the lowest 
decrease in the transepithelial resistance values (26). With respect to the effect of the 
type of salt on the penetration enhancing properties, the in vitro transport study 
performed by Kotze et al. (27) indicated the superiority of chitosan hydrochloride 
with respect to glutamate. 
On the other hand, from the analysis of the influence of chitosan molecular 
weight on its cytotoxicity in Caco-2 cells, it can be deduced that there is a tendency 
for the cytotoxicity to increase with the molecular weight (25, 26, 28). However, 
despite the difficulties of comparing these data, the differences in the toxicity values 
do not appear to be important. Similarly, there is preliminary evidence that the type 
of salt in which chitosan is presented may affect its cytotoxicity, chitosan 
hydrochloride being more toxic than glutamate, glycol or lactate (29). 
Finally, with respect to the influence of chitosan properties on its in vivo 
performance, the results reported up until now, either for chitosan solutions or 
chitosan nanoparticles have not made such influence evident (21, 30, 31). For 
example, we have previously shown that the ability of chitosan nanoparticles in 
enhancing the nasal absorption of insulin (21) or eliciting an immune response 
against tetanus toxoid administered intranasally was not or hardly affected by the 
molecular weight of chitosan (31). 
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Besides these previous reports, the influence of the above indicated 
parameters on the toxicity and efficacy of chitosan nanocapsules has never been 
reported. Therefore, taking into account this information, the aim of the present 
work was to investigate the effect of chitosan molecular weight and chitosan salt on 
the behaviour of chitosan nanocapsules upon contact with the Caco-2 cell 
monolayer. In addition, we studied the influence of these properties on the potential 
of chitosan nanocapsules as carriers for oral peptide administration using salmon 
calcitonin as a model peptide. 
 
Materials and Methods 
Materials 
Salmon calcitonin (sCT) was kindly donated by Almirall Prodesfarma, S.A. 
(Spain). Miglyol 812®, a triglyceride formed from medium chain fatty acids was 
supplied by Lemmel (Spain). The surfactant soybean L-α-lecithin and Poloxamer 
188 (Pluronic F-68®) were supplied from Sigma-Aldrich (Spain). Chitosans with an 
acetylation degree of 15% and different salts (glutamate and chloride) and 
viscosities (<20 mPa and 20-200 mPa) were purchased from FMC Biopolymer/ 
Novamatrix (Norway). The molecular weight of these different polymers is 
presented in table 1. For the purpose of this work, we consider low a molecular 
weight <100 kDa, medium, a molecular weight between 100-200 kDa and high, a 
molecular weight >200 kDa. 
 
Table 1: Physicochemical characterization of different types of chitosan. 
 
Chitosan brand name Salt form Viscosity (mPa) Molecular weight (kDa) 
Protasan® UP Cl 213 Chloride 71 270 
Protasan® UP G113 Glutamate 16 160 
Protasan® UP G213 Glutamate 133 450 
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The Caco-2 cell line was obtained from the European Collection of Cell 
Cultures (ECACC, UK). Minimum Eagle Medium (MEM), fetal bovine serum 
(FBS), non-essential amino acids, L-glutamine, 100 UI/ml penicillin/ 100 μg/ml 
streptomycin solution, 0.05% trypsin/0.02% EDTA solution and Hank’s balanced 
salt solution (HBSS) were purchased from Sigma (Spain). 
 
Preparation of chitosan nanocapsules 
Chitosan nanocapsules were prepared according to the procedure 
previously described by our group (22, 32), in two steps. First, we prepared a 
nanoemulsion (33) as a reference formulation by the solvent displacement technique. 
Secondly, this colloidal carrier was incubated with chitosan solutions leading to the 
formation of chitosan nanocapsules. Briefly, 125 µl de Miglyol were added to an 
organic phase composed of 40 mg of lecithin dissolved in 0.5ml of ethanol and 9.5 
ml of acetone. This organic solution was poured into 20 ml of an aqueous phase 
containing Poloxamer 188 (0.25% w/v). The mixture immediately turned milky due 
to the diffusion of the acetone towards the aqueous phase and the consequent 
formation of colloidal particles. Then, the solvent was evaporated under vacuum and 
the nanoemulsion was concentrated to a final volume of 10 ml. Finally, this 
nanoemulsion was coated by different types of chitosan (See Table 1) by simple 
incubation in polymer solutions. More specifically, 4 ml of the control 
nanoemulsion were incubated with 1 ml of chitosan aqueous solution (0.5% w/v) for 
1 h, leading to the formation of chitosan nanocapsules. 
 
Characterization of chitosan nanocapsules 
The mean particle size of the colloidal systems was analyzed by photon 
correlation spectroscopy (PCS). For the determination, samples were diluted to the 
appropriate concentration with filtered ultrapure water. Each analysis was performed 
at 25ºC with an angle detection of 90º. 
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The zeta potential was calculated from the mean electrophoretic mobility 
values, which were determined by laser Doppler anemometry (LDA). Nanocapsule 
suspensions were diluted with KCl 1mM and placed in the electrophoretic cell 
where a potential of ±150 mV was established. The PCS and LDA analysis were 
performed using a Zetasizer® 3000 HS (Malvern Instruments, Malvern, UK). Each 
batch was analyzed in triplicate. 
 
Salmon calcitonin encapsulation efficiency 
The encapsulation of sCT in chitosan nanocapsules made with different 
types of chitosan (see Table 1) as well as the control nanoemulsion was performed 
by incorporating 50 μl of an aqueous solution of sCT to the organic phase. The 
amount of sCT associated to the nanocarriers was indirectly calculated from the 
amount of free sCT in the supernatant of the nanocarriers. The non-encapsulated 
sCT was determined following separation of nanocapsules from the aqueous 
medium by a combined ultrafiltration-centrifugation technique (Centricon YM-100, 
Millipore, USA) at 1000 x g for 1h. The supernatant was diluted with pH=4 acetate 
buffer and assayed for sCT content by HPLC at 220 nm (Agilent Technologies, 
Germany), as described in the British Pharmacopoeia, 1998 (column: Vidac 218TP). 
A calibration curve was made with solutions of sCT in pH=4 acetate buffer at 
concentrations ranging from 5 to 100 μg/ml. Each sample was assayed in triplicate. 
 
In vitro release studies 
In vitro release studies of sCT from nanocapsules made of chitosan chloride 
and chitosan glutamate of different molecular weight were performed by incubating 
3 ml of the loaded nanocapsules in 3 ml of acetate buffer (pH= 4.0) at 37°C, under 
horizontal shaking (100-110 cycles min-1). At appropriate time intervals, the 
supernatant of chitosan nanocapsules was collected by ultrafiltration at 1000 xg for 1 
h. The amount of sCT released in each time-interval was determined by HPLC. 
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Cell culture experiments 
Caco-2 cells were cultivated in 80 cm2 flasks (Nunc, Denmark) using MEM 
supplemented with 10% FBS, 1% L-glutamine, 1% non-essential amino acids and 
penicillin/ streptomycin solution. Cells were maintained in a controlled atmosphere 
at 37oC with 95% of relative humidity and 5% CO2. The culture medium was 
changed every second day for approximately 5-6 days until cells reached 
approximately 80-90% of confluence. After the passage operation, cells were seeded 
approximately at 2.5 x 105 cells per flask. For the experiments, cells with passage 
numbers between 30 and 40 were used. 
 
Cytotoxicity studies 
Caco-2 cells were seeded at a cell density of 104 cells/cm2 into 96 multiwell 
plates and were allowed to grow for 7 days, until cell monolayer was obtained. 
Then, the medium was replaced by the formulations of chitosan nanocapsules (CS of 
different viscosities and salt form). The concentrations of nanocapsules assayed 
varied between 0.01 and 2 mg/ml, in a final volume of 0.2 ml. As a positive control 
we have used HBSS pH 6 and as a negative control 2% sodium dodecyl sulfate 
(SDS). Chitosan nanocapsules and the controls were put in contact with the 
monolayers for 90 min at 37ºC and 5% CO2. After this, the nanocapsule suspensions 
were removed and cell viability was determined using a colorimetric method (MTS, 
Promega), which determines the intracellular dehydrogenase activity. The 
absorbance was measured at 490 nm. 
 
Transepithelial electrical resistance studies 
The measurement of the transepithelial electrical resistance (TEER) was 
performed on TranswellTM plates with a cell density of 5.5 x 104 cells 21 days post-
seeding. The integrity of the monolayers was checked on the 21st day in MEM. The 
TEER measurements were performed with a Millicell®-ERS connected to a pair of 
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chopstick electrodes (Millipore, Spain). After these measurements, the medium was 
changed by HBSS in order to perform the experiments in buffer. After 1 hour of 
equilibrium, the apical solutions were replaced by the chitosan nanocapsule 
suspension (CS of different viscosities and salt form) and its respective control, 
HBSS pH 6. The concentration of chitosan nanocapsules was 250 and 450 µg/ml in 
a cell growing areas of 4.5 cm2 leading to a nanocapsule dose of 80 and 150 µg/cm2. 
Nanocapsule suspensions were incubated for 100 minutes and TEER measurements 
were performed every 25 minutes. After this, the solutions were removed and 
replaced by MEM in order to check the recuperation of the TEER values at 24 
hours. 
 
In vivo efficacy of chitosan nanocapsules 
Male Sprague-Dawley rats (225- 275 g), from the Central Animals House 
of the University of Santiago de Compostela (Spain), were fasted for 12 h before 
experiments, but allowed water ad libitum. Animals were kept conscious during the 
experiments. 
We have administered intragastrically chitosan nanocapsules with two 
different viscosities of chitosan (16 and 133 mPa). As controls we used the 
previously assayed sCT aqueous solution and the nanoemulsion (22). The dose 
administered in all the cases was 500 UI/kg in a volume of 0.5 ml. 
Blood samples were collected from the tail vein 30 min prior to the oral 
administration to establish the baseline calcium levels and at different times after 
dosing. The serum was separated by centrifugation at 3000 xg for 5 min. 
Hypocalcemic effect was determined in serum samples by a colorimetric method at 
570 nm (Kit OR-cresolphtalein v/v, Spinreact, Spain). 
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Statistical analysis 
Data from the in vitro experiments were analyzed using the statistical 
software package SPSS 11.5. Statistically differences were considered to be 
significant at a level of p <0.01. 
The mean serum calcium levels determined in samples collected before 
sCT administration were taken as the baseline levels. At each time interval the 
reduction of calcium percent was calculated. Using these values, the area above the 
time curve of the hypocalcemic effect was calculated and the statistical comparison 
was performed by ANOVA followed by the Student-Newman-Keuls test for 
multiple comparisons between treatments using the software SPSS 11.5. Differences 
were considered to be significant at a level of p <0.05. 
 
Results and discussion 
Chitosan nanocapsules were developed for oral peptide delivery with the 
idea of protecting the associated macromolecule from enzymatic attack and 
facilitating the interaction of the peptide with the intestinal mucosa. In a previous 
paper, we have presented preliminary data showing the role of a chitosan coating 
around a lipid core, either oily or solid, in the enhancement of the oral absorption of 
sCT (22). Indeed, in this previous work, we showed that the presence of the chitosan 
coating was critical for the effectiveness of chitosan nanocapsules and chitosan-
coated tripalmitin nanoparticles, since the uncoated formulations did not lead to a 
significant absorption of the associated peptide. In the present paper, we aimed at 
investigating how the physicochemical properties of chitosan (different salts and 
molecular weight) could affect the in vitro and in vivo behaviour of chitosan 
nanocapsules. 
Characterization of chitosan nanocapsules 
Chitosan nanocapsules were prepared by the solvent displacement 
technique (see properties of chitosan on Table 1) (22, 32). A control nanoemulsion 
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was also formed under the same conditions but avoiding the process of coating with 
chitosan. The process of coating with chitosan is based upon the ionic interaction 
between the negatively charged lecithin and the positively charged chitosan. The 
resulting complex lecithin-chitosan is responsible for the stabilization of the oily 
core (34). 
The influence of different types of salt (chloride and glutamate) and 
molecular weight (between 160 and 450 kDa) of chitosan (Table 1) on the physico-
chemical properties of chitosan nanocapsules is shown in Table 2. Additionally, this 
table shows the characteristics of the nanoemulsion used as a control. All the 
colloidal carriers presented a particle size in nanometre range. The coating of the 
nanoemulsion with chitosan caused an increase in the size of the system that was 
attributed to the thickness of the coat. The hydrodynamic diameter of chitosan 
nanocapsules was influenced by the chitosan molecular weight; however, the type of 
salt had no significant effect. More specifically, we observed that chitosan 
nanocapsules prepared with the larger chitosan molecular weight were larger than 
those prepared with the smaller molecular weight (330nm vs. 250 nm, respectively). 
These results are in agreement with those reported by Calvo et al (33) who found 
that the increase on the size of chitosan-coated poly-ε-caprolactone nanocapsules 
was dependent on the size of the chitosan molecules attached to the surface of the 
carrier. 
Table 2: Physicochemical properties and encapsulation efficiency of chitosan 
nanocapsules and nanoemulsions containing sCT (mean ± s.d.; n=3). 
 
Carrier Size(nm) ζ Potential (mV) 
Encapsulation 
efficiency (%) 
NE 195.8±1.1 -52.0±1.1 >98 
CS Cl213 NC 344.3±15.0 +32.0±0.8 37.93±2.65 
CS G113 NC 250.5±7.9 +34.4±0.7 39.17±3.83 
CS G213 NC 330.7±5.8 +31.3±1.6 38.30±1.56 
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Despite the effect of chitosan molecular weight on the size of the resulting 
nanocapsules, their surface charge did not suffer a significant change. Indeed, the 
zeta potential values were in all cases close to +30 mV, independent of the chitosan 
properties. However, a remarkable difference was noted when comparing these 
values with those corresponding to the control nanoemulsion, which displayed a 
high negative charge. This inversion in zeta potential confirmed the presence of 
chitosan adsorbed onto the surface of the colloidal carriers and suggested that this 
cationic polymer forms a coating around the oily cores, hence forming a reservoir 
structure. 
 
Salmon calcitonin encapsulation efficiency 
A comparison of the encapsulation efficiency of sCT in the different 
chitosan nanocapsules and the control nanoemulsion formulation is shown in Table 
2. The ability of these nanocarriers to entrap sCT into their structure was dependent 
on their composition. In fact, the control nanoemulsion showed a total encapsulation 
of sCT due to the strong binding affinity of the peptide, which is positively charged, 
for the anionic sites present in the nanoemulsion. This electrostatic interaction was 
diminished after incubation of sCT-loaded nanoemulsion with the different chitosan 
solutions, forming sCT-loaded chitosan nanocapsules. In this case, it was found that 
a certain amount of sCT was expelled from the system due to a competition between 
chitosan and sCT, both positively charged. The resulting encapsulation efficiency of 
sCT in chitosan nanocapsules was around 40%, independent of the physicochemical 
properties of chitosan (type of salt and molecular weight). The lack of influence of 
the chitosan properties on the encapsulation efficiency could be related to the fact 
that the surface charge of chitosan nanocapsules was the same regardless the 
structural properties of chitosan. 
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In vitro release studies 
The in vitro release behaviour of sCT from chitosan nanocapsules was 
investigated using acetate buffer pH=4. This buffer was selected because it is the 
optimum pH for the preservation of the stability of sCT during the incubation 
process (35). 
The release profiles of sCT from chitosan nanocapsules prepared with 
chitosan with different physicochemical properties is shown in figure 1. All the 
formulations displayed a release profile characterized by an initial burst and no 
further peptide release for up to 6 hours. It can also be noted that this initial release-
phase was not affected by the chitosan type of salt nor by the molecular weight. The 
initial release phase could correspond to the release of the amount of sCT that was 
entrapped on the chitosan coating, rather than in the core of the nanocapsules. The 
low affinity of this cationic peptide for chitosan could be an explanation for this fast 
initial release. On the other hand, the great affinity of the peptide for the lipids 
would justify the lack of further release under the experimental conditions of the 
study. 
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Figure 1: In vitro release profiles of salmon calcitonin from chitosan nanocapsules 
prepared with different salts and molecular weights of chitosan (mean ± s.d.; n=3). 
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Cytotoxicity studies 
An important aspect of the investigation of the potential of chitosan 
nanocapsules for oral delivery is the analysis of their toxicity upon interaction with 
the intestinal epithelium. It has been previously shown that the viability of Caco-2 
cells decreases in a dose-dependent manner after incubation with chitosan (25, 26, 
28). Additionally, it has been reported that specific properties of chitosan, such as 
salt form and molecular weight may influence this cytotoxic effect (25, 26, 28, 29). 
However, as indicated in the introduction, the influence of these properties has not 
been clearly elucidated. This is due, on the one hand, to the difficulties in comparing 
published data; and, on the other hand, to the fact that these differences are not 
remarkable. Moreover, it is important to keep in mind that the relevance of these 
properties may be dependent on the physical presentation of chitosan (as a solution, 
as a coating material or as a nanomatrice). 
Thus, in the present work we have evaluated the cellular viability of Caco-2 
monolayer after exposure to chitosan nanocapsules for up to two hours (Fig. 2). 
More specifically, we studied the effect of chitosan coating properties, salt form and 
molecular weight, on the intracellular dehydrogenase activity in Caco-2 cells. As 
shown in Figure 2, the first observation was that chitosan nanocapsules presented 
concentration-dependent cytotoxicity. Upon exposure of Caco-2 cells to 
concentrations of nanocapsules higher than 0.25 mg/ml (152 µg/cm2), the cellular 
viability started to decrease, reaching the 50% lethal concentration (LC50) at a 
concentration between 1 and 2 mg/ml. In addition, it can be observed that either the 
salt form of chitosan or its molecular weight have only a minor effect on the cell 
viability. These results agree with those previously reported for chitosan solutions 
and chitosan nanoparticles prepared with chitosan of molecular weights ranging 
between 4.7 and 213 kDa (25, 28). However, these results should not lead to the 
conclusion that chitosan molecular weight does not influence the cellular viability, 
but only that this effect was not seen within the range of chitosan molecular weight 
investigated (between 160-450 kDa). In fact, it has been recently reported that 
chitosan olygomers (molecular weight <10 kDa) have less cytotoxicity effects than 
high molecular weight chitosans (molecular weight 230 kDa) (26). 
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Figure 2: Effect of the different formulations of chitosan nanocapsules on the 
cellular viability of Caco-2 cells (mean ±d.e., n≥4). 
 
Transepithelial electrical resistance studies 
Chitosan is known for its ability to enhance the penetration of drugs across 
the epithelium by a mechanism involving the interaction of the positively charged 
amino groups of chitosan with the negatively charged sites on the cell surfaces and 
tight junctions (24, 25, 36, 37). A way to study the intensity of this effect is the 
measurement of the transepithelial electrical resistance of the monolayer. For 
example, in a previous work, we have shown that the exposure of the Caco-2 
monolayer to chitosan nanocapsules may lead to a reduction of the TEER (22). 
However, the results of this work also indicated that it was necessary to use a high 
concentration of nanocapsules (which are at the toxic level) in order to observe a 
significant reduction of the TEER value. Unfortunately, the comparison of these 
results with those obtained for chitosan solutions is unviable due to the different 
experimental conditions among experiments and to the absence of meticulous 
information concerning these conditions. 
Thus, in this work, our objective was to evaluate whether or not chitosan 
properties (molecular weight and salt form) affect the interaction (TEER value) of 
the nanocapsules with the monolayer. Additionally, we have analyzed the effect of 
the dose of chitosan nanocapsules on the TEER values, up to the limit to the 
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maximum dose which does not compromise cell viability. In figure 3, we can 
appreciate the evolution of TEER values after exposing the cells to chitosan Cl213 
nanocapsules and the previously assayed chitosan Cl110 nanocapsules (22). We can 
observe that the TEER values of the Caco-2 monolayer decreased slowly, over the 
time, upon exposure to high molecular weight chitosan hydrochloride (Protasan® Cl 
213; Mw: 270 kDa) nanocapsules, reaching a 10% reduction after 75 min. This 
slight reduction was similar to the one observed for medium molecular weight 
chitosan (Protasan® Cl 113; Mw: 140 kDa) nanocapsules (22). 
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Figure 3: Transepithelial electrical resistance (TEER) of Caco-2 cells after 
incubation with 250µg/ml of chitosan Cl 213 nanocapsules, chitosan Cl 110 
nanocapsules* and the control HBSS pH 6 in a surface area of 4.5 cm2 (mean ± s.d.; 
n= 3). *Data from Prego et al 2005 (22). 
 
The effect of chitosan glutamate nanocapsules, with two different 
molecular weights of chitosan (160 and 450 kDa), on their ability to modify TEER 
values is shown in figure 4. Additionally, this graph shows the influence of the dose 
of chitosan G113 nanocapsules (80 and 150 µg/cm2) on the TEER values. As it 
occurred in the case of chitosan hydrochloride nanocapsules, the different chitosan 
glutamate molecular weights (160 and 450 kDa) used to prepare chitosan 
nanocapsules led to a slight and similar modification of the TEER values at the dose 
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per surface area of 80 µg/cm2. An additional observation from this figure is that an 
increase in the dose of chitosan G113 nanocapsules from 80 to 150 µg/cm2 led to a 
significant and progressive reduction of the TEER values, reaching the 20% of 
reduction after 50 min of exposure to the cells. 
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Figure 4: Transepithelial electrical resistance (TEER) of Caco-2 cells after 
incubation with of chitosan G 113 nanocapsules, chitosan G 213 nanocapsules, at 
two does per surface area, 80 and 150 μg/cm2, as well as the control HBSS pH 6 
(mean ± s.d.; n= 3). * Significantly different from HBSS pH6 (p < 0.01). 
 
Consequently, these results led us to conclude that, within the chitosan 
molecular weight range of 140- 450 kDa and the salt form of chitosan chloride or 
glutamate, chitosan nanocapsules have a minor effect on the TEER values of the 
Caco-2 monolayer. Only when the dose of nanocapsules was increased up to the 
limit which does not compromise cell viability, we could observe a significant 
reduction (20%) in the TEER values. Despite the difficulties for a strict comparison 
of these results with those previously reported for chitosan solutions, there is an 
agreement in the irrelevance of chitosan properties on the transepithelial resistance 
values (38). It is also worthwhile to mention that, in all cases, there is a gradual 
recuperation of the original TEER values. 
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In vivo efficacy of chitosan nanocapsules 
As indicated above, we have already performed some preliminary studies, 
which showed that chitosan Cl110 nanocapsules are able to improve the 
pharmacological effect of sCT administered orally (22). In this study, we have 
attempted to evaluate this effect further by studying the behaviour of nanocapsules 
prepared with different types of chitosan (different salts and molecular weight). Fig. 
5 depicts the hypocalcemic profiles following oral administration of sCT associated 
to different formulations of chitosan nanocapsules. As reference formulations, we 
have also tested a sCT solution and a nanoemulsion (22). The results showed that 
the oral administration of sCT alone or associated to the nanoemulsion did not lead 
to a change in the serum calcium levels. On the contrary, chitosan nanocapsules 
showed an important hypocalcemic effect which was prolonged for, at least, 24 h. 
Moreover, it can be noted that the chitosan molecular weight did not affect this 
capacity of the nanocapsules to enhance the absorption of the associated peptide. 
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Figure 5: Hypocalcemic effect observed for salmon calcitonin-loaded chitosan 
nanocapsules prepared with chitosan glutamate of different molecular weight (CS 
G113 NC and CS G213 NC) as well as for a control nanoemulsion (NE) and for an 
aqueous solution of salmon calcitonin (sCT Sol), following oral administration to 
rats (mean ± s.e.; n=6). The dose of salmon calcitonin administered was 500UI. 
 
Finally, the comparison of areas above the hypocalcemic effect curve (AAC 
0-24h) obtained following administration of the different formulations (Fig. 6) 
confirms the significantly greater pharmacological effect of chitosan nanocapsules 
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with different chitosan molecular weights in comparison to the sCT aqueous 
solution and the nanoemulsion. 
 
Figure 6: Area above hypocalcemic effect curve (AAC0-24 hr) after oral 
administration to rats of salmon calcitonin in solution or incorporated in the 
nanoemulsions and chitosan nanocapsules made of chitosan glutamate of different 
molecular weight.* Significantly different from salmon calcitonin solution and the 
control nanoemulsion (p < 0.05). 
 
Therefore, a general conclusion from these in vivo studies is that the 
presence of chitosan was essential to obtain a pharmacological response. These 
results are in accordance with those previously found for other chitosan-coated 
based nanosystems such as chitosan-coated PLGA nanoparticles (12), chitosan-
coated liposomes (18) and chitosan-coated lipid nanoparticles (19) in the sense that 
all these colloidal systems led to an increase in the systemic absorption of sCT. 
However, an interesting observation from this comparative analysis is that the high 
response attained for nanostructures composed of a lipid core and a chitosan coating 
is more sustained and prolonged than that corresponding to chitosan-coated PLGA 
nanoparticles (12), chitosan-coated liposomes (18). 
Regarding the mechanism of action of these nanocapsules, we could 
speculate about their penetration enhancing effect. However, this hypothetic 
mechanism does not appear to be relevant given the minor effect in the TEER 
observed in vitro. A more probable mechanism would be the one related to the 
mucoadhesive properties of chitosan and, hence, to the efficient interaction of the 
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nanocapsules with the intestinal mucosa. In this sense, it is worthwhile to mention 
the fact that chitosan forming a coating around a colloidal carrier is critical. Indeed, 
previous studies performed by other groups (18) as well as by our own group have 
shown that chitosan in the form of a solution or in the form of spray-dried 
microparticles were not efficient at increasing the systemic absorption of sCT. It 
should also be taken into account that the fact that the peptide is entrapped in an oily 
core may help protect the peptide from hydrolytic and enzymatic degradation in the 
gastro-intestinal tract. 
 
Conclusions 
The results of this work confirm the potential of chitosan nanocapsules as 
carriers for improving the oral absorption of sCT. Additionally, they indicate that 
this positive behaviour is not affected either by the different type of salt used 
(hydrochloride or glutamate chitosan) or by the use of different chitosan molecular 
weights ranging between 140-450 kDa. 
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Abstract 
We have previously reported the formation and characterization of 
chitosan-coated oily nanodroplets, called chitosan nanocapsules, and showed their 
ability to enhance and prolong the oral absorption of peptides, i..e. salmon 
calcitonin. In the present work, our goal was to prepare a new type of nanocapsules, 
using chitosan chemically modified with poly(ethylene glycol) (PEG) (0.5 and 1% 
pegylation degree) and to investigate the consequences of this modification on the in 
vitro and in vivo behaviour of the nanocapsules. In addition, the properties of these 
chitosan-PEG nanocapsules were compared with those of PEG nanocapsules, used 
as a control. The hypothesis was that the presence of PEG in the coating of the 
nanocapsules would be advantageous in terms of improving their stability in contact 
with the gastrointestinal fluids as well as their cellular biocompatibility.  
Chitosan-PEG and PEG nanocapsules could be obtained using the solvent 
displacement technique. The size of the resulting nanocapsules was in the range of 
160-250 nm. Their zeta potential was greatly affected by the nature of the coating, 
being positive for chitosan-PEG nanocapsules and negative in the case of PEG 
nanocapsules. The presence of PEG, whether alone or grafted to chitosan, improved 
the stability of the nanocapsules in the gastrointestinal fluids. In addition, using the 
Caco-2 model it was observed that the pegylation of chitosan reduced the 
cytotoxicity of chitosan nanocapsules and also that these nanocapsules did not cause 
a significant change in the transepithelial resistance of the monolayer. Finally, 
following oral administration of chitosan-PEG nanocapsules containing salmon 
calcitonin, it was found that chitosan-PEG nanocapsules have the capacity to 
enhance the intestinal absorption of salmon calcitonin. Additionally, the results 
showed that an increase in the pegylation degree (from 0.5% to 1%) led to a 
reduction in the pharmacological response of the associated peptide. Therefore, 
modulating the pegylation degree of chitosan, it should be possible to obtain 
nanocapsules with a good stability, a low cytotoxicity and high absorption 
enhancing properties. 
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Introduction 
Despite the efforts dedicated over the last decades towards making the oral 
administration of peptides and proteins feasible, the actual fact is that this objective 
still remains a challenge. This is quite understandable if we take into account the 
great barriers that need to be overcome, such as the metabolic activity and the low 
permeability of the intestinal epithelium (1). However, in spite of these difficulties, 
the success of the formulations undergoing clinical trials (2-4) offers an optimistic 
prospect towards reaching this objective. 
The use of colloidal carriers such as nanoparticles and nanocapsules (5-7) 
has been reported to be a promising way to improve the oral bioavailability of 
peptides and proteins. The proposed mechanisms explaining the efficacy of these 
nanocarriers are: the great surface interaction of the nanocarrier with the absorptive 
epithelium, which can be further enforced by the use of bioadhesive materials, and 
the protective effect of the carrier for the associated peptide. Indeed, the 
effectiveness of nanocarriers at improving the absorption of labile macromolecules 
depends strongly on their polymer composition. For example, the simple surface 
modification of a nanocarrier using polymers with specific properties may be an 
easy approach to modulate its interaction with the epithelium. In this sense, an 
interesting polymer with a promising future in the biopharmaceutical and biomedical 
fields is the positively charged polysaccharide chitosan. In fact, chitosan has already 
been used in the form of nanoparticles and nanocapsules aimed at improving the 
transmucosal delivery of drugs across different mucosal surfaces (8-12). Among 
these different transmucosal drug delivery applications, we have found the use of 
chitosan nanocapsules for oral peptide delivery quite promising (13, 14). More 
specifically, following oral administration of chitosan nanocapsules containing 
salmon calcitonin, we have observed a great improvement on the pharmacological 
effect. 
Taking this previous information into account, the main purpose of this 
work was to explore the possibilities to further improve the surface properties of 
chitosan nanocapsules in terms of their interaction with the gastro-intestinal 
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environment. For this purpose, we chose as an additional polymer, poly(ethylene 
glycol) (PEG). The choice of this polymer was justified because of two main 
reasons. First, the chemical modification of chitosan with PEG was seen as a way of 
improving the biocompatibility of chitosan (15); second, we have previously 
observed that a PEG coating around the nanocarrier helps to improve their stability 
in the biological fluids and, as a consequence, facilitates the transport of bioactive 
macromolecules across the intestinal and nasal epithelium (10, 16, 17). 
Therefore, the objectives of the present work were: first, to obtain and 
characterize nanocapsules made of chitosan chemically modified with PEG, with 
two different substitution degrees (0.5 and 1%) and, second, to evaluate the effect of 
pegylation of the in vitro and in vivo behaviour of the resulting chitosan-PEG 
nanocapsules. More specifically, we evaluated the cytotoxicity of chitosan-PEG 
nanocapsules and their possible effect on the TEER of the Caco-2 cells monolayer 
and, finally, we investigated their efficacy at improving the intestinal absorption of 
the model peptide salmon calcitonin. 
 
Materials and Methods 
Materials 
Salmon calcitonin was kindly donated by Almirall Prodesfarma, S.A. 
(Spain). Miglyol 812®, a triglyceride formed from medium chain fatty acids was 
supplied by Lemmel (Spain). The surfactant soybean L-α-lecithin and poloxamer 
188 (Pluronic F-68®) were supplied from Sigma-Aldrich (Spain). Chitosan-PEG was 
synthesized from chitosan hydrochloride salt (Protasan® CL110) which was 
purchased from FMC Biopolymer/ Novamatrix, (Norway). Polyethylene glycol 
5000 monomethyl ether (PEG) was supplied by Fluka (Spain). NHS (N-
hydroxysuccinimide) and EDC [N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide 
hydrochloride] were purchased from Fluka (Spain). 
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Synthesis of Chitosan-g-PEG 
We have synthesized chitosan-PEG with two different degrees of 
substitution, 0.46% and 1.19%, called in this paper chitosan-PEG 0.5 and 1%, 
respectively. First of all, we characterized the polymers used to synthesize chitosan-
PEG: chitosan and PEG. The degree of acetylation of chitosan determined by 1H-
NMR according to our modification of the Hirai procedure (18, 19) was 7%. The 
average molecular weight of chitosan (Mw) was determined by size exclusion 
chromatography-multiangle laser-light scattering (SEC-MALLS). An Iso Pump 
G1310A (Hewlett Packard) was connected to a PSS Novema GPC column 10 µ (8 x 
50 mm) and a PSS Novema 3000 column (8 x 300 mm). A PSS SLD7000 MALLS 
detector (Brookhaven Instruments Corporation) operating at 660 nm and a G1362A 
refractive index detector (Agilent) were connected on line. A 0.15M NH4OAc/0.2M 
AcOH buffer (pH = 4.5) was used as eluent. Polymer solutions (0.1% w/v) were 
filtered on 0.45 µm pore size membranes (Millipore) before injection. Refractive 
index increment dn/dC was set at 0.1922 according to Schatz et al. (20). The 
resulting Mw was 87000 Da. MeO-PEG-CH2CO2H was synthesized from MeO-
PEG-OH (Fluka, Mn 5055.5, Mw 5087.8 determined by MALDI-TOF) according to 
Royer et al. (21). 
To perform the synthesis, chitosan⋅hydrochloride (80 mg, 0.40 mmol) was 
dissolved in 11.5 ml of water. MeO-PEG-CH2CO2H (Mn 5114.5, 14.2 mg, 2.79 
µmol) and NHS (1.6 mg, 0.014 mmol) were added to the solution. Then, EDC (21.7 
mg, 0.113 mmol) was added in small portions. The resulting solution was stirred at 
room temperature for 22 hours and afterwards ultrafiltered (Amicon, YM30) and 
lyophilized [degree of pegylation 0.46%, determined by 1H-NMR (2% DCl in 
D2O)]. 
Chitosan-PEG with a-1.19% substitution degree (determined by 1H-NMR 
(2% DCl in D2O)) was synthesized by the procedure indicated above from 
chitosan⋅hydrochloride (80 mg, 0.40 mmol), MeO-PEG-CH2CO2H (117 mg, 0.023 
mmol), NHS (13.5 mg, 0.117 mmol) and EDC (22.4 mg, 0.117 mmol). 
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Preparation of chitosan-PEG nanocapsules 
Chitosan-PEG nanocapsules were prepared in two steps. First, we prepared 
a nanoemulsion, which was taken as a reference formulation, by solvent 
displacement technique, as previously reported (22, 23). Secondly, this colloidal 
carrier was coated with chitosan-PEG with two pegylation degrees of chitosan, 0.5 
and 1%, by simple incubation in polymer solutions. More specifically, we prepared 
the nanoemulsions by adding an organic phase, composed of 125 µl de Miglyol, 40 
mg of lecithin dissolved in 10 ml of acetone was added to an aqueous phase 
containing poloxamer 188 (0.25% w/v). The mixture turned milky immediately due 
to the formation of the nanoemulsion. Then, the solvents were evaporated under 
vacuum. Finally, 4 ml of the nanoemulsion were incubated for one hour with 1 ml of 
chitosan-PEG aqueous solution (0.5% w/v) with different pegylation degrees of 
chitosan (0.5 and 1%), leading to the formation of chitosan-PEG 0.5% and chitosan-
PEG 1% nanocapsules, respectively. 
For the preparation of PEG nanocapsules we adopted the conditions 
described for the formation of the control nanoemulsion but introducing a little 
modification, which consisted in adding 40 mg of PEG-stearate to the organic phase 
prior to the mixing with the aqueous phase. 
 
Characterization of chitosan-PEG nanocapsules 
The size and polydispersion index of the colloidal systems were analyzed 
by photon correlation spectroscopy (PCS). For this analysis, samples were diluted to 
the appropriate concentration with filtered ultrapure water. Each analysis was 
performed at 25ºC with an angle detection of 90º. 
The zeta potential was determined by laser Doppler anemometry (LDA). 
For the determination of the electrophoretic mobility, samples were diluted with KCl 
1mM and placed in the electrophoretic cell where a potential of ±150 mV was 
established. 
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The PCS and LDA analysis were performed using a Zetasizer® 3000 HS 
(Malvern Instruments, Malvern, UK). Each batch was analyzed in triplicate. 
The morphology of the nanocarriers was visualized by transmission 
electron microscopy (TEM) (Philips CM12, Eindhoven, Netherlands). Images were 
taken following staining of the isolated chitosan-PEG nanocapsules with 2% w/v 
phosphotungstic acid for one minute and left drying overnight. 
 
Salmon calcitonin encapsulation efficiency 
Salmon calcitonin-loaded chitosan-PEG nanocapsules were prepared as 
described previously by incorporating 50 μl of an aqueous solution of salmon 
calcitonin to the organic phase containing the oil and phospholipids. Then, this 
organic phase was added to the external aqueous phase containing poloxamer 188 
(0.25%). 
The encapsulation efficiency of salmon calcitonin in the nanocapsules and 
control nanoemulsion was calculated by the difference between the total amount of 
salmon calcitonin used to prepare the loaded systems and the remaining amount of 
free salmon calcitonin in the aqueous medium. The amount of free salmon calcitonin 
was determined in the supernatant following the separation of nanocapsules from 
aqueous medium by a combined ultrafiltration- centrifugation technique (Centricon 
YM-100, Millipore, USA) at 1000 x g for 1h. The supernatant was diluted with 
pH=4 acetate buffer and assayed for salmon calcitonin content by HPLC at 220 nm 
(Agilent Technologies, Germany) as described in the British Pharmacopoeia, 1998 
(column: Vidac 218TP). A calibration curve was made with solutions of salmon 
calcitonin in pH=4 acetate buffer at concentrations ranging from 5 to 100 μg/ml. 
Each sample was assayed in triplicate. 
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In vitro release studies 
In vitro release studies of salmon calcitonin from chitosan-PEG 
nanocapsules was performed by incubating 3 ml of loaded nanocapsules in 3 ml of 
pH=4 acetate buffer under horizontal stirring at 37°C. At appropriate time intervals, 
individual samples were ultrafiltered at 1000 x g for 1 h. The amount of salmon 
calcitonin released at each time point was determined by HPLC. 
 
Stability of the nanocapsules in simulated gastrointestinal fluids 
Taking into account that these nanostructures were developed as carriers for 
oral administration of peptides, we consider it important to evaluate their stability in 
the gastrointestinal fluids. Consequently, chitosan-PEG nanocapsules, PEG 
nanocapsules, the unpegylated chitosan nanocapsules and the control nanoemulsion 
were incubated at 37ºC under moderate stirring, either in simulated gastric medium 
(USP XXVII, pH=1.2, pepsin 0.32% w/v) or in simulated intestinal medium (USP 
XXVII, pH=6.8, pancreatin 1% w/v). Samples were collected after 1h-incubation 
period and centrifuged for 2 min at 3000xg in order to precipitate the aggregates and 
enzymes. Finally, the mean particle size of the remaining non-aggregated 
nanocapsules was determined by PCS. 
 
Caco-2 cell culture experiments 
Caco-2 cells were cultivated in 80 cm2 flasks (Nunc, Denmark) using 
minimum essential medium (MEM) supplemented with 10% FBS, 1% L-glutamine, 
1% non-essential amino acids and penicillin/ streptomycin solution. Cells were 
maintained in a controlled atmosphere at 37oC with 95% of relative humidity and 
5% CO2. The culture medium was changed every second day for approximately 5-6 
days until cells reached approximately 80-90% of confluence. Then, these cells with 
passage numbers between 30 and 40 were seeded approximately at 2.5 x 105 cells 
per flask. 
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Cytotoxicity studies 
To investigate the biocompatibility of both types of chitosan-PEG 
nanocapsules, an in vitro experiment was performed using Caco-2 cell culture. Cells 
were seeded on 96 well plates with a cell density of 104 cells/cm2 for 7 days until 
cell monolayer was obtained. After 7 days, the medium was replaced by the 
nanocapsule suspensions at concentrations between 0.01 and 20 mg/ml in a final 
volume of 0.2 ml. As a positive control we have used Hank´s balanced salt solution 
(HBSS) pH 6 and as a negative control 2% sodium dodecyl sulfate (SDS). Chitosan-
PEG nanocapsules and the controls were in contact with the monolayers for 90 min 
at 37ºC and 5% CO2. Afterwards, the nanocapsule suspensions were removed. The 
cell viability was measured using a colorimetric method (MTS, Promega), which 
determines the intracellular dehydrogenase activity. The absorbance was measured 
at 490 nm. 
 
Transepithelial electrical resistance (TEER) studies 
Transepithelial electrical resistance was performed on Transwell® plates 
with a cell density of 5.5 x 104 cells 21 days post-seeding. The integrity of the 
monolayers was checked on the 21st day in MEM. The TEER measurements were 
performed with a Millicell®-ERS connected to a pair of chopstick electrodes 
(Millipore, Spain). After these measurements, the medium was changed by HBSS 
and let to equilibrate for 1 hour. Then, the apical solutions were replaced by the 
chitosan-PEG 0.5% nanocapsule suspension and its respective control, HBSS pH 6. 
The concentration of chitosan-PEG 0.5% nanocapsules was 250 µg/ml in a cell 
growing areas of 4.5 cm2 leading to a nanocapsule dose of 80 µg/cm2. Nanocapsule 
suspensions were incubated for 100 minutes and TEER measurements were 
performed every 25 minutes. After this, the solutions were removed and replaced by 
MEM in order to check the recuperation of the TEER values at 24 hours. 
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In vivo efficacy of chitosan-PEG  nanocapsules 
Male Sprague-Dawley rats (225- 275 g) from the Central Animals House of 
the University of Santiago de Compostela (Spain) were fasted for 12 h before 
experiments, but allowed water ad libitum. Animals were kept conscious during the 
experiments. 
Chitosan-PEG nanocapsules with two different degrees of pegylation 
degree of chitosan, 0.5 and 1% were administered intragastrically to rats. As a 
control, we have included the previously assayed nanoemulsions and salmon 
calcitonin solution (13). The dose administered in all the cases was 500 UI/kg in a 
final volume of 0.5 ml. 
Blood samples were collected from the tail vein 30 min prior to the oral 
administration to establish the baseline calcium levels and at different times after 
dosing. The serum was separated by centrifugation at 3000 x g for 5 min. The 
calcium levels in serum samples were determined by a colorimetric method at 570 
nm (Kit OR-cresolphtalein v/v, Spinreact, Spain). The area above the time curve of 
the hypocalcemic effect (AAC0-24h) was calculated by means of the trapezoidal 
method. Results are shown as the mean values of serum calcium levels (± s.e.) of 6 
animals. 
 
Statistical analysis 
Data from the in vitro cell culture experiments were analyzed by an 
ANOVA test followed by the Student-Newman-Keuls with the statistical software 
package SPSS 11.5. Differences were considered to be significant at a level of p 
<0.01. 
The mean serum calcium levels determined in samples collected before 
salmon calcitonin administration were taken as the baseline levels. At each time 
interval the percent of calcium reduction was calculated. Using these values, the area 
above the time curve of the hypocalcemic effect was calculated and the statistical 
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comparison was performed by ANOVA followed by the Student-Newman-Keuls 
test for multiple comparisons between treatments using the software SPSS 11.5. 
Differences were considered to be significant at a level of p <0.05. 
 
Results and discussion 
We have recently shown that chitosan nanocapsules are able to enhance the 
nasal and the intestinal absorption of peptides (13, 14, 23). On the other hand, 
previous work by our group has evidenced the positive role of a PEG coating around 
polyester nanocarriers with regard to their performance as transmucosal drug 
carriers (10, 16, 17). More specifically, this PEG coating was found to enhance the 
stability of the nanocarriers upon contact with mucosal fluids and, their subsequent 
transport across epithelia (10, 16). In addition, we have reported the comparative 
behaviour of chitosan-coated polyester nanocapsules vs. PEG-coated nanocapsules 
in terms of their capacity of overcoming the ocular mucosa (24). The results 
indicated that both types of coatings have a positive effect on the interaction of the 
nanocarriers with the mucosal surface (24). In the present work, our idea was that 
the combination of these two polymers, chitosan and PEG -pegylation of chitosan-, 
could be advantageous in terms of improving the cellular toxicity of chitosan as well 
as the stability of the oily cores in the gastrointestinal fluids. Therefore, with this 
idea in mind, we used three different polymers: PEG and chitosan-PEG with two 
degrees of substitution of chitosan, 0.5 and 1%, which means that 0.5 or 1% of the 
chitosan monomers have been covalently linked to a PEG chain of 5000 Da. The 
structure of chitosan-PEG comb-type polymer and that of the expected nanocapsule 
is shown in Figure 1. 
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Figure 1: Chemical structure of chitosan-PEG comb polymer and illustration of the 
theoretically resulting chitosan-PEG nanocapsule. 
 
Characterization of chitosan-PEG 
Chitosan-PEG with two degrees of substitution, 0.46 and 1.19%, was 
obtained under aqueous conditions by a classical amide formation with EDC 
between the amino groups of chitosan and a carboxylic acid derived PEG. The 
resulting copolymers were characterized by 1H-NMR (in 2% DCl solution), which 
clearly indicated the incorporation of PEG by the appearance of an intense signal at 
3.70 ppm corresponding to the PEG methylene units. The degree of pegylation was 
determined from the 1H-NMR spectrum by integration of the multiplet at 2.90-4.40 
ppm (H2-H6 protons of chitosan, and PEG protons) against the acetyl signals (1.95-
2.20 ppm; NAc, and AcOH from hydrolysis). As a representative example, the 1H-
NMR spectrum of chitosan-PEG 1.19% is included: 1H-NMR (2% DCl in D2O, 500 
MHz): δ 2.06-2.08 (m, 20.8 H, COCH3), 3.20 (br s, 95 H, H2 from GluNH2), 3.37 (s, 
MeO from PEG), 3.55-3.95 (m, 1040H, H2 from GluNHAc; H3, H4, H5, H6 from 
GluNH2 and GluNHAc, CH2O from PEG), 4.62 (br s, H1 from GluNHAc), 4.91 (d, 
J=6.7 Hz, H1 from GluNH2). 
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Characterization of chitosan-PEG nanocapsules 
The results of the physico-chemical characterization of the different 
systems developed are shown in Table 1. As a means of comparison, the oily cores, 
named nanoemulsions were also included. It can be seen that the size of the 
chitosan-PEG nanocapsules is significantly larger than that of the control 
nanoemulsion. In agreement with the observations made for chitosan nanocapsules 
(13, 23), this increase in particle size was a first indication of the attachment of the 
polymers to the surface of the oily cores, as illustrated in figure 1. This can be easily 
understood by the fact that chitosan-PEG nanocapsules were prepared by simple 
incubation of the nanoemulsion with the polymers solutions. The chitosan-PEG 
coating of the nanocapsules was formed due to the complexation between the 
negatively charged lecithin and the positively charged chitosan-PEG, this complex 
being responsible for the stabilization of the oily core. An additional observation 
from table 1 is that the size of PEG-coated nanocapsules was slightly smaller (161 
nm) than that corresponding to the control nanoemulsion (196 nm). This reduction 
of the size, despite the presence of a PEG coating was attributed to the tensoactive 
properties of PEG-stearate used for the formation of these nanocapsules. 
The second evidence of the chitosan-PEG coating comes from the results of 
the zeta potential. The nanoemulsion has a marked negative charge (-52 mV) which, 
after incubation with both chitosan-PEG polymers, was inverted to highly positive 
values (+30 mV), regardless of the pegylation degree of chitosan (Table 1). This 
inversion of the superficial charge of the system confirms the presence of chitosan-
PEG coating around the dispersed phase of the nanoemulsions, leading to a reservoir 
structure. In addition, the lack of influence of the chitosan pegylation degree could 
be an indication of the excess of positively charged chitosan around the 
nanostructure. On the other hand, it can be noted that the zeta potential of PEG 
nanocapsules was less negative (-45 mV) than that of the nanoemulsions (-52.0 
mV). This slight reduction in the negative charge of the nanoemulsions was 
attributed to a greater shift of the shear plane of the diffused nanocapsules layer due 
to the PEG coating (25). 
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Table 1: Physico-chemical properties of PEG nanocapsules, chitosan-PEG 0.5 and 
1% nanocapsules and the control nanoemulsion (mean ± s.d.; n=3). 
 
Type of nanosystem Size (nm) ζ Potential (mV) Encapsulation efficiency (%) 
NE1 195.8±1.1 -52.0±1.1 >98 
PEG NC 161.2±3.3 -45.6±1.8 --- 
CS-PEG 0.5% NC 247±7 +32.8±0.5 44.13±3.09 
CS-PEG 1% NC 251±17 +29.7±3.1 52.10±3.23 
1Data from Prego et al, (23). 
 
The morphological appearance of chitosan-PEG 0.5% nanocapsules and the 
control nanoemulsion was visualized using TEM (Figure 2). It could be observed 
that both types of nanostructures presented a spherical morphology. 
A B
 
Figure 2: Transmission electron micrographs of A) nanoemulsion and B) chitosan-
PEG 0.5% nanocapsules. 
 
Salmon calcitonin encapsulation efficiency 
The encapsulation efficiency of salmon calcitonin in chitosan-PEG 
nanocapsules with both pegylation degrees is shown in Table 1. As comparison, we 
have also included the encapsulation efficiency of salmon calcitonin in the oily core. 
The results show that the association of salmon calcitonin was dependent on the 
composition of the carrier. Indeed, the peptide exhibited a high affinity for the 
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nanoemulsions, its encapsulation efficiency being close to 100%. However, the 
encapsulation efficiency in chitosan-PEG nanocapsules was reduced and affected by 
the chitosan pegylation degree (44% and 52% for 0.5 and 1% pegylation degree 
respectively). These results agree with those previously found for chitosan 
nanocapsules (13, 23) and suggest that, under the experimental conditions of the 
study, the attachment of chitosan-PEG leads to a displacement of the peptide 
molecules associated to the surface of the oily cores. This could be justified by the 
positive charge of both, salmon calcitonin and chitosan-PEG. This mechanism 
would also explain the fact that the chitosan with less positive charges (more 
pegylated) has a lower interference in the encapsulation of salmon calcitonin. 
Overall, these results indicate that the attachment of polymers onto the surface of 
nanoemulsions may interfere with the surface localization of some peptide 
molecules. 
 
In vitro release studies 
In agreement with the observed effect of the pegylation degree of chitosan 
on the encapsulation efficiency of salmon calcitonin, we found that the extra PEG 
coating also affects the release behaviour of the resulting nanocapsules. Indeed, as 
shown in Figure 3, both types of chitosan-PEG nanocapsules presented an initial fast 
release of salmon calcitonin followed by a non-release phase for up to 6 hours. It 
should be noted that the percentage of peptide released in the initial phase from 
chitosan-PEG 0.5% nanocapsules was moderate (20%) and similar to that observed 
for chitosan nanocapsules (23). However, an increase in the pegylation degree of 
chitosan led to a significant decrease in the percentage of salmon calcitonin released 
in the initial phase (10%). In other words, the pegylation of the chitosan coating 
facilitated the retention of the peptide in the nanocapsules. This could be related to 
both the greater amount of peptide associated to chitosan-PEG nanocapsules and to 
the different composition and organization of the coating. 
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Figure 3: In vitro release profiles of salmon calcitonin from chitosan-PEG 0.5% 
nanocapsules (grey line) and chitosan-PEG 1% nanocapsules (black line). (Mean ± 
s.d.; n=3). 
 
Stability of the nanocapsules in simulated gastrointestinal fluids  
It is known that nanocarriers are susceptible to aggregation in media with 
high ionic strength, extreme pH or high enzyme/protein content, and that the surface 
composition of the nanocarrier plays an important role in its stability. In this study, 
we have investigated the effect of PEG at improving the stability of the 
nanoemulsions and chitosan nanocapsules in the gastrointestinal fluids. Accordingly, 
we have monitored the size of PEG nanocapsules and chitosan-PEG nanocapsules 
with 0.5 and 1% of pegylation degree, after incubation in gastrointestinal fluids 
(Figure 4 and 5). As a means of comparison we also investigated the unpegylated 
chitosan nanocapsules and the nanoemulsion. As shown in Figure 4b, in the gastric 
medium without enzymes, all nanocarriers maintained their original size. A different 
situation was observed in the gastric medium containing enzymes (Figure 4a) where 
the presence of PEG, chitosan or chitosan-PEG attached to the oily core was found 
to improve the stability of the nanoemulsion, which otherwise aggregated massively 
upon dilution in the incubation medium. The increase on size observed for the 
nanoemulsion was attributed to the presence of pepsin, since the nanoemulsion 
maintained its particle size in absence of enzymes. In fact, taking into account that 
the isoelectric point of the pepsin is 3.5 (26) and the pH of the simulated gastric fluid 
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is 1.2, the enzyme was probably adsorbed onto the negatively surface of the 
nanoemulsion. Consequently, and in agreement with the PEG stabilizing effect 
previously reported by Tobio et al. (16), the explanation of the positive effect of 
either PEG or chitosan-PEG coatings was the reduction in the interaction of the 
nanocarrier with the digestive enzymes. With regard to the ability of chitosan in 
preventing the desestabilization of the systems, previous studies showed the positive 
effect of this polymer at stabilizing poly-ε-caprolactone nanocapsules in the 
presence of lysozyme (27). 
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Figure 4: Stability of PEG nanocapsules and chitosan-PEG nanocapsules with 0.5% 
and 1% pegylation degrees, in simulated gastric fluid with enzymes (a) and without 
enzymes (b) (Mean ± s.d.; n=3). 
 
The behaviour of the nanocarriers upon incubation in simulated intestinal 
fluids was quite different (Figure 5). In this medium, PEG nanocapsules and the 
nanoemulsion were stable, however, the stability of chitosan nanocapsules was 
influenced by the degree of pegylation of chitosan (Figure 5a). Chitosan 
nanocapsules were massively aggregated and precipitated after one hour of 
incubation in intestinal fluids. A pegylation degree of chitosan of 0.5% did not lead 
to a particle precipitation although a certain aggregation was noticed, whereas those 
with a 1% PEG were totally stable. An explanation of these results could be that 
PEG grafted to chitosan would reduce the interaction of the nanocarrier with the 
intestinal enzymes probably by a steric stabilization effect. In order to verify this 
hypothesis, we incubated the nanocapsules in intestinal fluid without enzymes 
(Figure 5b). The results showed that as expected, the size of PEG nanocapsules and 
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chitosan-PEG 1% nanocapsules remained unchanged, however a significant size 
increase, although much less significant than in the presence of enzymes, was noted 
for chitosan-PEG 0.5% nanocapsules. In the case of the unpegylated chitosan 
nanocapsules, they were not massively aggregated although a size increase was 
clearly distinguished. 
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Figure 5: Stability of PEG nanocapsules and chitosan-PEG nanocapsules with 0.5% 
and 1% pegylation degrees, in simulated intestinal fluid with enzymes (a) and 
without enzymes (b). (Mean ± s.d.; n=3). 
 
Consequently, from these studies, we can conclude that the chemical 
modification of chitosan with PEG helps to maintain the stability of the 
nanocapsules in either the gastric or the intestinal medium. Moreover, the degree of 
pegylation particularly affects the stability of the nanocarrier in the intestinal 
medium containing enzymes. 
More specifically, we noticed that chitosan-PEG nanocapsules with the 
lowest pegylation degree (0.5%) suffered a certain aggregation, whereas those with 
1% PEG were totally stable. An explanation of these results could be that PEG 
grafted to chitosan would reduce the interaction of the nanocarrier with the intestinal 
enzymes probably by a steric stabilization effect. 
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Cytotoxicity studies in Caco-2 cells 
Previous studies in Caco-2 cells have made it clear that the toxicity of 
chitosan depends on its physico-chemical properties but mainly on the concentration 
of the polymer exposed to the epithelium (28, 29). Additionally, we have reported 
that chitosan nanocapsules have a dose-dependent cytotoxicity, the 50% lethal 
concentration (LC50) being around 1 mg/ml (13). In this study, our purpose was to 
determine whether or not the pegylation of chitosan could help in improving the 
biocompatibility of the nanocarrier with the Caco-2 cells. Figure 6 shows the effect 
of chitosan-PEG nanocapsules with different chitosan pegylation degrees on the 
cellular viability of Caco-2 cells. Interestingly, the results showed that chitosan-PEG 
nanocapsules have a very good biocompatibility with the monolayers. More 
specifically, the LC50 for chitosan-PEG nanocapsules was between 10-20 mg/ml. 
This indicates that the cytotoxicity inherent to chitosan nanocapsules was reduced by 
10-20 times thanks to the pegylation of chitosan. 
 
Figure 6: Cytotoxicity study: fraction of NADH+ activity measured in Caco-2 as a 
function of the concentration of the nanoemulsion and chitosan-PEG 0.5 and 1% 
nanocapsules. (Mean ±SD, n=4-8). 
 
Transepithelial electrical resistance studies 
The ability of chitosan to decrease the TEER values across the Caco-2 cell 
monolayers has been thoroughly investigated (30-32). Recently, we also evaluated 
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the TEER of the Caco-2 monolayer exposed to chitosan nanocapsules and found that 
a significant decrease in the original TEER value was only noted for a relatively 
high concentration of nanocapsules (13). In the present work, we found it important 
to evaluate if the pegylation of chitosan, could affect to the interaction of the 
nanocarrier with the tight junctions of the monolayer. To perform this experiment, 
we have selected chitosan-PEG 0.5% nanocapsules, which were applied to the 
monolayer at a concentration of 80 µg/cm2. The results in Figure 7 show that 
chitosan-PEG 0.5% nanocapsules caused a slight but significant reduction in TEER 
values at 100 minutes after exposure to the nanocapsules. It was also noted that the 
original TEER value of monolayers was recuperated after the removal of the 
nanocapsules. Consequently, these results indicate that chitosan-PEG 0.5% 
nanocapsules have a minor effect on the TEER of the monolayer; an effect that was 
comparable to that previously observed for chitosan nanocapsules (13).. 
 
Figure 7: Transepithelial electric resistance (TEER) of Caco-2 monolayers exposed 
to 250 μg/ml of chitosan-PEG 0.5% nanocapsules (solid black line) and its 
respective control of HBSS pH 6 (dotted black line). (Mean ± SD, n=3). 
* Significantly different from HBSS pH6 (p < 0.05). 
 
In vivo efficacy of chitosan nanocapsules 
In a previous work, we have shown the ability of chitosan nanocapsules to 
increase the intestinal absorption of salmon calcitonin (13, 14). These positive 
results were mainly attributed to the special role of chitosan at improving the 
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interaction of the nanocapsules with the absorptive epithelium. In the present study, 
our objective was to investigate if the pegylation of chitosan, which was found to 
affect very positively the cytotoxicity and the stability of the nanocapsules in 
biological fluids, could also influence the efficacy of the nanocapsules as carriers for 
oral peptide administration. With this idea in mind, we tested the ability of chitosan-
PEG nanocapsules in promoting the absorption of salmon calcitonin and, hence 
improving its pharmacological response, using rats as an animal model. 
Figure 8 shows the profiles of the calcium levels achieved following oral 
administration of both chitosan-PEG formulations assayed as well as the controls, 
the nanoemulsion and a salmon calcitonin aqueous solution. The first observation is 
that, as expected, the controls showed a negligible hypocalcemic effect. On the 
contrary, following oral administration of chitosan-PEG nanocapsules we observed a 
significant reduction in the serum calcium levels and this important response was 
maintained for at least 24 hours. In addition, it should be noted that the response 
elicited by the two types of chitosan-PEG nanocapsules varied depending on the 
pegylation degree of chitosan. Indeed, the most important response was obtained for 
the nanocapsules prepared with the lowest degree of substitution of chitosan (0.5%), 
this response being similar to the one corresponding to chitosan nanocapsules (13). 
 
Figure 8: Hypocalcemic effect after oral administration in rats of chitosan-PEG 0.5 
and 1% nanocapsules as well as the control nanoemulsion (NE) and the aqueous 
solution of salmon calcitonin (sCT Sol). Dose of salmon calcitonin: 500 IU (Mean ± 
s.e.; n=6). 
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Finally, the comparison of areas above the hypocalcemic effect curve (AAC 
0-24h) obtained following administration of the different formulations (Figure 9) 
confirms the efficacy of chitosan-PEG nanocapsules in comparison to the controls. 
In fact, the AAC0-24h of the serum calcium levels-time curve after oral administration 
of both chitosan-PEG nanocapsules, 0.5 and 1%, was significantly higher than that 
of the nanoemulsion and salmon calcitonin aqueous solution. In addition, it can be 
noted that the AAC values of both types of chitosan-PEG nanocapsules were 
statistically different. 
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Figure 9: Area above hypocalcemic effect curve (AAC 0-24 hr) after oral 
administration to rats of salmon calcitonin in solution or incorporated in the 
nanoemulsions and chitosan-PEG 0.5 and 1% nanocapsules. Dose of salmon 
calcitonin: 500 IU. 
* Significantly different from salmon calcitonin solution and the control 
nanoemulsion (p < 0.05). 
# Significantly different from chitosan-PEG 1% nanocapsules (p < 0.05). 
 
As in the case of chitosan nanocapsules (13, 14), the explanation of the 
efficacy of chitosan-PEG nanocapsules could be found in the efficient interaction of 
the nanocapsules with the intestinal mucosa, forming a depot from which the peptide 
can be slowly released. This efficient interaction is possibly due to the small size of 
the nanocapsules but also due to the mucoadhesive properties of chitosan. In this 
sense, and given the fact that chitosan-PEG nanocapsules are very stable in the 
gastrointestinal fluids, one could argue that the reduction of their efficacy with the 
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increase in the pegylation degree could be related to the partial mask of the chitosan 
mucoadhesive properties. Indeed, it is plausible that PEG partially hides the positive 
charge of the amino groups, thereby altering their interaction with the negatively 
charged mucosa. On the other hand, although we can not discard the possible 
decrease in the TEER of the intestinal epithelium, the slight reduction observed in 
vitro under quite drastic conditions, suggests that this effect is not responsible for the 
efficacy of these new nanocarriers. 
Overall, these results highlight the crucial role of the modulation of 
chitosan with PEG at stabilizing nanocapsules, maintaining the oral absorption of 
salmon calcitonin. 
 
Conclusions 
In this paper we have evaluated the efficacy of a novel nanocarrier 
consisting of chitosan-PEG nanocapsules, for the oral administration of the model 
peptide salmon calcitonin. Additionally, we compared the behaviour of these comb 
polymer nanocapsules with that of chitosan nanocapsules and PEG nanocapsules. 
The results showed an improvement of the in vitro stability of the nanocarriers when 
PEG is present in the formulations. Moreover, the pegylation of chitosan increased 
the cellular viability of Caco-2 cells. Finally, after oral administration of chitosan-
PEG nanocapsules to rats, a great pharmacological response was obtained. 
Therefore, chitosan-PEG nanocapsules have a great potential as carrier for 
improving the oral absorption of peptide drugs. 
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Abstract 
We have previously shown that high molecular weight (Mw>100kDa) 
chitosan nanocapsules are efficient vehicles for improving the oral absorption of 
salmon calcitonin (sCT). In the present work, our goal was to further investigate the 
potential of these nanocapsules by studying the effect of different variables, such as 
the use of chitosan olygomers, the amount of lecithin used to prepare the 
nanocapsules and the dose of sCT, on the response elicited by the peptide-loaded 
chitosan nanocapsules administered orally to rats. In addition, in this work we aimed 
at elucidating the mechanism of action of chitosan nanocapsules as carriers for oral 
peptide delivery. 
The different formulations of chitosan nanocapsules, prepared by the 
solvent displacement technique, presented a particle size in nanometer range, a 
positive surface charge and the ability to encapsulate efficiently sCT. Following oral 
administration to rats, all formulations of sCT-loaded chitosan nanocapsules 
exhibited the ability to reduce the calcemia levels, however, the intensity of the 
response varied depending on the variables investigated. An increment on the 
amount of lecithin did not modify significantly the extension of the hypocalcemic 
effect which lasted for at least 24 hours. However, the use of chitosan olygomers 
reduced the duration of the response up to 4 hours post-administration. Finally, the 
reduction of the peptide dose led to a reduction of the intensity, but not the duration, 
of the hypocalcemic effect. 
The mechanism of action of chitosan nanocapsules was investigated by 
confocal fluorescence microscopy, after incubation of the nanocapsules with the 
Caco-2 cell model or in the co-culture of Caco-2 with HT29-M6 cells. The confocal 
xz images evidenced that chitosan nanocapsules are associated and remain in the 
apical side of both model cell cultures. Moreover, no fluorescence associated to the 
nanocapsules was observed either in the paracellular region or in the basolateral side 
of cells monolayer. In the co-culture, the association pattern of chitosan 
nanocapsules was not equal for both cell types, showing a preferable association to 
the mucus secreting cells (HT29-M6). Therefore, these results indicate that the 
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mucoadhesive character of chitosan nanocapsules may be taken as responsible for 
the enhancement of the intestinal absorption of peptides. 
Keywords: chitosan, nanocapsules, oral peptide delivery, 
mucoadhesion 
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Introduction 
Peptide drugs are poorly absorbed after oral administration because of their 
susceptibility to enzymatic degradation and their low permeability across the 
intestinal epithelium. Being conscious of these important biopharmaceutical 
limitations, many pharmaceutical scientists have taken the challenge of designing 
new delivery strategies intended to enhance the oral absorption of these 
macromolecules. Among them, the encapsulation of macromolecular drugs in 
nanoparticles/nanocapsules is considered a promising approach towards overcoming 
the mentioned barriers. Indeed, nowadays it is known that these nanosystems can 
protect sensitive molecules against degradation in the gastrointestinal environment 
(1, 2) and also favour the interaction of the associated biomolecule with the 
intestinal epithelium (3-5). In addition, with respect to the factors that affect this 
interaction, it has been clearly demonstrated that the size of the particles has a 
critical role in their interaction with the intestinal barrier (6-8). Knowing this, 
recently, the challenge has been oriented towards elucidating how the surface 
properties and composition affects the interaction of the nanosystems with the 
intestinal epithelium (9). 
Mucoadhesive polymers represent one class of biomaterials with an 
interesting potential for the design of transmucosal nanoparticulate carriers. These 
polymers offer the possibility to facilitate the interaction of the nanocarrier with the 
intestinal mucosa and, hence, its access to the underlying epithelium. Indeed, this 
mechanistic principle has been adopted to explain the efficacy of particles made of 
acrylic polymers (10, 11), polyanhydrides (12, 13) and chitosan (14, 15) as carriers 
for the transmucosal delivery of peptides. More specifically, it has been suggested 
that, because of their composition, these particles are targeted to the mucus covering 
the intestinal epithelium. Once the particles reach the mucus blanket, they are able to 
diffuse through it and reach the underlying epithelium, where they may stay for 
extended periods of time (16). Interestingly, the behaviour of these particles is quite 
different compared to that of polymer solutions or large polymer devices. 
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In recent years, we have particularly focused our work on designing and 
evaluating the potential of nanosystems based on the mucoadhesive polysaccharide 
chitosan. More specifically, we have observed that chitosan nanocapsules are able to 
enhance and prolong the systemic absorption of the model peptide, sCT 
administered orally (17). Additionally, recent experiments have indicated that the 
modification of chitosan molecular weight (within the range of 160-450 kDa) or the 
chitosan salt form (glutamate vs. hydrochloride) does not affect the efficacy of the 
nanocapsules as carriers for sCT (18). These nanocapsules consist of an oily core, 
conveniently stabilized with lecithin, and surrounded by a chitosan coating. The 
formation of this coating is mediated by the interaction between the negatively 
charged phospholipids and the positively charged chitosan molecules. Taking this 
previous information into account, we found it important to further evaluate the 
determinants of the in vivo performance of these nanocapsules by analyzing other 
experimental factors such as: (i) the use of chitosan olygomers (Mw <10kDa), (ii) 
the use of high lecithin concentration, which might affect the amount of chitosan 
associated to the surface of the nanocapsules and (iii) the reduction of the dose of 
nanocapsules containing sCT administered. 
Another important goal of the present work was to elucidate the mechanism 
of action of chitosan nanocapsules. In previous studies in Caco-2 cells we have 
observed that the association of chitosan nanocapsules to the monolayer is low and 
similar to that observed for the control non-coated nanoemulsion (17). This lack of 
evidence of the role of the chitosan coating led us to consider the necessity of 
selecting a different model cell line in order to investigate the mechanism of action 
of chitosan nanocapsules. Indeed, Caco-2 cells undergo spontaneous differentiation 
forming a monolayer of polarized enterocytes that possess morphologic and 
functional similarities to the small intestine (19). However, a disadvantage of this 
well-establish cell culture model is the lack of the mucus layer. Thus, in this study 
we analyzed and compared the behaviour of chitosan nanocapsules upon incubation 
with the Caco-2 monolayer and also with the co-culture of Caco-2 and mucus 
secreting cells (HT29-M6). 
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Therefore, the aims of the present work were, first to investigate further the 
determinants of the efficacy of chitosan nanocapsules as carriers for the oral 
administration of peptides, and, second, to elucidate the mechanistic events of 
chitosan nanocapsules responsible for the enhancement of the oral peptide delivery. 
 
Materials and Methods 
Materials 
sCT was kindly donated by Almirall Prodesfarma, S.A. (Spain). Miglyol 
812®, a triglyceride formed from medium chain fatty acids was supplied by Lemmel 
(Spain). The surfactant soybean L-α-lecithin and Poloxamer 188 (Pluronic F-68®) 
were supplied from Sigma-Aldrich (Spain). Chitosan chloride with a deacetylation 
degree of 85% and viscosity of 16 mPa was purchased from FMC Biopolymer/ 
Novamatrix with the name of Protasan® Cl 113 (Norway). N- (fluorescein-5-
thiocarbamoyl)-1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine, 
triethylammonium salt was purchased from Molecular Probes Europe BV (The 
Netherlands). 
 
Preparation of chitosan olygomers 
Chitosan olygomers were prepared from medium molecular weight 
chitosan (medium Mw chitosan) by oxidative degradation using sodium nitrite 
(NaNO2) according to the procedure described by Janes et al (20). For this propose, 
0.1 ml of NaNO2 (0.1 M) were added to 2 ml of a chitosan solution (1% w/v) at 
room temperature under magnetic stirring. The reaction was left overnight in order 
to ensure completion of the degradation. Finally, the resulting chitosan solution was 
freeze-dried. 
The molecular weight of chitosan was estimated from the viscosity values, 
measured in a capillary viscosimeter (Automated Microviscometer, Anton Para 
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GMBH, Austria) at 25ºC. The capillary diameter used was 1.6 mm. To measure the 
viscosity of the polymer, chitosan solutions were prepared at concentrations lower 
than 1% (w/v). The solvents used were 2% acetic acid with 0.2 M sodium acetate. 
The intrinsic viscosity was determined by linear extrapolation to infinite dilution and 
used with the appropriate Mark-Houwink parameters (21) in order to obtain the 
molecular weight of the original (medium Mw) and the resulting chitosan 
olygomers. 
 
Preparation of chitosan nanocapsules 
Chitosan nanocapsules were prepared according to the procedure 
previously described by our group (17). First, we prepared a lecithin-stabilized 
nanoemulsion (22, 23) as a reference formulation by solvent displacement 
technique. Briefly, an organic phase composed of 125 µl de Miglyol, 40 mg of 
lecithin dissolved in 0.5ml of ethanol, and 9.5 ml of acetone was added to 20 ml of 
an aqueous phase containing Poloxamer 188 (0.25% w/v), under magnetic stirring. 
The mixture turned milky immediately as a result of the formation of the 
nanoemulsion. Then, the solvents were evaporated under vacuum until a final 
volume of 10 ml. In a second step, this nanoemulsion was coated with chitosan by 
simple incubation in the polymer solutions. More specifically, 4 ml of the control 
nanoemulsion were incubated with 1 ml of chitosan aqueous solution (chitosan 
olygomers or medium molecular weight chitosan, Cl113) (0.5% w/v) for 1 h, 
leading to the formation of chitosan nanocapsules. 
In a different experiment, chitosan nanocapsules were prepared according 
to the conditions indicated above but increasing the amount of lecithin up to 120 mg. 
sCT-loaded chitosan nanocapsules were obtained following the procedure 
described above but adding 50 μl of an aqueous solution of sCT (20 mg/ml) to the 
organic phase containing the oil. 
For the in vitro cell culture studies, fluorescent nanostructures were 
prepared. In this case, 0.5 mg of fluorescein-phosphoetanolamine (λex496/λem519 
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nm) were added to the organic phase and, then, the procedure was followed as 
indicated above. 
 
Characterization of chitosan nanocapsules 
The size and polydispersion index of the nanocapsules were analyzed by 
photon correlation spectroscopy (PCS), following appropriate dilution with ultrapure 
water. Each analysis was performed in triplicate at 25ºC with an angle detection of 
90º. The zeta potential was determined by laser Doppler anemometry (LDA). For 
the determination of the electrophoretic mobility, samples were diluted with KCl 
1mM and placed in the electrophoretic cell where a potential of ±150 mV was 
established. The PCS and LDA analysis were performed using a Zetasizer® 3000 HS 
(Malvern Instruments, Malvern, UK). Each batch was analyzed in triplicate. 
The morphological analysis was performed by transmission electron 
microscopy (TEM), (Philips CM12, Eindhoven, Netherlands). Samples were stained 
with phosphotungstic acid solution (2% w/v) for 1 minute and, then dried overnight. 
 
Salmon calcitonin encapsulation efficiency and in vitro release studies 
sCT was associated to low molecular weight chitosan nanocapsules. The 
amount of peptide encapsulated was determined indirectly in the supernatant, 
following separation of nanocapsules from aqueous medium by a combined 
ultrafiltration- centrifugation technique (Centricon YM-100, Millipore, USA) at 
1000 x g for 1h. The supernatant was diluted with acetate buffer pH=4 and assayed 
for sCT content by HPLC at 220 nm (Agilent Technologies, Germany), as described 
in the British Pharmacopoeia, 1998 (column: Vidac 218TP). A calibration curve was 
made with solutions of sCT in acetate buffer, pH=4.0, at concentrations ranging 
from 5 to 100 μg/ml. Each sample was assayed in triplicate. 
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The in vitro release studies of sCT from chitosan nanocapsules were 
performed by incubating the loaded nanocapsules in acetate buffer (pH=4), under 
horizontal stirring at 37°C. At appropriate time intervals, individual samples were 
ultrafiltered at 1000 x g for 1 h. The sCT released was determined by HPLC. 
 
In vivo efficacy of chitosan nanocapsules 
To perform the in vivo studies, male Sprague-Dawley rats (225- 275 g), 
from the Central Animals House of the University of Santiago de Compostela 
(Spain), were fasted for 12 h before experiments, but rats were allowed access to 
water ad libitum. Animals were kept conscious during the experiments. All animal 
experiments were approved by the Ethical Committee of the Faculty of Medicine of 
the University of Santiago de Compostela.  
In this study, we analyzed the effect of some experimental variables on the 
efficacy of chitosan nanocapsules to induce a pharmacological effect, after oral 
administration: (i) the effect of the nature of the coating, using chitosan olygomers 
(10 kDa vs. 100 kDa); (ii) the effect of the nature of the coating, using a high amount 
of the surfactant lecithin (120 mg vs. 40 mg); (iii) the effect of the dose of sCT-
containing nanocapsules (250 vs. 500 IU). 
Blood samples were collected from the tail vein 30 min prior to the oral 
administration of the different formulations, in order to establish the baseline 
calcium levels, and also at different times after dosing. The serum was separated by 
centrifugation at 3000 xg for 5 min. Hypocalcemic effect was determined in serum 
samples by a colorimetric method at 570 nm (Kit OR-cresolphtalein v/v, Spinreact, 
Spain). 
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Cell culture experiments 
Caco-2 (enterocyte-like cells) and HT29-M6 (mucus secreting cells) were 
cultivated in 80 cm2 flasks (Nunc, Denmark) using Minimum Eagle Medium 
(MEM) supplemented with 10% fetal bovine serum (FBS), 1% L-glutamine, 1% 
non-essential amino acids and penicillin/ streptomycin solution. Cells were 
maintained in a controlled atmosphere at 37ºC with 95% of relative humidity and 
5% CO2. The culture medium was changed every second day for approximately 5-6 
days until cells reached approximately 80-90% of confluence. After the passage 
operation, cells were seeded approximately at 2.5 x 105 cells per flask. For the 
experiments, Caco-2 cells at passage number 67 and HT29-M6 at passage number 
11 were used. 
 
Qualitative study of the interaction of chitosan nanocapsules with the 
Caco-2 and HT29-M6 cells 
The study of the interaction of chitosan nanocapsules with the cell cultures 
was performed on TranswellTM filter inserts (0.4 µm pore size diameter, area 0.33 
cm2). For this purpose, Caco-2 (enterocyte like cells) and HT29-M6 (mucus 
secreting cells) models cell lines were seeded with a density of 6 x 104 cells/cm2, 
either as a single cell type (Caco-2) or as co-culture (Caco-2:HT29-M6 as 1:1 ratio). 
Cells were left to grow over 21 days until differentiation and the barrier integrity 
was checked. 
Prior to the experiment, cells were rinsed with Hank´s balanced salt 
solution (HBSS) pH 6.5-5% glucose and allowed to equilibrate at 37ºC. After this 
time, the apical medium was removed and cells were incubated with fluorescent 
chitosan Cl113 nanocapsules in HBSS-5% glucose pH 6.5 for 1 h. After incubation, 
the suspensions were removed and the epithelium was thoroughly washed with PBS-
CaMg. The samples were fixed with paraformaldehyde 3% in MTSB buffer and 
paraformaldehyde 3% with 0.2% saponin for 5 min. After permeabilization, the cells 
were washed and the intercellular protein, E-cadherin, was stained using the 
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immunofluorescence method. The cells were incubated with the primary antibody 
for 1 h and then, after extensive washing with PBS, with the secondary antibody, an 
anti-mouse IgG antibody, covalently attached to Alexa 546 (λex550/λem580nm) 
together with Hoechst reagent (λex350/λem461nm) at 1μg/ml for nuclear labelling for 
45 min. After labelling, the cells were thoroughly washed with PBS, filters were cut 
out and directly embedded in one drop of the mounting medium Dako®. 
Preparations were examined under a confocal laser scanning microscope (Leica 
TCS-SP2, Leica Microsystems). The same protocol was followed for the 
experiments in Caco-2 cells and in the co-culture (Caco-2 and HT29-M6 cells). 
 
Results and discussion 
As indicated in the introduction, we have previously shown that chitosan 
nanocapsules are able to enhance the oral absorption of the peptide sCT, leading to 
an important and long-lasting hypocalcemic effect (17, 18). Interestingly, the 
uncoated formulation, a nanoemulsion, led to an insignificant response; a result that 
evidenced the important role of the chitosan coating for the successful delivery of 
the associated peptide. In the present work, our first goal was to evaluate the effect 
of some technological factors inherent to the formation of the chitosan nanocapsules, 
i.e. the use of chitosan olygomers and the amount of lecithin used to prepare 
nanocapsules, as well as the effect of the dose of sCT-loaded nanocapsules on their 
in vivo efficacy. In the second part of this work, our aim was to elucidate the 
mechanism of action of chitosan nanocapsules as potential nanocarriers for oral 
peptide delivery. 
 
Production and characterization of low molecular weight chitosan 
Chitosan is commercially available with a molecular weight (Mw) of 
around 100 kDa and higher. Therefore, in order to obtain chitosan olygomers, an 
initial step of this work was to depolymerize chitosan by oxidative degradation using 
sodium nitrite. Using this procedure, the degree of depolymerization of chitosan can 
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be accurately controlled, since the number of glycosidic linkages broken is 
stoichiometric with the moles of sodium nitrite added. After incubation of the 
polymer solutions with sodium nitrite and using the parameters previously reported 
(21), straight-line fits were obtained for chitosan olygomers and chitosan 
commercially available (Protasan® Cl 113) (R2 > 0.9). The molecular weight 
calculated for chitosan olygomers and the undepolymerized chitosan Cl 113 gave 
estimated values of 10 kDa and 100 kDa respectively.  
 
Production and characterization of chitosan nanocapsules 
Chitosan nanocapsules were obtained by attaching chitosan onto preformed 
nanoemulsions. The attachment of chitosan was mediated by the ionic interaction 
between the negatively charged phospholipids and the positively charged chitosan 
molecules. The evidence of the coating was obtained from the analysis of the size 
and zeta potential of the different formulations (Table 1). The results show that the 
size of chitosan nanocapsules is significantly larger than that of the control 
nanoemulsion and also that it decreases with the molecular weight of chitosan. 
These results could be well explained by the fact that the thickness of the chitosan 
coating is expected to be dependent on the chain length of chitosan molecules. These 
differences in the coating were not translated into differences in the surface charge. 
Indeed, both formulations of nanocapsules exhibited very similar zeta potential 
values, thus confirming the effective coating of the nanoemulsion irrespective of the 
chitosan Mw. On the other hand, with respect to the influence of the amount of 
lecithin, it was found that an increase in this amount from 40 to 120 mg, led to a 
significant enlargement of the nanocapsules (from 266 to 333 nm, which was also 
accompanied by a reduction of the surface charge from +35 to +28 mV (23). These 
results suggest the formation of a larger coating caused by the interaction of lecithin 
and chitosan. Additionally, the presence of a greater amount of lecithin at the inter-
phase would justify the reduction of the zeta potential. 
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Table 1: Physicochemical properties and encapsulation efficiency of different 
nanocarriers (mean ± s.d.; n=3). 
Nanocarrier Polymer 
Mw (kDa) 
Lecithin 
(%) w/v 
Size (nm) ζ Potential 
(mV) 
Encapsulation 
efficiency (%) 
Nanoemulsion --- 0.4 195.8±1.1 -52.0±1.1 >90 
Medium Mw 
Chitosan nanocapsules
100 1.2 333.0±6.1 +28.3±2.1 51.9±1.9 
Medium Mw 
Chitosan nanocapsules
100 0.4 266.6±7.6 +34.8±0.6 44.12±3.24 
Olygomer 
Chitosan nanocapsules 
10 0.4 202.1±1.3 +30.7±1.9 60±2.65 
 
The morphological appearance of the nanocapsules prepared with low and 
high Mw chitosan are shown in Fig. 1. Both formulations presented a spherical 
morphology, however, their appearance was drastically different: high Mw chitosan 
nanocapsules exhibit a thick coating, whereas low Mw chitosan nanocapsules do not 
show an apparent coating. These results agree with those of the particle size, which 
indicated that the thickness of the coating is greatly dependent on the chitosan Mw. 
 A  B 
 
Figure 1: Transmission electron micrographs of A) chitosan olygomers 
nanocapsules and B) chitosan medium molecular weight nanocapsules. 
 
On the other hand, the preparation of fluorescent nanocapsules, using 
FITC-phosphoethanolamine as a marker, for in vitro cell culture experiments did not 
lead to any change in the physicochemical properties of the nanostructures as 
compared to the blank formulations. 
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Encapsulation efficiency and in vitro release studies of salmon calcitonin 
We have already shown that the encapsulation efficiency of sCT into 
chitosan nanocapsules was reduced when compared to that attained in the non-
coated nanoemulsion (17). This effect was attributed to a competition between the 
peptide and the chitosan, both positively charged in their association to the surface 
of the nanoemulsion. In the present study, we observed that the encapsulation 
efficiency was also dependent on the chitosan molecular weight. In fact, as shown in 
Table 1, olygomer chitosan nanocapsules showed slightly higher encapsulation 
efficiencies (60%) than medium Mw chitosan nanocapsules (44%). This indicates 
that the olygomer chitosan coating was not able to displace sCT in the same 
extension than medium Mw chitosan coating. This result could be an indirect 
indication of the reduced amount of chitosan olygomers forming the coating as 
compared to that corresponding to the medium Mw chitosan. Unfortunately, the 
experimental approaches aimed at quantifying the chitosan coating were 
unsuccessful. However, the indirect observation of the lower amount of chitosan 
olygomers forming the coating is in agreement with the smaller size of the resulting 
chitosan nanocapsules. 
The results of the in vitro release studies of sCT from olygomer chitosan 
nanocapsules indicated that the amount of peptide released from the carrier was 
negligible for up 6 hours. These results are comparable to those obtained for the 
control nanoemulsion; however, they differ from those observed for medium Mw 
chitosan nanocapsules. In fact, this latter formulation released 20% of the 
encapsulated sCT very rapidly (17). This fast release was assigned to the amount of 
peptide that was expelled from the oily cores due to the competition with chitosan 
molecules. Consequently, the lack of this fast release phase in the olygomer chitosan 
nanocapsules could be, as suggested above, in relation with the reduced amount of 
chitosan on the coating of these nanocapsules. 
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In vivo efficacy of chitosan nanocapsules 
We have previously shown that chitosan nanocapsules are able to enhance 
the oral absorption of sCT (17, 18). In the present work, one of the modifications we 
have introduced into the formulation is an increase in the amount of lecithin from 
0.4% to 1.2% w/v. The idea behind this modification was that the use of a greater 
amount of lecithin would probably lead to a denser coating and, as a consequence, to 
a different in vivo behaviour. This was assumed based on the mechanism of coating 
formation due to the complexation of chitosan and lecithin at the interphase of the 
emulsion. In agreement with this hypothesis, we observed an increase in the size and 
a reduction in the zeta potential of the nanocapsules (as previously discussed). 
However, as shown in Figure 2, this change in the formulation did not have a 
consequence on the in vivo performance of the nanocapsules. Indeed, the response 
elicited by the new formulation was not significantly different of the one 
corresponding to the chitosan nanocapsules already described (17). In both cases, an 
important and long-lasting reduction of the serum calcium levels was also observed 
after oral administration of the sCT-loaded nanocapsules. 
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Figure 2: Hypocalcemic effect after oral administration to rats of chitosan 
nanocapsules prepared with 0.4% and 1.2% w/v of lecithin (0.4L-CS NC and 1.2L-
CS NC, respectively) and a sCT aqueous solution (sCT Sol). The dose administered 
in all the cases was 500IU. (Mean ± s.e.; n=6). 
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An alternative for modifying the coating of the nanocapsules was based 
upon the use of chitosan olygomers. Fig. 3 depicts the pharmacological response 
attained after oral administration of olygomer chitosan nanocapsules (Mw=10 kDa) 
and medium Mw chitosan nanocapsules (Mw=100 kDa). The results indicate that 
olygomer chitosan nanocapsules led to an enhancement of the hypocalcemic effect 
when compared to the peptide solution. However, the improvement of the response 
associated to this formulation only lasted 4 hours, whereas that corresponding to 
medium Mw chitosan nanocapsules was maintained for at least 24 hours.  This 
reduction in the efficacy of the formulation could be related with the limited amount 
of chitosan around these nanocapsules, as suggested above. In fact, in a previous 
work we observed that the performance of chitosan nanoparticles as nasal vaccine 
carriers was not significantly affected by the molecular weight of chitosan (24). 
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Figure 3: Hypocalcemic effect after oral administration to rats of chitosan 
olygomers nanocapsules (olygomer CS NC), chitosan medium molecular weight 
nanocapsules (CS medium Mw NC) and a sCT aqueous solution. The dose of sCT 
was 500IU. (Mean ± s.e.; n=6). 
 
Finally, we found it important to determine the relationship between the 
dose of sCT (250 IU vs. 500 IU), and consequently of chitosan nanocapsules, 
administered orally and the resulting pharmacological response. As shown in Fig. 4, 
there was a clear effect of this parameter, the response being greatly reduced for the 
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lowest dose of sCT (250 IU). This was expected since most of the oral 
administration studies performed with this peptide have used doses of 500 IU or 
higher. However, the fact that the low dose led to a pulsatile pharmacological 
profile, characterized by one peak at 1-2 hours and a secondary response between 
12-24 hours was surprising. This kind of profile could be related to the release 
behaviour of the nanocapsules. We could speculate that there is a certain amount of 
sCT retained in the chitosan coating which would be available for a fast release, 
whereas most of the well-encapsulated peptide will require a certain time to be 
released from the carrier and then, absorbed. This long-term controlled delivery 
hypothesis would only be acceptable if we could assume that the nanocapsules are 
associated to the intestinal mucosa. The following experiments were intended to 
clarify this. 
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Figure 4: Hypocalcemic effect after oral administration to rats of chitosan 
nanocapsules prepared with 0.4% w/v of lecithin with two different doses of sCT: 
250 UI (CS NC 250IU) and 500 IU (CS NC 500IU). As a control, we have included 
a sCT aqueous solution of 500IU (sCT Sol). (Mean ± s.e.; n=6). 
 
Qualitative study of the interaction of chitosan nanocapsules with the 
Caco-2 and HT29-M6 cells 
We have previously performed some mechanistic studies in Caco-2 cells, 
aimed at understanding the greater in vivo performance of chitosan nanocapsules 
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compared to the control nanoemulsion (17). An observation from this previous study 
was that chitosan nanocapsules are able to open the tight junctions only when 
applied at a very high dose. Therefore, we concluded that, such a situation is not 
likely to happen in vivo and, consequently, the slight increase in the permeability can 
not be taken as a unique mechanism in explaining the in vivo efficacy of the 
nanocapsules. On the other hand, we performed a quantitative analysis association of 
fluorescent nanocarriers to the Caco-2 monolayer and observed a very similar 
association chitosan nanocapsules and the control nanoemulsion (17). Thus, we 
concluded that the chitosan coating did not affect the association of the nanocarrier 
with the cells. 
Taking these previous results into account, in this study, our goal was to 
further elucidate the mechanism of action of chitosan nanocapsules by comparing 
their qualitative interaction with the Caco-2 cell monolayer and also with a co-
culture of enterocytes and mucus-secreting cells (Caco-2:HT29-M6). Using confocal 
laser scanning microscopy, we could visualize the intercellular unions of cells after 
immunostaining of the intercellular protein E-cadherin, as well as the nucleus 
labelled with Hoechst. The localization of the nanocapsules was possible after 
labelling the formulations with phosphoethanolamine covalently attached to 
fluorescein. The incorporation of the marker to the nanocapsules did not modify 
their physicochemical properties. 
The results of the study with the Caco-2 cell monolayer indicated that 
chitosan nanocapsules (green spots) were able to interact with the cells, showing a 
random distribution (Fig. 5A1). In addition, the images of consecutive cross-sections 
suggest that the nanocapsules are able to enter the cell by a transcellular pathway. In 
fact, the lack of co-localization of the nanocapsules (green) with the E-cadherin 
marker (red), led us to exclude the presence of the nanocapsules in the paracellular 
region (which should appear in yellow). Furthermore, the analysis of the xz section 
of the monolayer indicated that, after one hour of incubation, the nanosystems have 
not crossed the monolayer, but they rather remained at the apical side of the 
monolayer (Fig. 5A2). These observations corroborate with those from our previous 
studies which suggested the intracellular presence of chitosan nanocapsules (17) and 
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also those reported about the interaction of chitosan nanoparticles with Caco-2 cells 
(4, 25). Nevertheless, an additional conclusion from this study is that, despite their 
apparent intracellular localization, the nanocapsules do not exhibit a capacity to 
cross the epithelium. The reason for their permanence at the upper level of the 
monolayer is still unknown and requires further investigation.. 
A1)             A2) 
             APICAL SIDE 
   
 
 
 
 
 
 
 
 
      BASOLATERAL SIDE 
 
 
B1)             B2) 
         
APICAL SIDE
BASOLATERAL SIDE  
Figure 5: Confocal scanning microscopy images showing the association of 
fluorescent nanocapsules (green) to Caco-2 cells and to the co-culture Caco-2:HT29-
M6 (E-cadherin in red and nucleus in blue).  
Caco-2: A1) Montage of 24 horizontal cross sections illustrating the interaction of 
fluorescent chitosan nanocapsules to the cells (step size in z-axis of 0.5 μm) and A2) 
Confocal xz section showing the accumulation of fluorescent chitosan nanocapsules 
in the apical side of the monolayer. 
Co-culture Caco-2:HT29-M6: B1) Montage of 16 horizontal cross sections showing 
the association of fluorescent chitosan nanocapsules to HT29-M6 cells (step size in 
z-axis of 0.5 μm). B2) Confocal scanning microscopy xz section showing the 
accumulation of fluorescent chitosan nanocapsules (green) in the apical side of the 
HT29-M6 cells. 
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Interestingly, the images obtained upon exposure of the formulations with 
the co-culture Caco-2:HT29-M6 are slightly different. First, we have evidenced a 
great interaction of chitosan nanocapsules with the cells (Fig. 5B1), which was not 
seen for the nanoemulsion control. In addition, we have observed that the 
association pattern of chitosan nanocapsules to both cell types was quite different. 
Indeed, there was a remarkable and preferable association of the nanocapsules with 
one cell type, HT29-M6 cells. Fig. 5B2 shows a xz-image of a region consisting of a 
multilayer of HT29-M6 cells (nuclei labelled in blue). As in the case of the Caco-2 
monolayer, the nanocapsules (green) remained associated to the apical side of the 
co-culture and the paracellular transport of the carriers was excluded. Unfortunately, 
it was not feasible to take a xz confocal image showing the Caco-2 cells in 
alternation with the HT29-M6 cells due to their different organizational depth 
(Caco-2 in monolayer and HT29-M6 in multilayer). However, it was possible to 
observe the surface of the co-culture by fluorescent microscopy (Fig. 6B). This 
image shows an important number of fluorescent chitosan nanocapsules specifically 
located on the top of Goblet islets, thus evidencing the mucoadhesive character of 
the nanocapsules. 
 
Figure 6: Fluorescent microscopy image of the co-culture Caco-2:HT29-M6 
showing chitosan nanocapsules labelling specifically on top of goblet islets. 
 
Consequently, from this study, we can infer that the mucoadhesive 
character of chitosan nanocapsules is determinant for their ability to interact with the 
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intestinal mucosa and facilitate the intestinal absorption of sCT. Theoretically, this 
mechanistic behaviour would also be applicable to other chitosan-coated 
nanostructures such as lipid nanoparticles (26) or PLGA nanoparticles (14). In fact, 
Kawashima et al (14), using the everted rat intestinal sac model, found that the 
mucoadhesive properties of chitosan-coated PLGA nanoparticles were responsible 
for the intimate contact of the nanosystem with the intestine and, thus, for the 
improvement on the peptide absorption. 
These mucoadhesive properties apply not only to chitosan nanocarriers but 
also to chitosan solutions. However, it has been indicated that the ability of chitosan 
to enhance the absorption of drugs is greatly reduced in mucus-covered cultures and 
that the concentration of both chitosan and the drug into a nanoparticulate form 
could help favouring the absorption of the drug (27). Moreover, regarding the oral 
administration of chitosan as such, it should be kept in mind that it precipitates upon 
reaching the intestinal region and, consequently, it is not expected to enhance drug 
absorption. 
Finally, it should be emphasized that despite this first evidence of the 
mucoadhesive properties of chitosan nanocapsules, further studies are required in 
order to fully elucidate the mechanism of action of chitosan nanocapsules.  
 
Conclusions 
In the present report we observed that the in vivo efficacy of chitosan 
nanocapsules, as carriers for sCT, can be modulated by adjusting the formulation 
parameters. In addition, the mechanistic studies performed in Caco-2 cells and in a 
co-culture with mucus secreting cells have revealed that the mucoadhesive 
properties of chitosan nanocapsules may represent a key factor for their ability in 
improving the peptide absorption after oral administration. 
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Entre los distintos nanosistemas desarrollados con el fin de mejorar la 
absorción de biofármacos de naturaleza peptídica a través de mucosas, las 
nanocápsulas, compuestas por un núcleo oleoso y un recubrimiento polimérico se 
presentan como una opción atractiva1, 2. Las ventajas que ofrecen estos sistemas 
coloidales residen en la capacidad del núcleo oleoso para proteger la molécula 
encapsulada frente a la degradación enzimática3, 4 y, al mismo tiempo, promover la 
absorción de fármacos a través del epitelio5. Por otro lado, el recubrimiento 
polimérico del núcleo oleoso ofrece interesantes ventajas inherentes al material 
                                                 
1 Legrand P., Barrat G., Mosqueira V. Fessi H., Devissaguet J.P. Polymeric nanocapsules as 
drug delivery systems. A review. S.T.P. Pharma (1999) 9: 411-418. 
2 Couvreur P., Barrat G., Fattal E., Legrand P., Vauthier C. Nanocapsule Technology: A 
review. (2002) 19: 99-134. 
3 Lowe P.J., Temple C.S. Calcitonin and insulin in Isobutylcyanoacrylate nanocapsules: 
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(1994) 46: 547-552. 
4 Damgé C., Michel C., Aprahamian M., Couvreur P., Devissaguet J.P. Nanocapsules as 
carriers for oral peptide delivery. J.Control. Release (1990) 13: 233-239. 
5 Murashini S. Absorption enhancers, Crit. Rev. Therap. Drug Carrier Systems. (1990) 7: 1-
33. 
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seleccionado. Entre los distintos polímeros empleados, el polisacárido quitosano se 
presenta como una atractiva alternativa debido a sus propiedades mucoadhesivas6 y 
promotoras de la absorción7. De hecho se ha comprobado que su presencia en los 
sistemas nanoparticulares, ya sea como material constituyente de los mismos 8, 9, 10, 
11, 12, o como material de recubrimiento 13, 14 ejerce un papel fundamental en su 
capacidad para mejorar la absorción de fármacos y vacunas administradas por vías 
mucosas. Además, es importante destacar que se trata de un polímero biocompatible 
15, 16 que presenta una muy baja toxicidad por vía oral 17. 
                                                 
6 Lehr C-M., Bouwstra J.A., Schacht E.H., Junginger H.E. In vitro evaluation of 
mucoadhesive properties of chitosan and some other natural polymers. Int. J. Pharm. (1992) 
78: 43-48. 
7 Artursson P., Lindmark T., Davis S.S., Illum L. Effect of chitosan on the permeability of 
monolayers of intestinal epithelial cells (Caco-2). Pharm. Res. (1994) 11: 1358-1361. 
8 Pan Y., Li Y., Zhao H., Zheng J., Xu H., Wei G., Hao J, Cui F. Bioadhesive polysaccharide 
in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin 
in vivo. Int. J. Pharm. (2002) 249: 139-147. 
9 Ma Z., Lim T..M., Lim L.Y. Pharmacological activity of peroral chitosan-insulin 
nanoparticles in diabetic rats. Pharm. Nanotechnol. (2005) 293: 271-280. 
10 Fernández-Urrusuno R., Calvo P., Remuñán-López C., Vila-Jato J.L., Alonso M.J. 
Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharm. Res. (1999) 
16: 1576-1581. 
11 Vila A., Sanchez A., Tobio M., Calvo P., Alonso M.J. Design of biodegradable particles for 
protein delivery. J. Control. Release. (2002) 78: 15-24. 
12 Vila A., Sanchez A., Janes K., Behrens I., Kissel T., Vila-Jato J.L., Alonso M.J. Low 
molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. 
Eur. J. Pharm. Biopharm. 57 (2004) 123-131. 
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carbopol and chitosan-coated liposomes and their effectiveness in the oral administration of 
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Por otro lado, se sabe que la peguilación de los polímeros, como el PLA, no 
sólo permite modificar las propiedades superficiales de los mismos sino también 
mejorar la estabilidad de los nanosistemas en contacto con los fluidos biológicos 18. 
Por tanto, presumiblemente, la peguilación del quitosano (quitosano-PEG) podría 
aportar una mejor estabilidad a las nanocápsulas en contacto con los fluidos 
gastrointestinales. 
En la presente tesis hemos estudiado el potencial de las nanocápsulas de 
quitosano como vehículos para la administración de péptidos a través de la mucosa 
nasal e intestinal. 
 
Desarrollo y caracterización de nanocápsulas de quitosano 
La elaboración de nanocápsulas de quitosano se llevó a cabo mediante la 
técnica de desplazamiento del disolvente, previamente desarrollada en nuestro 
laboratorio19. En una etapa inicial del trabajo experimental, se procedió a la 
optimización del proceso de obtención de las nanocápsulas de quitosano, 
evaluándose distintos factores: la concentración de lecitina, la concentración de 
quitosano y la etapa del proceso en la que el quitosano es incorporado. Esta 
incorporación puede producirse en la fase acuosa sobre la que se adiciona la fase 
orgánica o mediante incubación de una nanoemulsión previamente formada en una 
solución de quitosano. Para la caracterización de las nanocápsulas de quitosano, se 
determinó el tamaño de partícula y la carga eléctrica superficial. Asimismo, se 
visualizó la morfología de los sistemas mediante microscopía de transmisión 
electrónica. 
                                                 
18 Tobío M., Sánchez A., Vila A., Soriano I., Evora C., Vila-Jato J.L., Alonso M.J. The role of 
PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following 
oral administration. Colloids and Surfaces. (2000) 18: 315-323. 
19 Calvo P., Remuñan C., Vila-Jato J.L., Alonso M.J. Development of positively charged 
colloidal carriers: chitosan-coated polyester nanocapsules and submicron emulsions, Colloid. 
Polym. Sci. (1997) 275: 46-53. 
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El análisis del tamaño de partícula de las nanocápsulas de quitosano, 
realizado mediante espectroscopía de correlación fotónica, mostró que los sistemas 
se encuentra en rango nanométrico que oscila entre 200 y 570 nm, dependiendo de 
las variables estudiadas. Además, se observó que, independientemente del momento 
de incorporación del polímero, tanto la lecitina como el quitosano ejercieron un 
efecto estadísticamente significativo sobre el tamaño de partícula, siendo la 
concentración de quitosano el principal factor que afecta a dicho parámetro. 
Con respecto a la influencia de la concentración de quitosano, se apreció 
que, independientemente del método de preparación, la incorporación de pequeñas 
cantidades de quitosano no se traducía en cambios significativos en el tamaño (Fig. 
1). Sin embargo, para la concentración más alta de quitosano (0.3% p/v), el tamaño 
de partícula sufrió un importante aumento que fue atribuido al depósito de 
cantidades crecientes de quitosano sobre la superficie del núcleo oleoso. De hecho, 
el aumento de tamaño lleva consigo una progresiva inversión de la carga superficial 
del sistema, hecho igualmente observado en otros estudios al aumentar la cantidad 
de quitosano 20 o el peso molecular del polímero 21. 
En cuanto a la influencia de la concentración de lecitina, se observaron 
distintos comportamientos dependiendo del método de preparación empleado en la 
elaboración del sistema. Así pues, como se muestra en la Fig 1A, cuando el 
quitosano se incorpora en la fase acuosa sobre la que se adiciona la fase orgánica, el 
tamaño de partícula disminuye significativamente al aumentar la concentración de 
lecitina, especialmente con la concentración más alta de quitosano (0.3%). Este 
hecho podría atribuirse a la presencia de una segunda  población de nanocomplejos 
de la lecitina-quitosano acompañando a las nanocápsulas. En consecuencia, de este 
estudio se pudo concluir que tanto la concentración de lecitina como de quitosano 
poseen un valor crítico en la formación de nanocápsulas de quitosano. 
                                                 
20 Calvo y col., 1997. ibid pag. 213. 
21 Ogawa S., Decker E.A., McClements D.J. Production and characterization of O/W 
emulsions containing cationic droplets stabilized by lecithin-chitosan membranes. J. Agric. 
Food Chem. (2003) 51: 2806-2812. 
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Fig. 1: Superficies de respuesta que muestran el efecto de la concentración de 
lecitina y quitosano sobre el tamaño de las nanocápsulas, en las que el quitosano se 
incorporó en la fase acuosa de las nanoemulsiones (A) o tras la incubación de las 
nanoemulsiones en soluciones de quitosano (B). 
 
Por otro lado, cuando la incorporación del quitosano re realizó mediante 
incubación de una nanoemulsión previamente formada en una solución de quitosano 
(Fig. 1B), se pudo constatar un aumento de tamaño del nanosistema. Además dicho 
aumento se hizo más apreciable al aumentar la concentración de lecitina; resultado 
que fue hipotéticamente atribuido a un mayor depósito del quitosano. 
La evidencia de la presencia de la cubierta de quitosano fue corroborada 
mediante la medida de la carga superficial de las nanocápsulas. En efecto, la 
inversión del potencial zeta desde valores altamente negativos, en el caso de la 
nanoemulsión, a valores positivos, en el caso de las nanocápsulas de quitosano, 
permitió confirmar el recubrimiento de los núcleos oleosos con quitosano (Fig. 2). 
No se observó una influencia de la concentración de lecitina en la carga superficial 
de los sistemas. No obstante, el quitosano ejerció un efecto sobre dicho parámetro, 
aumentando el valor del potencial zeta al incrementar la concentración del 
polisacárido. 
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Fig. 2: Superficie de respuesta que muestra el efecto de la concentración de lecitina 
y quitosano sobre el potencial ζ de las nanocápsulas preparadas tras la incubación de 
las nanoemulsiones en soluciones de quitosano. 
 
Una vez evaluados los distintos factores que afectan al proceso de 
preparación de las nanocápsulas de quitosano, se seleccionó la formulación 
preparada mediante incubación de la nanoemulsión con quitosano, utilizando una 
concentración de lecitina de 0.4% p/v y de quitosano de 0.1% p/v. 
A continuación, se procedió a evaluar el efecto del peso molecular del 
quitosano y del tipo de sal sobre las características del sistema (Tabla 1). Los 
resultados mostraron un aumento del tamaño de partícula en función del peso 
molecular; sin embargo, no se observó efecto del tipo de sal de quitosano sobre el 
tamaño de las nanocápsulas resultantes. Además de las variedades de quitosano 
disponibles comercialmente, en el presente estudio se utilizaron oligómeros de 
quitosano. Para la obtención de dichos oligómeros se procedió a la 
despolimerización o fraccionamiento del quitosano mediante la adición de nitrito 
sódico a una solución acuosa de quitosano Cl110 (PM~140 kDa), obteniendo 
oligómeros de quitosano cuyo peso molecular (PM~10 kDa) se determinó a partir de 
medidas de viscosidad. En cuanto a la carga superficial de los sistemas, no se 
observó efecto del peso molecular de polímero sobre el potencial zeta de las 
nanocápsulas de quitosano. No obstante, el hecho de que ambos sistemas presenten 
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carga superficial positiva, confirma un recubrimiento de la nanoemulsión por ambos 
tipos de quitosano. 
Tabla 1: Propiedades del quitosano empleado en la preparación de nanocápsulas de 
quitosano y características de los sistemas desarrollados. 
 
Sistema 
Tipo de sal 
del 
quitosano 
Peso molecular 
del quitosano 
(kDa) 
Tamaño de 
partícula (nm) 
Potencial ζ 
(mV) 
NE ---- ---- 195.8±1.1 -52.0±1.1 
NC CS Cl 110 Clorhidrato 140 266.6±7.6 +34.8±0.6 
NC CS Cl 213 Clorhidrato 270 344.3±15.0 +32.0±0.8 
NC CS G 113  Glutamato 160 250.5±7.9 +34.4±0.7 
NC CS G 213  Glutamato 450 330.7±5.8 +31.3±1.6 
NC CS bajo 
PM Clorhidrato 10* 202.1±1.3 + 30.7±1.9 
* Obtenido a patir de medidas de viscosidad. 
 
Por último se investigó el efecto de la peguilación del quitosano en las 
características del sistema (Tabla 2). Se estudiaron dos grados de peguilación, 0.5 y 
1% del clorhidrato de quitosano de peso molecular 140 kDa (CS Cl110). Esto 
significa que el 0.5 ó 1% de los grupos amino del quitosano se encuentran 
covalentemente unidos a una cadena de PEG de 5000 Da. Tras la caracterización de 
los sistemas, se observó que tanto las medidas de tamaño de partícula como de carga 
superficial de las nanocápsulas peguiladas al 0.5 y 1%, fueron muy similares a las 
características de las nanocápsulas sin peguilar. 
Tabla 2: Propiedades de las nanocápsulas de quitosano y 
quitosano-PEG con dos grados de peguilación. 
 
Sistema Tamaño de partícula (nm) 
Potencial ζ 
(mV) 
NC CS 266±7 +34.8±0.6 
NC CS-PEG 0.5% 247±7 +32.8±0.5 
NC CS-PEG 1%  251±17 +29.7±3.1 
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Para finalizar la caracterización de los sistemas, se realizó un estudio 
morfológico de los vehículos previa tinción de los mismos con ácido fosfotúngstico 
(Fig. 3). La visualización mediante microscopía de transmisión electrónica reflejó la 
esfericidad y el rango nanométrico de los sistemas. Para las nanocápsulas de 
quitosano Cl110 fue posible la identificación del recubrimiento de los núcleos 
oleosos con el polímero. Desafortunadamente, ni el recubrimiento con oligómeros 
de quitosano ni con quitosano-PEG pudo ser identificado. 
BA
 
 
 
 
 
DC
 
 
 
 
Fig. 3: Fotografías de microscopía de transmisión electrónica: A) nanoemulsión, B) 
nanocápsulas de quitosano Cl110, C) nanocápsulas de oligómeros de quitosano y D) 
nanocápsulas de quitosano-PEG 0.5%. 
 
Eficacia de encapsulación y liberación de calcitonina a partir de las 
nanocápsulas 
La incorporación de la calcitonina a las nanocápsulas se realizó en la fase 
orgánica previa disolución del péptido en agua. A continuación, se determinó la 
encapsulación de la calcitonina en los sistemas indirectamente mediante el análisis 
del péptido libre (no encapsulado), utilizando cromatografía líquida de alta 
resolución. Los resultados mostraron que la eficacia de encapsulación era 
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dependiente de la composición del sistema. Así pues, en el caso de la nanoemulsión 
se obtuvo una eficacia de encapsulación del 100%, resultado que fue atribuido a la 
interacción electrostática entre la calcitonina (pI=10.4) y los fosfolípidos cargados 
negativamente, así como también a la interacción de las regiones hidrofóbicas de la 
calcitonina con los componentes lipídicos22. Por otro lado, se observó que la 
asociación de calcitonina a las nanocápsulas de quitosano era del 40%. Esta 
reducción de la eficacia de asociación fue atribuida a una competición entre el 
péptido y el quitosano, ambos cargados positivamente, en su interacción con los 
glóbulos de la nanoemulsión. Cabe destacar que las propiedades estructurales del 
quitosano no ejercieron ningún efecto sobre la cantidad de fármaco asociado al 
sistema, a excepción de los oligómeros de quitosano cuya eficacia de encapsulación 
fue del 60%. 
En cuanto al efecto de la peguilación del polímero sobre la eficacia de 
asociación de la calcitonina, se observó un pequeño incremento en la cantidad de 
fármaco encapsulado en las nanocápsulas de quitosano-PEG (52%) con respecto a 
las nanocápsulas de quitosano sin peguilar (40%). Las diferencias en la eficacia de 
asociación de la calcitonina a las distintas formulaciones de nanocápsulas podrían 
guardar relación con las distintas cantidades de quitosano presentes en la superficie 
de las nanocápsulas.  
La liberación de la calcitonina a partir de las nanocápsulas de quitosano y 
de las nanocápsulas de quitosano-PEG mostró un perfil bifásico, caracterizado por 
una liberación inicial (“burst effect”) seguida de una ausencia de liberación durante 
6 horas (Fig. 4). Cabe mencionar que se observaron ciertas diferencias en la cantidad 
de fármaco liberado en la fase inicial dependiendo del las características del 
polímero: peso molecular, tipo de sal y grado de peguilación. Asimismo, en el caso 
de las nanocápsulas de oligómeros de quitosano y la nanoemulsión control, no hubo 
una liberación apreciable de calcitonina durante el tiempo que duró el estudio. 
Curiosamente, al igual que se observó en los estudios de asociación, la intensidad de 
                                                 
22 Epand R.M., Epand R.F., Orlowski R.C., Schlueter R.J., Boni L.T., Hui S.W. Amphipathic 
helix and its relationship to the interaction of calcitonin with phospholipids. Byochemistry 
(1983) 22: 5074-5084. 
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la fase de liberación inicial fue superior para las formulaciones elaboradas con 
quitosano de alto peso molecular. Este hecho podría atribuirse al desplazamiento de 
las moléculas de calcitonina debido a la presencia de quitosano en la superficie de 
las nanocápsulas. 
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Fig. 4: Perfil de liberación de calcitonina de salmón a partir de nanocápsulas con 
distintos recubrimientos. 
 
Estabilidad de las nanocápsulas en fluidos biológicos 
Teniendo en cuenta que los sistemas coloidales son susceptibles a la 
agregación en medios de elevada fuerza iónica conteniendo enzimas, en el presente 
trabajo se consideró importante investigar el comportamiento de los sistemas 
nanocapsulares tras su incubación en fluidos biológicos (gástrico e intestinal). Con 
el fin de evaluar el efecto de la cubierta polimérica en la estabilidad de los sistemas 
se incluyeron en ele estudio las nanocápsulas de quitosano Cl110 y ambos tipos de 
nanocápsulas de quitosano-PEG (0.5 y 1% de peguilación) así como el sistema 
control, la nanoemulsión. Adicionalmente, en este estudio se incluyó una 
formulación conteniendo únicamente PEG en la cubierta, denominadas nanocápsulas 
de PEG (tamaño 161 nm y carga superficial -45 mV). 
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La evaluación de la estabilidad de estos sistemas se realizó siguiendo la 
evolución del tamaño de partícula tras su incubación en los fluidos biológicos 
simulados (USP XVII), observándose distintos comportamientos dependiendo de las 
características del nanosistema y también de las del medio de incubación (fluido 
gástrico o intestinal). Más concretamente, en fluido gástrico simulado (Fig. 5), la 
nanoemulsión sufrió un proceso de agregación, mientras que la presencia de una 
cubierta polimérica ya sea de quitosano, PEG o quitosano-PEG estabilizó el sistema 
en dicho medio (Fig. 5a). El incremento de tamaño observado en la nanoemulsión se 
atribuyó a la presencia de pepsina ya que en ausencia del enzima, el sistema se 
mantuvo estable. La explicación de este hecho está relacionada con la adsorción del 
enzima a la superficie de la nanoemulsión cargada negativamente, si se tiene en 
cuenta que el pI de la pepsina es 3.5 23 y el pH del fluido gástrico es 1.2. Sin 
embargo una cubierta con PEG, a pesar de no modificar la carga superficial del 
sistema, proporciona una estabilización estérica que impide la adsorción del enzima. 
Un efecto similar fue el observado por Tobio y col. 24, quienes encontraron que un 
recubrimiento de las nanopartículas de PLA con PEG reduce la interacción con los 
enzimas. En cuanto a la capacidad de quitosano para prevenir la desestabilización de 
los sistemas, estudios previos mostraron el efecto positivo de este polisacárido para 
prevenir la agregación de las nanocápsulas de poli-ε-caprolactona en presencia de 
lisozima25. Para corroborar que el incremento de tamaño se debe a la presencia de 
enzimas, se estudió la estabilidad de los sistemas en ausencia del enzima (Fig. 5b), 
observando el mantenimiento del tamaño de la nanoemulsión. En el caso de las 
nanocápsulas, como era de esperar, no se observó cambio alguno en su 
granulometría. 
 
 
                                                 
23 Chaiyasut C., Tsuda T. Isoelectric points estimation of proteins by electroosmotic flow: pH 
relationship using physically adsorbed proteins. Chromatography. (2001) 22: 91-95. 
24 Tobio y col.; 2000. ibid pag 213. 
25 Calvo P., Vila-Jato J.L., Alonso M.J. Effect of lysozyme on the stability of polyester 
nanocapsules and nanoparticles: stabilization approaches. Biomaterials (1997) 18: 1305-1310. 
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Fig. 5: Estabilidad en fluido gástrico con enzimas (A) y sin enzimas (B) de los 
distintos sistemas nanocapsulares desarrollados: nanoemulsión (NE), nanocápsulas 
de PEG (NC PEG), nanocápsulas de quitosano, nanocápsulas de quitosano-PEG 
0.5% (NC CS-PEG 0.5%) y nanocápsulas de quitosano-PEG 1% (NC CS-PEG 1%). 
 
Por el contrario, la estabilidad de los sistemas en fluido intestinal simulado 
fue variable dependiendo de su composición (Fig. 6). La nanoemulsión y las 
nanocápsulas de PEG permanecieron estables, sin embargo, las nanocápsulas de 
quitosano sufrieron una agregación importante al cabo de 1 hora de incubación (Fig. 
6a). La utilización del quitosano-PEG 0.5 % permitió reducir la agregación del 
sistema, aunque no de forma importante. Sin embargo, al aumentar el grado de 
peguilación del quitosano al 1% se obtuvo una estabilización completa del sistema, 
mostrando una vez más la importancia de la composición de la cubierta.  
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Con el fin de elucidar si el proceso de agregación de las nanocápsulas de 
quitosano y quitosano-PEG 0.5% se debe, al pH y fuerza iónica del medio o a la 
presencia de enzimas, se evaluó la estabilidad en ausencia de enzimas (Fig. 6b). En 
dicho medio se observó un aumento significativo del tamaño de las nanocápsulas de 
quitosano, si bien no se apreció un proceso de agregación masiva. Asimismo, como 
era de esperar, el tamaño de las nanocápsulas de quitosano-PEG 1%, así como el de 
la nanoemulsión permanecieron inalterados. Por tanto, de dicho estudio se pudo 
concluir que el principal factor responsable del proceso de agregación fue la 
presencia de enzimas. Además, el PEG ejerció un efecto estabilizante, siendo 
necesario una peguilación del 1% para mantener la estabilidad del vehículo en este 
medio. 
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Fig. 6: Estabilidad en fluido intestinal con enzimas (A) y sin enzimas (B) de los 
distintos sistemas nanocapsulares desarrollados: nanoemulsión (NE), nanocápsulas 
de PEG (NC PEG), nanocápsulas de quitosano, nanocápsulas de quitosano-PEG 
0.5% (NC CS-PEG 0.5%) y nanocápsulas de quitosano-PEG 1% (NC CS-PEG 1%). 
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Estudios en cultivos celulares 
Un objetivo importante del presente trabajo fue el de dilucidar el 
mecanismo de interacción de los nanosistemas con los epitelios y con las mucosas. 
Para ello, se seleccionó el cultivo celular Caco-2, línea celular proveniente de 
adenocarcinoma de colon, que presenta gran similitud morfológica y bioquímica con 
los enterocitos26, por lo que es ampliamente utilizada en la evaluación de la 
permeabilidad de fármacos y sistemas de liberación. Los estudios realizados en estos 
cultivos incluyen la determinación de la citotoxicidad, la medida de resistencia 
transepitelial y el análisis de la asociación de los nanosistemas a la monocapa, tanto 
desde un punto de vista cuantitativo como cualitativo. 
 
Estudios de citotoxicidad en células Caco-2 
Hasta el momento se sabe que la viabilidad de las células Caco-2 tras su 
exposición a soluciones de quitosano, es dosis-dependiente27, 28. No obstante, 
también se sabe que, además de la dosis, las propiedades del quitosano tales como el 
peso molecular, el grado de deacetilación o el tipo de sal, juegan un papel 
importante en la toxicidad celular29, 30, 31. Lamentablemente, la comparación 
rigurosa de los resultados obtenidos en los diferentes estudios publicados resulta 
                                                 
26 Artursson P. Cell cultures as models for drug absorption across the intestinal mucosa. Crit. 
Rev. Ther. Drug Carrier System. (1991) 8: 305-330. 
27 Dodane V., Khan M.A., Merwin J.R. Effect of chitosan on epithelial permeability and 
structure. Int. J. Pharm. (1999) 182: 21-32. 
28 Smith J., Wood E., Dornish M. Effect of chitosan on epithelial cell tight junctions. Pharm. 
Res. (2004) 21: 43-49. 
29 Schipper N.G.M., Varum K.M., Artursson P. Chitosans as absorption enhancers for poorly 
absorbable drugs.1: Influence of the molecular weight and the degree of acetylation on drug 
transport across human intestinal epithelium (Caco-2) cells Pharm. Res. (1996) 13: 1686-
1692. 
30 Carreno-Gomez B., Duncan R. Evaluation of the biological properties of soluble chitosan 
and chitosan microspheres. Int. J. Pharm. (1997) 148: 231-240. 
31 Huang M., Khor E., Lim L. Uptake and cytotoxicity of chitosan molecules and 
nanoparticles: effects of molecular weight and degree of deacetylation. Pharm. Res. (2004) 
21: 344-353. 
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difícil debido a las distintas condiciones experimentales empleadas y también a la 
carencia de información minuciosa relativa a dichas condiciones. 
En el presente trabajo decidimos evaluar la toxicidad de los sistemas 
desarrollados, determinando para ello la actividad mitocondrial de las células tras su 
exposición a los distintos tipos de nanocápsulas. Más concretamente, las 
nanocápsulas difieren en cuanto al peso molecular y tipo de sal del quitosano, así 
como en la peguilación del mismo. 
La nanoemulsión presentó una muy baja citotoxicidad, no alcanzándose la 
dosis letal 50 (DL50) en las condiciones experimentales de este estudio. Por otro 
lado, las nanocápsulas de quitosano, mostraron una citotoxicidad que fue 
dependiente de las propiedades del quitosano. Más concretamente, se pudo apreciar 
una dependencia del tipo de sal, siendo el glutamato de quitosano la variedad menos 
tóxica. Por el contrario, el peso molecular del polímero no mostró una influencia 
clara en la viabilidad celular (Fig. 7). De hecho la DL50 tras la exposición de las 
nanocápsulas de quitosano fue de 606 μg/cm2 (1 mg/ml) para ambos tipos de 
nanocápsulas de clorhidrato de quitosano y en torno a de 1212 μg/cm2 (2 mg/ml) 
para las nanocápsulas de glutamato de quitosano. 
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Fig 7: Efecto de diferentes formulaciones de nanocápsulas de quitosano (NC CS 
G113 y NC CS G213: nanocápsulas de glutamato de bajo y alto peso molecular, 
respectivamente; NC CS Cl110 y NC CS Cl213: nanocápsulas de clorhidrato de bajo 
y alto peso molecular, respectivamente), así como de la nanoemulsion (NE), sobre la 
viabilidad celular en cultivos Caco-2. 
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Por otro lado, como puede observarse en la figura 8, la peguilación del 
quitosano, mostró un efecto positivo en la viabilidad celular. Más concretamente, 
tras exponer el cultivo celular a las nanocápsulas de quitosano-PEG 0.5 % y 1% se 
observó una viabilidad del 100% hasta concentraciones superiores a 2mg/ml, siendo 
la DL50 de 6 mg/cm2 (10 mg/ml) para el 0.5 % de peguilación y entre 6 y 12 
mg/cm2 (10 y 20 mg/ml) para el 1%. 
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Fig. 8: Efecto de diferentes formulaciones de nanocápsulas de quitosano-PEG NC 
CS PEG 0.5% y NC CS PEG 1% (nanocápsulas de quitosano-PEG con un grado de 
peguilación del 0.5 y 1% respectivamente), así como de la nanoemulsion (NE), 
sobre la viabilidad celular en cultivos Caco-2. 
 
Por tanto, de este estudio se puede concluir que las nanocápsulas de 
quitosano presentan una baja toxicidad celular y que dicha citotoxicidad se reduce 
como consecuencia de la peguilación del quitosano. 
 
Estudios de interacción con células Caco-2: medida de la resistencia 
transepitelial 
Diversos estudios han puesto de relieve la capacidad del quitosano para 
alterar las uniones estrechas existentes entre las células, dando lugar a una 
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disminución acusada de la resistencia transepitelial32, 33. Con el objeto de comprobar 
si esta propiedad inherente al quitosano se mantiene cuando forma parte de 
estructuras nanocapsulares, se evaluó la modificación de la resistencia transepitelial 
de la monocapa celular Caco-2 tras su exposición a las diferentes formulaciones 
nanocapsulares desarrolladas. Asimismo, en dicho experimento se analizó el 
comportamiento de la nanoemulsion sin recubrir (Fig. 9). Los resultados obtenidos 
mostraron que, mientras que la nanoemulsión no dio lugar a ninguna variación en la 
resistencia transepitelial, las nanocápsulas de quitosano provocaron un descenso en 
dicho parámetro cuya extensión resultó ser dosis-dependiente. De hecho, la 
reducción de la resistencia transepitelial fue marcada únicamente tras la exposición a 
dosis de nanocápsulas relativamente elevadas (204.5 µg/cm2), estando dicha dosis 
asociada a un descenso de la viabilidad celular. Si comparamos estos resultados con 
los obtenidos en experimentos independientes, para otros sistemas a base de 
quitosano, nos encontramos con que el efecto permeabilizante (reducción de la 
resistencia transepitelial) fue superior para las nanopartículas lipídicas recubiertas de 
quitosano 34 e inapreciable para las nanopartículas de quitosano35. La explicación a 
estos diferentes comportamientos se puede atribuir a que, en este último caso, el 
quitosano forma parte de una partícula sólida y, sin embargo, tanto en las 
nanocápsulas como en las nanopartículas lipídicas, el quitosano se encuentra como 
un recubrimiento soluble. Asimismo el mayor efecto observado para las 
nanopartículas lipídicas, con respecto a las nanocápsulas, podría guardar relación 
con la naturaleza del lípido. 
                                                 
32 Artursson y col.; 1994. ibid pag 212. 
33 Dodane y col.; 1999. ibid pag 224. 
34 Garcia-Fuentes M., Prego C., Torres D., Alonso M.J. A comparative study of the potential 
of solid triglyceride nanostructures coated with chitosan or poly (ethylene glycol) as carriers 
for oral calcitonin delivery. Eur J Pharm Sci. (2005) 25: 133-143. 
35 Behrens I., Vila-Pena A.I., Alonso M.J., Kissel T. Comparative uptake studies of 
bioadhesive and non-bioadhesive nanoparticles in human intestinal cell lines and rats: the 
effect of mucus on particle adsorption and transport. Pharm. Res. (2002) 19: 1185-1193. 
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Fig. 9: Resistencia transepitelial (TEER) del cultivo celular Caco-2 expuesto a la 
nanoemulsión y a distintas dosis por área de superficie de nanocápsulas de quitosano 
(CS Cl110), así como a los controles, HBSS y HBSS pH 6.  
 
Por otro lado, como se muestra en la Fig. 10, no se constató una influencia 
del peso molecular ni del tipo de sal de quitosano en la capacidad permeabilizante de 
las nanocápsulas. Estos resultados concuerdan con los estudios realizados por 
Schipper y col36, en los cuales se demuestra que el peso molecular del polímero no 
afecta su capacidad permeabilizante. Por otro lado, en la Fig. 10 también puede 
observarse que la peguilación no dio lugar a una variación significativa en la 
resistencia transepitelial con respecto al sistema sin peguilar, para la concentración 
estudiada (80 μg/cm2). Por último, es importante destacar que con todos los sistemas 
ensayados, se recobraron los valores normales de resistencia transepitelial a las 24 
horas. 
En su conjunto, estos resultados sugieren que la capacidad permeabilizante 
de las nanocápsulas es limitada y que dicha capacidad no se ve influenciada por el 
peso molecular o la peguilación del quitosano. 
 
                                                 
36 Schipper y col.; 1996. ibid pag 224. 
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Fig. 10: Resistencia transepitelial (TEER) del cultivo celular Caco-2 expuesto a 
nanocápsulas de quitosano de distintos pesos moleculares (Cl 110, Cl 213, G113 y 
G213) y a nanocápsulas de quitosano-PEG 0.5%, así como a HBSS pH 6. La dosis 
de nanocápsulas fue de 80μg/cm2 en todos los casos. 
 
Estudios de interacción con células Caco-2: análisis cuantitativo y 
cualitativo 
En una primera fase, la cuantificación de la interacción de las nanocápsulas 
de quitosano con las células Caco-2 se realizó previo marcaje de las mismas con 
rodamina. De este modo, tras la incubación de distintas concentraciones de los 
nanosistemas, se determinó la concentración de rodamina asociada a las células. Los 
resultados de este estudio mostraron una relación lineal entre la concentración de 
nanocápsulas en el medio de incubación y la cantidad de nanocápsulas asociadas a 
las células. Estos resultados sugieren que, en el rango de concentraciones ensayado, 
no se alcanza la saturación de dicho proceso (Fig. 11). Asimismo, cabe destacar que 
la asociación a las células fue muy similar para ambos tipos de sistemas, no 
apreciándose una influencia de la cubierta de quitosano. Estos resultados contrastan 
con los obtenidos para las nanopartículas lipídicas recubiertas de quitosano37, para 
las cuales se observó una asociación muy superior, aunque también se mostró 
                                                 
37 Garcia-Fuentes y col.; 2005. ibid pag 227. 
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independiente de la presencia de quitosano en la cubierta. No obstante, dada la no 
influencia de la cubierta de quitosano, la importante asociación del nanosistema se 
debe relacionar con la naturaleza sólida del núcleo lipídico. Asimismo, se ha de 
destacar que la baja asociación observada en este estudio para las nanocápsulas de 
quitosano fue comparable a la observada previamente para las nanopartículas de 
quitosano 38. Por tanto, cabe concluir que no solo la composición, sino también la 
disposición de los diferentes componentes de los nanosistemas, juegan un papel muy 
importante en su interacción con las células. 
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Fig. 11: Cantidad de nanocápsulas de quitosano y nanoemulsión fluorescentes 
asociadas a células Caco-2 tras 1 hora de incubación en relación a la concentración 
incubada 
 
Una vez observado que tanto la nanoemulsión como las nanocápsulas de quitosano 
se asocian en cuantías similares a las células Caco-2, decidimos evaluar 
cualitativamente la interacción de las nanocápsulas de quitosano mediante el análisis 
por microscopía confocal. Para ello se marcaron los vehículos con fluoresceína 
(verde) y para las células se utilizó un doble marcaje: la E-cadherina, proteína 
intercelular que se marcó con Alexa 546 (rojo) y los núcleos con Hoescht (azul). El 
                                                 
38 Behrens y col.; 2002. ibid pag 227. 
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análisis del comportamiento de las nanocápsulas de quitosano tras la incubación con 
las células Caco-2, aparece reflejado en la figura 12A. 
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Fig. 12: Imágenes de microscopía confocal que muestran la asociación de las 
nanocápsulas de quitosano fluorescentes (verde) a las células Caco-2 (E-cadherina 
en rojo y núcleos en azul). A) Montaje de 24 secciones horizontales que ilustra la 
interacción de las nanocápsulas de quitosano con las células Caco-2. B) Sección xz 
que muestra la acumulación de nanocápsulas de quitosano en la zona apical de la 
monocapa de células. 
 
En dicha figura puede apreciarse una asociación importante de las 
nanocápsulas a las células, situándose preferentemente en la superficie e interior de 
las células y no en las regiones paracelulares, dada la ausencia de co-localización de 
los dos marcadores. 
Por otro lado, como se desprende de la figura 13, las nanocápsulas 
asociadas permanecieron en el borde apical de la monocapa, no habiéndose 
detectado la presencia de las mismas en la zona basolateral. Por tanto, esta 
observación lleva a concluir que las nanocápsulas de quitosano no atraviesan la 
monocapa de células (Fig. 12B). 
Con el fin de profundizar en el análisis de la interacción de ambos sistemas 
con modelos celulares intestinales, se investigó el comportamiento de las 
nanocápsulas de quitosano y de la nanoemulsión control con el co-cultivo Caco-
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2:HT29-M6 (células secretoras de mucus). Las imágenes de microscopía 
evidenciaron una asociación muy importante en el caso de las nanocápsulas de 
quitosano, mientras que la asociación de la nanoemulsión fue muy débil. Además, 
cabe destacar que la interacción de las nanocápsulas no fue igual en los dos tipos 
celulares, siendo particularmente remarcable en las células secretoras de mucus (Fig. 
13). Estos resultados ponen claramente de manifiesto las propiedades 
mucoadhesivas de las nanocápsulas de quitosano. 
 
Fig. 13: Imagen de microscopía de fluorescencia que muestra las nanocápsulas de 
quitosano fluorescentes marcando específicamente los islotes mucosecretores. 
 
Por último, igual que sucedía en el monocultivo de células Caco-2, el 
sistema permaneció en la zona apical de las células, no observándose el transporte 
de los mismos al compartimento basolateral (Fig. 14). 
        ZONA APICAL 
 
 
 
 
 
 
 
 
 
   ZONA BASOLATERAL 
Fig. 14: Sección xz de microscopía confocal que muestra la acumulación de 
nanocápsulas de quitosano (verde) en la zona apical de las células HT29-M6 (E-
cadherina en rojo y núcleos en azul). 
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Evaluación in vivo de las nanocápsulas 
Respuesta farmacológica tras la administración nasal de calcitonina 
encapsulada en nanocápsulas de quitosano 
En los últimos años, la administración nasal ha recibido una atención 
considerable, especialmente para conseguir un efecto sistémico de fármacos 
peptídicos con dificultad para ser administrados por otras vías no parenterales como 
es la vía oral. Esto se debe a las características diferenciales de la cavidad nasal con 
respecto al tracto gastrointestinal, como son la escasa actividad enzimática, el pH y 
la ausencia de efecto de primer paso hepático. No obstante, a pesar de las ventajas 
que ofrece esta modalidad de administración, la biodisponibilidad nasal de fármacos 
peptídicos es aún baja39, por lo que la búsqueda de vehículos para aumentar la 
absorción nasal de péptidos continúa siendo necesaria. 
En el presente trabajo se exploró el potencial de las nanocápsulas como 
vehículos para mejorar la biodisponibilidad de la calcitonina por vía nasal. Se 
investigó la eficacia in vivo de las nanocápsulas de quitosano, así como de la 
nanoemulsión y de una solución acuosa de calcitonina en presencia y ausencia de 
quitosano. Tras la administración por vía nasal se evaluó la respuesta hipocalcémica 
mediante la medida del nivel de calcio sérico.  
Como se desprende de la figura 15, tanto las nanocápsulas de quitosano 
como la nanoemulsión dieron lugar a disminuciones significativas de la calcemia, 
mientras que la calcitonina en solución, ya sea en presencia o no de quitosano, no 
mejoró apreciablemente la absorción del péptido. La reducción del nivel de calcio 
observada en el caso de la nanoemulsión pudo estar relacionada con un efecto 
estabilizador y/o promotor de la absorción atribuido a los lípidos. En efecto, Mitra y 
col. 40 observaron que las gotículas de aceite de una emulsión o/w juegan un papel 
                                                 
39 Lee W.A., Ennis R.D., Longenecker J.P., Bengtsson P. The bioavailability of intranasal 
salmon calcitonin in healthy volunteers with and without a permeation enhancer, Pharm. Res. 
(1994) 11: 747-750. 
40 Mitra R., Pezron I., Chuw A., Mitra A.K. Lipid emulsions as vehicles for enhanced nasal 
delivery of insulin. Int. J. Pharm. (2000) 205: 127-134. 
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importante en la absorción de insulina por vía nasal. Además de esta capacidad 
promotora, los lípidos han mostrado la facultad de ofrecer protección frente a la 
degradación enzimática 41, 42. No obstante, como se demuestra en este estudio, el 
recubrimiento de la nanoemulsión con quitosano permite intensificar y prolongar el 
efecto hipocalcémico de la calcitonina. Estos resultados concuerdan con los 
obtenidos para las nanopartículas de quitosano conteniendo insulina43. De este 
modo, mientras que las soluciones de quitosano parecen actuar significativamente 
sobre las uniones intercelulares, los sistemas particulados no parecen ejercer este 
efecto de forma apreciable. Por otro lado, si bien las soluciones y sistemas 
particulados exhiben un carácter mucoadhesivo, el resultado de esta mucoadhesión 
es distinto. En efecto, el quitosano en solución interacciona con el moco dando lugar 
a la formación de un gel viscoso44, mientras que las nanocápsulas interaccionan 
favorablemente con el moco, pero siguen manteniendo su forma particulada, no 
causando una modificación apreciable en la viscosidad de la mucina (resultados no 
mostrados). 
 
                                                 
41 Damgé C., Michel C., Aprahamian M., Couvreur P., Devissaguet J.P. Nanocapsules as 
carriers for oral peptide delivery. J.Control. Release (1990) 13: 233-239. 
42 Lowe P.J., Temple C.S. Calcitonin and insulin in Isobutylcyanoacrylate nanocapsules: 
Protection against proteases and effect on intestinal absorption in rats. J. Pharm. Pharmacol. 
(1994) 46: 547-552. 
43 Fernández-Urrusuno R., Calvo P., Remuñán-López C., Vila-Jato J.L., Alonso M.J. 
Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharm. Res. (1999) 
16: 1576-1581. 
44 Illum L., Farraj N.F., Davis S.S. Chitosan as a novel nasal delivery system for peptide 
drugs. Pharm. Res. (1994) 11: 1186-1189. 
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Fig. 15: Efecto hipocalcémico tras la administración nasal a ratas de nanocápsulas de 
quitosano Cl 110, nanoemulsión y una solución acuosa de calcitonina. 
 
Respuesta farmacológica tras la administración oral de calcitonina 
encapsulada en nanocápsulas 
Teniendo en cuenta los resultados positivos obtenidos tras la administración 
por vía nasal de la calcitonina encapsulada en las nanocápsulas de quitosano, 
decidimos ahondar en el estudio de dichos vehículos, retando la administración por 
vía oral de péptidos. 
Inicialmente investigamos la eficacia de las nanocápsulas de quitosano 
Cl110 utilizando como control una solución acuosa de calcitonina y la 
nanoemulsión. A continuación procedimos a evaluar las siguientes variables de 
formulación: peso molecular y tipo de sal del quitosano, concentración de lecitina, 
dosis de calcitonina y, por último, la influencia de la peguilación del polímero. 
A diferencia de lo ocurrido tras la administración por vía nasal de la 
nanoemulsión conteniendo calcitonina, este vehículo no logró inducir una reducción 
de los niveles de calcio séricos tras su administración oral. Sin embargo, el 
recubrimiento con quitosano -nanocápsulas de quitosano- dio lugar a una eficacia 
farmacológica acentuada, obteniéndose una reducción del nivel de calcio sérico del 
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25-30% desde la primera hora hasta al menos 24 horas post-administración (Fig. 
16). Estos resultados ponen de manifiesto, una vez más, la capacidad del quitosano 
para interaccionar con el epitelio y promover la absorción del fármaco encapsulado.  
Las diferencias encontradas entre las nanocápsulas de quitosano y la 
nanoemulsión se explican fácilmente si se tienen en cuenta los resultados obtenidos 
en cultivos celulares, Caco-2:HT29-M6, donde la presencia de mucus favoreció la 
interacción con las células de las nanocápsulas de quitosano. Por otro lado, estos 
resultados están en concordancia con los obtenidos en estudios realizados con otros 
nanosistemas, tales como liposomas y nanopartículas de poliésteres, recubiertos de 
quitosano45, 46, 47. Asimismo, la falta de respuesta inducida por la solución de 
quitosano45 pone de manifiesto la importancia de que el quitosano se presente en 
forma de sistema particulado. 
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Fig. 16: Efecto hipocalcémico tras la administración oral a ratas de nanocápsulas de 
quitosano Cl 110, nanoemulsión y una solución acuosa de calcitonina. 
                                                 
45 Takeuchi H., Yamamoto H., Niwa T., Kawashima Y. Enteral absorption of insulin in rats 
from mucoadhesive chitosan-coated liposomes. Pharm. Res. (1996) 13: 896-901. 
46 Kawashima Y., Yamamoto H., Takeuchi H., Kuno Y. Mucoadhesive DL-lactide/glycolide 
copolymer nanospheres coated with chitosan to improve oral delivery of elcatonin. Pharm. 
Dev. Technol. (2000) 5: 77-85. 
47 Takeuchi H., Matsui Y., Yamamoto H., Kawashima Y. Mucoadhesive properties of 
carbopol and chitosan-coated liposomes and their effectiveness in the oral administration of 
calcitonin to rats. J. Control. Release (2003) 86: 235-242. 
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En cuanto a las variables de formulación evaluadas, no se observó 
influencia ni del tipo de sal del quitosano ni de la concentración de lecitina en la 
eficacia de las nanocápsulas de quitosano. Con todas ellos se consiguieron 
resultados satisfactorios, sin observar diferencias significativas en los perfiles de 
calcio obtenidos (Fig. 17). Por otro lado, la variación del peso molecular del 
quitosano no se tradujo en un cambio significativo en la respuesta salvo para los 
oligómeros, en cuyo caso se logró una reducción de los niveles de calcio sérico que 
se prolongó solamente hasta las cuatro horas post-administración. La explicación a 
estos resultados es difícil de precisar ya que los resultados hallados en la bibliografía 
hasta el momento no han revelado una influencia clara de este parámetro. De hecho 
mientras Chae y col48 observaron que la reducción del peso molecular del quitosano 
para un grado de deacetilación >85%, reduce la interacción del polímero con las 
células, Schipper y col49 mostraron que, para quitosano con un grado de 
deacetilación >85%, tanto el quitosano de bajo peso molecular como de alto peso 
molecular poseen una capacidad permeabilizante muy similar. 
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Fig. 17: Efecto hipocalcémico tras la administración oral a ratas de nanocápsulas de 
quitosano de distintos pesos moleculares, así como la nanoemulsión y una solución 
acuosa de calcitonina. 
                                                 
48 Chae S.Y., Jang M-K., Nah J-W. Influence of molecular weight on oral absorption of water 
soluble chitosans. J. Control. Release. (2005) 102: 383-394. 
49 Schipper y col.; 1996. ibid pag 224. 
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Con respecto al efecto de la reducción de la dosis de calcitonina 
administrada (250 UI vs. 500UI), se apreció una importante reducción del nivel de 
calcio sérico durante las dos primeras horas post-administración. No obstante, 
sorprendentemente, a partir de las 12 horas se vuelve a apreciar un importante efecto 
hipocalcémico que se mantiene al menos hasta las 24 post-administración. 
Por último, según muestra la figura 18, la peguilación del quitosano 
también mostró un efecto en la respuesta hipocalcémica. La eficacia farmacológica 
mejoró para nanocápsulas de quitosano-PEG con respecto a la nanoemulsión y a la 
solución de calcitonina. Sin embargo, se observó un comportamiento diferente de 
estas formulaciones dependiendo del grado de peguilación. Mas concretamente, el 
efecto hipocalcémico resultó más pronunciado para las nanocápsulas de quitosano-
PEG 0.5%, siendo dicho efecto similar al observado para las nanocápsulas sin 
peguilar. Las diferencias observadas dependiendo del grado de peguilación del 
quitosano pueden estar relacionadas con una reducción del efecto mucoadhesivo o 
promotor de la absorción del polisacárido. En efecto, es probable que el PEG cause 
un efecto estérico que, aunque contribuye a la estabilidad del sistema en los fluidos 
gastrointestinales, pudiera ocultar parcialmente la carga positiva de los grupos amino 
del quitosano, alterando así la interacción del sistema con la carga negativa del 
mucus. 
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Fig. 18: Efecto hipocalcémico tras la administración oral a ratas de nanocápsulas de 
quitosano-PEG al 0.5 y 1% de peguilación así como las nanocápsulas de quitosano, 
la nanoemulsión y una solución acuosa de calcitonina.  
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Los resultados obtenidos en el trabajo experimental que se describe en esta 
memoria ponen de manifiesto el potencial de las nanocápsulas de quitosano como 
vehículos destinados a la administración de péptidos por vías no parenterales como 
son la vía nasal y la vía oral. De un modo más detallado, se han extraído las 
siguientes conclusiones: 
1. La técnica de desplazamiento del disolvente ha permitido la obtención de 
nanocápsulas constituidas por un núcleo oleoso y una cubierta de 
quitosano o de quitosano-PEG. Dichas nanocápsulas han sido obtenidas 
utilizando quitosano de diferente peso molecular (desde menos de 10 kDa 
hasta más de 200 kDa) y en forma de distintas sales (clorhidrato y 
glutamato de quitosano). Las nanocápsulas resultantes tiene un tamaño 
nanométrico (entre 200 y 570 nm), dependiente de ciertas variables de 
formulación y una carga superficial positiva (en torno a +30 mV) e 
independiente de las variables de formulación ensayadas. Asimismo, se 
ha logrado encapsular eficazmente el péptido calcitonina en los distintos 
tipos de nanocápsulas obtenidas. 
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2. La cubierta polimérica de las nanocápsulas, ya sea de quitosano o 
quitosano-PEG estabiliza los núcleos oleosos en fluido gástrico. En fluido 
intestinal se observó un importante efecto de la peguilación del quitosano 
en la estabilidad de las nanocápsulas. 
3. Los estudios de citotoxicidad llevados a cabo en cultivo celular Caco-2 
reflejaron una baja toxicidad de las nanocápsulas de quitosano, estando la 
DL50% comprendida entre 606 μg/cm2 (1 mg/ml) y 1212 μg/cm2 (2 
mg/ml). Además, se observó una reducción de dicha toxicidad como 
consecuencia de la peguilación del quitosano. 
4. La facultad de las nanocápsulas de quitosano para interaccionar con el 
cultivo celular Caco-2, determinada mediante medidas de resistencia 
eléctrica transepitelial, reflejó una capacidad permeabilizante reducida e 
independiente del peso molecular y del tipo de sal del quitosano, así 
como de su grado de peguilación. 
5. La asociación de las nanocápsulas de quitosano a células Caco-2 fue baja 
y muy similar a la de la nanoemulsión control. Las imágenes obtenidas 
mediante microscopía de confocal de fluorescencia han permitido 
localizar las nanocápsulas de quitosano únicamente en la zona apical de 
las células y no en las uniones intercelulares ni en la zona basolateral, lo 
que ha llevado a descartar la capacidad de las mismas para atravesar la 
monocapa. Asimismo, las imágenes correspondientes a la interacción con 
el cocultivo Caco-2:HT29-M6 (enterocitos y células secretoras de mucus) 
pusieron de manifiesto una importante asociación de las nanocápsulas de 
quitosano a las células secretoras de mucus, constatando así sus 
propiedades mucoadhesivas. 
6. Los resultados de los niveles de calcemia obtenidos tras la administración 
de las formulaciones de calcitonina por vía nasal revelaron la capacidad 
de las nanocápsulas de quitosano para aumentar la absorción de la 
calcitonina. Además dicha respuesta fue significativamente superior a la 
conseguida tras la administración de una solución de quitosano y 
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calcitonina, lo que demuestra la importancia de que el quitosano se 
presente formando una estructura coloidal. 
7. Los resultados de la eficacia farmacológica obtenidos tras la 
administración de las formulaciones de calcitonina por vía oral 
permitieron concluir el potencial de las nanocápsulas de quitosano para la 
administración oral de calcitonina. Más concretamente, las nanocápsulas 
dieron lugar a una reducción significativa de los niveles de calcemia (en 
torno al 30%), respuesta que se prolongó durante al menos 24 horas. 
Asimismo, se observó que modulando el grado de peguilación del 
quitosano es posible obtener un sistema estable en los fluidos 
gastrointestinales, de toxicidad muy reducida y con capacidad para 
promover la absorción oral de péptidos. 
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Abstract 
We have previously reported the formation and characterization of 
poly(ethylene glycol) (PEG)-coated and chitosan (CS)-coated lipid nanoparticles. In 
the present work our goal was to study the interaction of these surface-modified lipid 
nanoparticles with Caco-2 cells and to evaluate the potential of these nanostructures 
as oral delivery systems for salmon calcitonin (sCT).  
The interaction of rhodamine®-loaded nanoparticles with the Caco-2 cell 
monolayers was evaluated quantitatively and qualitatively by confocal laser 
scanning microscopy and fluorimetry, respectively. The ability of these 
nanoparticles to reversibly enhance the transport of hydrophilic macromolecules 
through the monolayers was investigated by measuring the transepithelial electric 
resistance and the permeability to Texas Red®-dextran. Finally, in vivo studies of 
the response to sCT-loaded nanoparticles were performed in rats.  
The results showed that the association of rhodamine®-loaded 
nanoparticles to the Caco-2 cell monolayer was independent of the surface coating 
of the nanoparticles (CS-coated versus PEG-coated nanoparticles). However, while 
PEG-coated nanoparticles did not affect the permeability of Caco-2 monolayers, CS-
coated nanoparticles produced a dose-dependent reduction in the transepithelial 
electric resistance, simultaneously to an enhanced dextran transport. The results 
obtained following oral administration of sCT-loaded CS-coated nanoparticles to 
rats showed a significant and prolonged reduction in the serum calcium levels as 
compared to those obtained for control (sCT solution). In contrast, the hypocalcemic 
response of sCT-loaded PEG-coated nanoparticles was not significantly different of 
that provided by the control (sCT solution). Therefore, these results indicate that the 
surface composition of the particles is a key factor in the improvement of the 
efficiency of oral sCT formulations. Moreover, the encouraging results obtained for 
CS-coated nanoparticles underline their potential as carriers for peptide delivery.  
Keywords: Nanoparticles; Chitosan; PEG; Peptide delivery; Transepithelial 
transport. 
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Introduction 
The low transepithelial transport together with the instability in the 
gastrointestinal tract, are the main obstacles for making the oral administration of 
peptides feasible. Among the alternatives explored so far to overcome these 
limitations, the design of submicrometric carriers appears to be a promising 
approach (Chen and Langer, 1998). For example, it has already been shown that the 
nanoencapsulation of proteins in colloidal particles protects them against the harsh 
environment of the gastrointestinal tract (Lowe and Temple, 1994), and enhances 
their transmucosal transport (Mathiowitz et al., 1997 and Tobío et al., 1998). This 
ability of the colloidal carriers to enhance the transport of the associated 
macromolecules has been attributed to different mechanisms depending on the 
nanocarrier composition. These mechanisms are (i) mucoadhesion, (ii) particle 
internalization phenomenon and (iii) permeation enhancing effect.  
The adhesion of a carrier system to the mucus may improve the residence 
time and contact of the drug with the underlying epithelium, thus increasing the drug 
concentration in the site of absorption (Mikos et al., 1991). Such mechanism of 
transport enhancement has led to the idea of modifying the surface of colloids in 
order to optimize their mucoadhesion. Hydrophilic polymers such as polyacrylate 
derivatives and chitosan are examples of mucoadhesive materials used to coat 
colloidal carriers. For example, polyacrylate derivatives in the form of nanoparticles 
with mucoadhesive characteristics have recently been proposed for the oral 
administration of sCT (Torres-Lugo et al., 2002). Similarly, Sakuma et al. (1997) 
reported an enhancement of the oral absorption of sCT following its association to 
poly(N-isopropylacrylamide) nanoparticles. Moreover, the formation of a 
mucoadhesive CS coating around PLGA nanoparticles has shown a positive effect in 
improving the oral absorption of sCT (Kawashima et al., 2000). Moreover, in our 
group, we have shown that CS-based colloidal particles, in which CS is in the form 
of a coating or a nanomatrice, are able to improve the transport of drugs across the 
nasal (Vila et al., 2002) and the ocular mucosa (Calvo et al., 1997 and De Campos et 
al., 2003).  
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In contrast with the well-defined role of mucoadhesion in drug absorption, 
the factors that affect the interaction and internalization of colloidal particles with 
epithelia remain unclear. In fact, despite the deep understanding achieved of the 
transport of non-degradable polystyrene particles (Florence and Hussain, 2001), 
little is still known about the behaviour of colloids of pharmaceutical interest. For a 
number of years it was broadly accepted that nanoparticles with hydrophobic 
surfaces are taken up more extensively by the intestinal epithelium than those with 
hydrophilic surfaces (Eldridge et al., 1990). However, some recent results have 
suggested that the presence of hydrophilic polymers such as PEG (Tobío et al., 
2000) or CS (Vila et al., 2002) on the surface of nanoparticles can increase the 
transport of these systems through mucosal surfaces. Overall, these results indicated 
that the composition of the nanoparticle could affect not only the intensity but also 
the mechanism of transport. Indeed, mechanistic studies performed with different 
types of nanoparticles indicated that hydrophobic nanoparticles are preferentially 
transported through the gut associated lymphoid tissue, whereas particles with a 
more hydrophilic nature are transported across the regular enterocytes (Mathiowitz 
et al., 2000).  
Finally, with respect to the permeation enhancing effect, this has been 
extensively investigated for polymer solutions, however, whether or not this effect 
remains unaltered when the polymer is in the form of nanoparticles or attached to 
them, needs to be further clarified. For example, in the case of poly(methacrylic) 
derivatives (Torres-Lugo et al., 2002), it has been shown that their typical 
permeation enhancing effect is maintained when they are in the form of nanogels. 
However, in the case of CS based colloidal systems, the maintenance of the inherent 
capacity of CS to open the tight junctions (Lueben et al., 1997) has not been fully 
identified (Behrens et al., 2002).  
In the present work our goal was to investigate the in vitro and in vivo 
behaviour of two new drug nanocarriers consisting of a lipid nanoparticles coated by 
a hydrophilic coating (either PEG or CS). More specifically, we studied the 
interaction of polymer-coated lipid nanoparticles with the Caco-2 cell culture model 
and, then, we evaluated the pharmacological response of sCT associated to both 
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types of nanoparticles following oral administration to rats. The preparation of the 
lipid nanoparticles made of tripalmitin and coated with PEG or CS was previously 
reported by our group (Garcia-Fuentes et al., 2002; Garcia-Fuentes et al., in press). 
Moreover, we have already shown that these systems are stable in simulated 
gastrointestinal media and capable of effectively associating and releasing sCT. 
Therefore, the purpose of the studies reported here were to identify the role of the 
polymer coating on the efficacy and mechanism of action of the nanosystems as 
carriers for the oral administration of sCT. 
 
Materials and methods 
Materials 
The Caco-2 cell line was obtained from the European Collection of Cell 
Cultures (ECACC, UK). Minimum Essential Medium Eagle (MEM), fetal bovine 
serum (FBS), non-essential amino acids, l-glutamine, 100 UI/ml 
penicillin/100 μg/ml streptomycin solution, 0.05% trypsin/0.02% EDTA solution, 
Dulbecco's phosphate buffered saline (DPBS) and Hank's balanced salt solution 
(HBSS) were purchased from Sigma (Sigma, Spain). Tripalmitin [Dynasan® 116] 
(Condea, Germany) was the lipid used for nanoparticle core formation. l-α-lecithin 
(Sigma, Spain), poloxamer 188 [Symperonic® F68] (ICI, Spain) and poly(ethylene 
glycol)-stearate (PEG, Mw≈2000 Da) [Simulsol® M52], a gift from Seppic 
(France), were used as surfactants. Chitosan (CS) (specifications: 75–85% of 
deacetylation degree, viscosity 20–200 cP at 1% in 1% acetic acid) in basic form 
was purchased from Aldrich (Spain). Rhodamine® was from Sigma (Spain) and 
Texas Red®-dextran and Bodipy® 650/665-Phalloidin from Molecular Probes 
Europe BV (The Netherlands). Salmon calcitonin (sCT) was a kind donation from 
Almirall Prodesfarma S.A. (Spain). Other reagents were analytical grade or better. 
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Nanoparticle preparation 
Prior to the preparation of nanoparticles, CS was dissolved in 0.1 M 
hydrochloric acid and purified. More specifically, the CS solution was filtered and 
washed by dialysis for a period of three days. Then, the filtrate was centrifuged at 
30,000×g for 1h to eliminate non-dissolved impurities. The supernatant from the 
centrifugation was freeze-dried, leading to a powder readily soluble in water.  
CS-coated nanoparticles were prepared following a two-step procedure: 
first, tripalmitin nanoparticles, used as cores for their further coating with CS, were 
prepared by a double emulsion solvent evaporation method, as previously described 
(Garcia-Fuentes et al., 2002). This procedure was adopted because of its 
effectiveness for the encapsulation of peptides. Briefly, 50 μl of an aqueous solution 
of sCT (10 mg/ml) were added to a 0.5 ml solution of 25 mg of lecithin and 50 mg 
of tripalmitin in methylene chloride. A water-in-oil emulsion was formed upon 15 s 
of sonication (20 W). Then, 1 ml of water was added to the first emulsion, and 
sonicated again for 60 s (20 W). The solvent was eliminated by evaporation, first 30 
min at room temperature and afterwards 30 min under vacuum. In the second step, 
tripalmitin nanoparticles at 1% (w/v) final concentration were incubated for 10 min 
in a 0.05% (w/v) CS/1.5% poloxamer 188 solution in order to allow the formation of 
a CS coating by simple interaction of the positively charged CS molecules and the 
negatively charged lipid cores. Nanoparticles were isolated by ultracentrifugation for 
1 h at 50,000 × g and resuspended in purified water.  
PEG-coated tripalmitin nanoparticles were prepared by an analogous 
procedure to that used to obtain tripalmitin nanoparticles, plus 25 mg of PEG-
stearate added to the organic phase. Nanoparticles were isolated by 
ultracentrifugation for 1 h at 85,000 × g and then, resuspended in purified water.  
For the preparation of rhodamine®-labeled nanoparticles, a 10 mg/ml 
methanol stock solution was prepared. Five microliter from this stock solution were 
diluted in the organic phase of the double emulsion method described. 
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Blank nanoparticles (non-loaded with sCT) were obtained following the 
procedure described above but substituting the aqueous solution of the peptide by 
water. 
 
Physicochemical characterization of the nanoparticles and sCT association 
efficiency 
The size and polydispersity of the nanoparticle suspensions were 
determined by Photon Correlation Spectroscopy (PCS) (Zetasizer® 3000HS, 
Malvern, UK), following appropriate dilution in purified water. The zeta potential of 
the nanoparticles was measured by Laser Doppler Anemometry (Zetasizer® 
3000HS, Malvern, UK) upon dilution in a 1 mM NaCl solution.  
The amount of rhodamine® encapsulated and released from the 
rhodamine®-loaded nanoparticles was determined from the supernatant after 
ultracentrifugation and measured by fluorimetry (λex = 525 nm; λem = 550 nm). 
The association efficiency of sCT to the nanoparticles was calculated from 
the difference between the total amount of peptide added in the encapsulation 
process and quantity of non-encapsulated peptide. The separation of the 
nanoparticles from the non-encapsulated peptide was performed by ultrafiltration 
(Contricom® YM-100, Millipore, Spain) for PEG-coated nanoparticles or by 
ultracentrifugation for CS-coated nanoparticles (50,000 × g). Ultrafiltration was 
found to be more suitable to completely isolate sCT from PEG-coated nanoparticles, 
due to the high centrifugation speed required for their sedimentation. In contrast, 
CS-coated nanoparticles could be isolated by ultracentrifugation due to their 
adequate sedimentation characteristics. The concentration of sCT was determined by 
HPLC as described (British Pharmacopoeia (BP) 1998).  
For the cell culture experiments, nanoparticles were isolated by 
ultracentrifugation and resuspended at proper concentrations in HBSS (pH 7.4). CS-
coated nanoparticles were resuspended in HBSS with a pH value of 6.5 in order to 
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avoid particle aggregation. Control experiments for this formulation were also 
performed with the same HBSS solution. 
 
Cell culture experiments 
Caco-2 cells were cultivated on 80 cm2 flasks (Nunc, Denmark) using 
MEM supplemented with 10% FBS, 1% l-glutamine, 1% nonessential amino acids 
and penicillin/streptomycin solution. Cells were maintained on a controlled 
atmosphere at 37ºC with 95% of relative humidity and 5% CO2. The culture 
medium was changed every other day for approximately 5–6 days until cells reached 
approximately 80–90% confluency. After the passage operation, cells were seeded 
approximately at 2.5×105 cells per flask. For the experiments, cells with passage 
numbers between 25 and 35 were used.  
 
Cytotoxicity studies 
Cells were cultivated on 96-well plates (0.33 cm2/well) (Nunc, Denmark) 
with a cell density of 1.4×104cells/cm2 for approximately 7 days until a 
homogeneous cell monolayer was obtained.  
Cytotoxicity experiments were conducted for PEG- and CS-coated 
nanoparticles at concentrations between 0.1 and 20 mg/ml (0.2 ml/well). Monolayers 
were in contact with the suspension of nanoparticles for 2.5 h. After this time, the 
nanoparticle suspensions were removed and cell viability was determined using a 
colorimetric method (Cell Titer 96®, Promega, Madison, WI) where the reagents are 
bioreduced by the cells to a colored formazan product (readable at 490 nm) through 
a pathway where NADPH or NADH are involved. HBSS was used as a negative 
control, whereas a 2% sodium dodecyl sulfate (SDS) solution in HBSS as a positive 
control.  
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Results from the colorimetric assay were obtained by normalizing the 
absorbance of experimental wells with that of the controls: the absorbance value of 
the negative control was subtracted from the absorbance of positive controls and 
experimental wells. Then, these corrected observances were multiplied to equal the 
positive controls to one. 
 
Qualitative analysis of the interaction of nanoparticles with the Caco-2 
cells 
Caco-2 cells were seeded with a density of 5.5×104 cells/cm2 on sterile 
coverslips placed in 6-well plates and left to grow until differentiation (19–21 days). 
Cell membranes were incubated with rhodamine®-loaded nanoparticles 
formulations (0.25 mg/ml) in HBSS for 1 h. Then, nanoparticle suspensions were 
withdrawn and monolayers were rinsed five times with fresh DPBS. The samples 
were fixed for 10 min with 3.7% formaldehyde, and then permeabilized for 20 min 
with a 1% bovine serum albumin (BSA)/0.1% Triton X-100 solution in DPBS. After 
permeabilization, the cytoskeleton of the cells was stained with a 1% BSA/0.1% 
Triton X-100/5 UI/ml Bodipy® 650/665-Phalloidin solution for 20 min. After 
staining, the monolayers were thoroughly washed with DPBS, the coverslips 
separated from the wells, and the sample embedded in one drop of the mounting 
medium Fluorsave® (Carbiochem, US). 
Samples were examined under a confocal laser scanning microscope (Leica 
TCS-SP2, Leica Microsystems). The excitation wavelengths used were 514 nm for 
rhodamine® and 633 nm for Bodipy® 650/665. 
 
Qualitative analysis of the interaction of nanoparticles with the Caco-2 
cells 
Caco-2 cells were seeded with a density of 5.5×104 cells/cm2 on 12-well 
plates and left to grow until full differentiation (19–21 days). Culture medium was 
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replaced by rhodamine®-loaded nanoparticles in HBSS at concentrations of 0, 0.25, 
0.5 and 1 mg/ml and allowed for 1 h of contact. Then, the nanoparticle suspensions 
were removed and the cell monolayers washed thoroughly with Dulbecco's PBS (pH 
5.0) in order to remove the nanoparticles which are not effectively associated to the 
cells. Finally, Caco-2 monolayers were dried overnight and dissolved in a 2% 
SDS/50 mM EDTA/DPBS at pH 6 (“lysis medium”). The remaining nanoparticles 
were quantified by fluorimetry. To calculate the amount of nanoparticles from the 
fluorescence, calibration curves (fluorescence versus nanoparticles concentration) 
were prepared in the same lysis medium. Before entering fluorescence values in the 
calibration curves, the fluorescence of monolayers without nanoparticles (0 mg/ml 
samples) in lysis medium was subtracted from the experimental values.  
 
Measurement of the transepithelial electric resistance 
Cells were seeded on 6-well Transwell® plates (4.71 cm2/well, pore size 
3 μm) (Costar®, Corning Inc., NY) with a cell density of 5.5×104 cells/cm2. The 
plates were cultivated in MEM for 19–21 days. The integrity of cell monolayers was 
confirmed taking an initial transepithelial electric resistance (TEER) measurement. 
This initial value was recorded to follow the recuperation of the initial TEER of the 
monolayer. After this initial TEER measurement, cell monolayers were equilibrated 
with HBSS for 1 h prior the beginning of the experiment. For one set of experiments 
(test of the CS-coated nanoparticles and controls) the pH of the HPSS was adjusted 
to 6.5 in order to ensure the stability of the nanoparticles in the culture medium. For 
the other set of experiments (test of the PEG-coated nanoparticles and controls) the 
pH of the HBSS was 7.4. After the equilibration period, the apical solutions of the 
transwells were replaced by the nanoparticle suspensions (1 mg/ml of nanoparticles 
concentrations) or the control buffer (HBSS). Nanoparticle suspensions were kept in 
contact with the monolayers for 2.5 h and TEER measurements performed every 30 
min. After this period of time, apical media were replaced again with MEM to check 
for recuperation of the control values. TEER values were monitored for the next 24 
h and compared with the initial TEER measurement in order to check the 
recuperation of the membrane functionality. No significant differences in the 
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TEER/permeability experiments were found for the controls at pH 6.5 or 7.5. 
Therefore, for the sake of simplicity no mention to the pH of the HBSS solution will 
be made through the rest of the text.  
TEER measurements were performed with a Millicell®-ERS connected to a 
pair of chopstick electrodes (Millipore, Spain). All values were corrected taking 
measurements from transwells with the same buffer/culture media but without cell 
monolayers. 
 
Study of the transmembrane permeability 
Cells were seeded on 6-well Transwell® plates (4.71 cm2/well, pore size 3 
μm) (Costar®, Corning Inc., Corning, NY) with a cell density of 5.5×104 cells/cm2. 
The plates were cultivated in MEM for 19–21 days. Prior to the experiment, cells 
were pre-equilibrated for 1 h with their corresponding experimental buffers (HBSS 
at pH 6.5 or 7.5). Apical medium of experimental well was changed by a suspension 
of nanoparticles (1 mg/ml concentration) containing free Texas Red®-dextran 
(approximately 300 μg/ml). In the control wells, the same media without 
nanoparticles were used. In all cases, the basolateral medium used was HBSS pH 
7.4. At the beginning of the experiment, samples from the apical media were 
collected to precisely calculate the total amount of Texas Red®-dextran present in 
the apical chamber. Samples were collected from the basolateral chamber and 
replaced by fresh HBSS every 30 min for up to 2.5 h. 
The concentration of Texas Red®-dextran was measured by fluorimetry. 
The apparent permeability of the monolayers to the paracellular marker calculated 
from the following equation: Papp(cm/s)=dQ/dt/(A×C0), where Papp is the apparent 
permeability coefficient, dQ/dt the rate of appearance of Texas Red®-dextran in the 
basolateral side, A the surface area of the monolayers and C0 the initial 
concentration of Texas Red®-dextran in the apical side. 
 
 
Anexo 279 
Oral administration of sCT loaded nanoparticles 
All animal experiments were approved by the Ethical Committee of the 
Faculty of Medicine of the University of Santiago de Compostela. Male Sprague–
Dawley rats (225–275 g) from the Central Animals House of the University of 
Santiago de Compostela (Spain) were fasted for 12 h before experiments but 
allowed water ad libitum. Animals were kept conscious during the experiments.  
The following formulations were administered intragastrically to rats: (1) 
sCT aqueous solution, (2) PEG-coated nanoparticles and (3) CS-coated 
nanoparticles. In all cases the sCT dose administered was 500 UI/kg and the 
volumes of formulations used were 0.5 ml. Due to the different sCT loading of the 
particles, the dose of nanoparticles administered varied between 19.2 mg/kg for the 
PEG-coated nanoparticles and 70.8 mg/kg for the CS-coated nanoparticles. Blood 
samples were collected from the tail vein 30 min prior to the administration of the 
formulations in order to establish the baseline calcium level. Then, blood samples 
were collected at different time intervals for up to 24 h. The serum was separated by 
centrifugation at 3000×g for 5 min. Hypocalcemic effect was determined in serum 
samples by a colorimetric method at 570 nm (Kit OR-cresolphtalein v/v, Spinreact, 
Spain). Results are shown as the mean values of serum calcium levels (±S.E.M.) of 
six animals. An ANOVA test was performed on the data (α<0.01) with the statistical 
software package SPSS 11.0. 
 
Results and discussion 
In the present report, the behaviour of two innovative colloidal systems, 
differing in their surface composition, in terms of their utility for oral peptide 
administration is discussed. These are PEG-coated (PEG-coated nanoparticles) and 
CS-coated lipid nanoparticles (CS-coated nanoparticles). As indicated in Section 1, 
the selection of the polymer coating was based on previous work performed in our 
laboratory, which underlined the positive role of these polymer coatings at 
improving the interaction of colloidal systems with mucosal surfaces (De Campos et 
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al., 2003, Tobío et al., 2000, Vila et al., 2002 and Vila et al., 2004). On the other 
hand, the selection of a lipid core was based on the recognized ability of lipids to 
protect macromolecules against degradation, as well as to enhance the permeability 
of some epithelia (Muranishi, 1985). 
 
Characteristics of the surface-modified lipid nanoparticles 
In the present study the solid lipid cores were prepared using a multiple 
emulsion solvent evaporation technique (Garcia-Fuentes et al., 2002). CS was 
simply added to the external aqueous phase of the suspension, as this polymer is 
expected to attach to the core particles due to the formation of an ionic complex 
between the negatively charged lipids (tripalmitin and lecithin) and the positively 
charged polymeric chains. In the case of PEG-coated nanoparticles, the formation of 
the hydrophilic coating was achieved by adding PEG-stearate to the organic solution 
containing the lipid mixture. It was assumed that the amphiphilic nature of this 
polymer would facilitate the orientation of the lipid part (stearate) towards the lipid 
core and the hydrophilic PEG towards the external aqueous medium of the emulsion.  
The physicochemical characteristics of the polymer-coated and uncoated 
blank nanoparticles are displayed in Table 1. The first general observation is that 
both hydrophilic coatings (PEG and CS) led to a logical increment in the size of the 
nanoparticles. However, this increase was more pronounced for CS- than for PEG-
coated nanoparticles. Simultaneously, it can be seen that the zeta potential (ζ), 
indicative of the surface characteristics, is greatly affected by the nature of the 
coating. Logically, tripalmitin nanoparticles presented a marked negative charge due 
to the presence of anionic lipids in their composition. This negative charge was 
reduced in the case of PEG-coated nanoparticles due to the extension in the plane of 
shear produced by the presence of this polymer on the surface (Garcia-Fuentes et al., 
2002). On the other hand, an inversion of the zeta potential from negative to positive 
values was observed for the CS-coated nanoparticles, a change attributed to the 
attachment of the cationic polymer CS to the surface of the cores. 
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Table 1: Physicochemical characteristics of blank uncoated and PEG- and CS-coated 
nanoparticles and the association efficiency (A.E.) of sCT to the different 
nanoparticles (mean±S.D., n=3). 
 
Formulation Particle size 
(nm) 
ζ potential 
(mV) 
A.E. (%) 
Uncoated nanoparticles 200±2 −50.3±1.8 >90 
PEG-coated nanoparticles 226±7 −34.8±2.8 >90 
CS-coated nanoparticles 537±16 +29.2±6.2 30.7±2.3 
 
Both types of surface-modified nanoparticles were fluorescently labeled 
with rhodamine®. This fluorochrome showed an encapsulation efficiency of 75% 
and less than 0.1% release for a 12 h period. The retention of the fluorescence 
associated to the nanocarrier was important in order to use it as a tracer for the study 
of the internalization of the particles.  
Finally, the three carriers exhibited a high capacity to associate sCT. As 
reported in a previous work (Garcia-Fuentes et al., in press) this high association 
was attributed to a facilitated interaction of the cationic peptide with the negatively 
charged lipids. This mechanism of association justifies the reduction of the 
association efficiency caused by the CS coating. Indeed, it has been shown that the 
attachment of CS leads to the partial displacement of the surface-associated sCT 
(Garcia-Fuentes et al., in press). 
 
Studies in the Caco-2 model cell line 
Recent studies performed in the Caco-2 model cell line have provided 
evidence on the ability of polymer nanoparticles to cross epithelia (Desai et al., 1997 
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and Behrens et al., 2002). On the other hand, indirect observations by Gasco and 
coworkers (Bargoni et al., 1998) have led to the conclusion that lipid nanoparticles 
are able to cross the intestinal epithelium. However, despite the value of this 
previous information, no studies have been reported so far aimed at investigating the 
factors that affect the interaction of lipid nanoparticles with the intestinal epithelium. 
Consequently, one of the primary goals of this work was to study the interaction of 
these lipid nanostructures with the Caco-2 cells and to investigate whether or not the 
polymer coating affects this interaction. Before these transport studies, the cellular 
toxicity of the different types of particles was also evaluated. 
 
Cytotoxicity of the nanoparticles 
The evaluation of the cytotoxicity of the nanoparticles had a double 
objective: (i) to determine the concentrations that could interfere with the cellular 
metabolism in further studies in Caco-2 and (ii) to obtain a preliminary estimation of 
the safety of these new formulations.  
The toxicity of the lipid core was expected to be very low given the fact 
that tripalmitin is a physiological triglyceride. In addition, the low toxicity of lipid 
nanoparticles has already been shown in human promyelotic cells (HL60) and 
human granulocytes (Müller et al., 1997). Therefore, the evaluation of the toxicity of 
the lipid cores was excluded from this study. As shown in Fig. 1, nanoparticles 
coated with PEG, a polymer of very low toxicity, showed high viabilities even at 
concentrations as high as 20 mg/ml. On the other hand, CS-coated nanoparticles 
exhibited certain toxicity at concentrations above 1 mg/ml, having an IC50 of 3.3 
mg/ml. These values, indicative of a toxic effect of the CS coating are in agreement 
with those previously reported for CS solutions (Schipper et al., 1996). 
Consequently, from these studies we concluded that PEG-coated nanoparticles 
showed an extremely low cytotoxicity while CS-coated nanoparticles appeared to 
have a low toxicity. Therefore, a concentration of 1 mg/ml was selected as the 
threshold nanoparticles concentration for further Caco-2 experiments.  
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Fig. 1: Relative viability of Caco-2 cells following incubation with different 
concentrations of PEG-coated nanoparticles ( ) and CS-coated nanoparticles ( ) 
for 2.5 h (mean±S.D., n=8).  
 
Qualitative and quantitative analysis of the interaction of nanoparticles 
with the Caco-2 cells 
In order to visualize the limits of the cellular compartments and, thus, to 
help the localization of the nanoparticles associated to the monolayers we used 
Bodipy® 650/665-Phalloidin. This fluorescent dye binds selectively to F-actin, 
which is a major component of the cytoskeleton (Artursson et al., 1994). Control 
experiments showed that cells had low self-fluorescence and that no cross-
fluorescence between the fluorochromes occurred.  
Confocal laser scanning microscopy images show that both, CS and PEG, 
surface-modified nanoparticles were able to penetrate through the Caco-2 
monolayers (Figs. 2 and 3, supplementary material). More specifically, after 1 h of 
incubation, both nanoparticles formulations were seen in consecutive confocal 
sections of the monolayer. The disposition and appearance of the fluorescence spots 
varied depending on the depth of the section. In the apical side (top images of Fig. 2 
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and Fig. 3) the nanoparticles are randomly distributed. However, in the underlying 
sections, the nanoparticles are preferentially co-localized with Bodipy®-Phalloidin 
in the cytoskeleton. In addition, as the sections are taken deeper into the cell, the 
fluorescent spots appear less aggregated and with a smaller size. Under the 
conditions of the present study, the observed localisation of the nanoparticles, does 
not allow us to discriminate between paracellular and/or transcellular internalization. 
Therefore, we could hypothesize that nanoparticles can enter the epithelium by 
either or both paracellular and transcellular mechanisms of transport. Despite these 
possible routes, previous reports on the internalization of CS nanoparticles by the 
Caco-2 monolayers, led us to accept the transcellular internalization as the most 
plausible mechanism (Ma and Lim, 2003 and Behrens et al., 2002).  
 
 
 
 
 
 
 
 
 
 
Fig. 2: Confocal scanning microscopy images of Caco-2 cell monolayers exposed to 
PEG-coated nanoparticles (0.25 mg/ml) and Bodipy® 650/665-Phalloidin for 1 h. 
The left column shows four sections collected at the Bodipy® 650/665-Phalloidin 
emission wavelength. The right column shows the same sections collected at the 
rhodamine® emission wavelength. The images are sections separated 3 μm each 
starting from the apical side (top).  
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Fig. 3: Confocal scanning microscopy images of Caco-2 cell monolayers exposed to 
CS-coated nanoparticles (0.25 mg/ml) and Bodipy® 650/665-Phalloidin for 1 h. The 
left column shows four sections collected at the Bodipy® 650/665-Phalloidin 
emission wavelength. The right column shows the same sections collected at the 
rhodamine® emission wavelength. The images are sections separated 3 μm each 
starting from the apical side (top).  
 
Therefore, the analysis of this previous information and the results of the 
present study led us to suggest that the polymer-coated lipid systems may enter the 
Caco-2 monolayer. Nevertheless, a more detailed study using different fluorescence 
markers would be necessary in order to understand the determinants of the 
mechanism of transport of the nanoparticles.  
The quantitative analysis indicated that both nanoparticles formulations 
have an important interaction with the Caco-2 cells (Fig. 4). Interestingly, 
irrespective of the nature of the coating, the amount of nanoparticles bound to the 
cells increased linearly with the concentration of nanoparticles, reaching values of 
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around 15% of the dose. The similarity of the results obtained for CS-coated 
nanoparticles and PEG-coated nanoparticles was surprising for us, given the 
different nature of both coatings. In fact, the association values of PEG-coated PLA 
nanoparticles to the Caco-2 cells were much less important than those observed in 
the present work for PEG-coated lipid nanoparticles (Behrens et al., 2002). 
Consequently, more comparative studies are needed in order to identify the 
importance of the core and the coating in these mechanistic studies.  
 
Fig. 4: Quantity of fluorescent nanoparticles (PEG-coated nanoparticles ( ), CS-
coated nanoparticles ( )) bound to Caco-2 monolayers after 1 h of incubation as a 
function of the concentration (mean±S.D., n=3).  
 
Transepithelial electrical resistance and Texas Red®-dextran transport 
A number of polymers, CS among them, have shown the ability to 
permeabilize the intestinal epithelium (Artursson et al., 1994). However, whether or 
not particles prepared from these polymers maintain their intrinsic capacity to 
modify the epithelial permeability remains unknown. Consequently, in the present 
work, we found it important to determine if this association has a consequence in the 
epithelial permeability.  
The measurement of the transepithelial electrical resistance (TEER) is a 
common way to determine paracellular permeability to ions and their changes upon 
exposure to a permeation enhancer. This information is relevant as reductions in the 
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TEER can be correlated with partial disruption of the tight junction complex that 
restricts the paracellular route for hydrophilic compounds. In the present study, no 
significant changes were appreciated in the control wells during the experiment (Fig. 
5). In addition, the TEER values of the monolayers exposed to PEG-coated 
nanoparticles exhibited a profile that was not significantly different than that of the 
control experiment: a small initial drop in TEER followed by a progressive 
recuperation of the initial TEER value. On the other hand, CS-coated nanoparticles 
presented a different behaviour compared to that of the corresponding control 
experiment. More specifically, the TEER values of the monolayers exposed to CS-
coated nanoparticles decreased continuously during the experiment (2.5 h). Then, 
after removal of the nanoparticles formulations from the apical side, the monolayers 
were washed and incubated with MEM for the next 24 h. During this 24 h period, a 
slow recuperation of the TEER values was observed, reaching half of the initial 
TEER value after 6 h, and total recuperation in 24 h.  
 
Fig. 5: Transepithelial electric resistance (TEER) of Caco-2 monolayers exposed to 
PEG-coated nanoparticles (1 mg/ml) (◊), CS-coated nanoparticles (1 mg/ml) (▲) or 
their respective controls (HBSS (□), HBSS pH 6.5 (●)) (mean±S.D., n= 3–6).  
 
The apparent permeability (Papp) of the fluorescent marker Texas Red®-
dextran (3000 Mw) was in good agreement with the TEER data (Table 2). The 
results showed that PEG-coated nanoparticles do not have a permeability enhancing 
effect. In contrast, CS-coated nanoparticles elicited a very marked transport 
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enhancing effect compared with their control. Indeed, the permeability values of the 
monolayers incubated with CS-coated nanoparticles were almost four-fold those of 
the controls. This transport enhancing effect is in good agreement with that 
previously reported for CS solutions (two- to four-fold enhance in manitol 
permeability with respect to the control) (Artursson et al., 1994 and Schipper et al., 
1996).  
 
Table 2. Apparent permeability coefficient (Papp) of Texas Red®-dextran (3000 
Mw) determined in Caco-2 cell monolayers exposed to PEG-coated nanoparticles, 
CS-coated nanoparticles and their controls (mean±S.D., n= 3–6). 
 
Treatment Papp (×10
−7 cm/s) Relative Papp 
(carrier/control) 
HBSS 1.70±0.86 – 
PEG-coated nanoparticles 1.83±0.18 1.08 
CS-coated nanoparticles 6.12±1.45 3.6 
 
Overall, these results indicate that CS-coated nanoparticles produce a 
transient increase in the transepithelial permeability. This effect could be related to 
an opening of the paracellular route due to the interactions of CS with the proteins 
involved in the tight junctions between epithelial cells (Artursson et al., 1994 and 
Smith et al., 2004). Nevertheless, in the interpretation of these results we should be 
conscious of the fact that in these cell culture experiments an important amount of 
nanoparticles (0.333 mg/cm2) is forced to be directly in contact with the cells, a 
situation that differs substantially from that expected following oral in vivo 
administration. 
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Oral administration of sCT-loaded surface modified nanoparticles 
As a final step of the present work, and in order to elucidate the role of the 
polymer coating around the lipid nanoparticles in their ability to enhance the 
intestinal absorption of peptides, we determined the calcemia levels following the 
oral administration of the nanoparticles and the corresponding control (sCT 
solution). Two very distinct profiles were observed for PEG- and CS-coated 
nanoparticles (Fig. 6). PEG-coated nanoparticles did not produce any significant 
effect on serum calcium levels. In contrast, CS-coated nanoparticles showed a rapid 
and drastic reduction in serum calcium levels. Moreover, these low calcemia levels 
were maintained for at least 24 h. This hypocalcemic effect was significantly lower 
than that of the control for all the time points (α < 0.01). This important extent of 
reduction of the serum calcium levels is similar to that previously reported for other 
systems, such as CS-coated poly(lactic-co-glycolide) nanoparticles and poly(N-
isopropyl acrylamide)-coated polystyrene nanoparticles (Kawashima et al., 2000 and 
Sakuma et al., 2002). However, to our knowledge, the ability of CS-coated 
nanoparticles to prolong the pharmacological response is superior to that of the 
previously reported systems.  
 
Fig. 6: Serum calcium levels after oral administration to conscious rats of sCT in 
solution (□), or associated to PEG-coated nanoparticles (◊) or CS-coated 
nanoparticles (▲) (mean±S.D., n= 6). *Significant differences from the sCT 
solution (α<0.01).  
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At the present stage, our hypothesis to explain the success of the CS-coated 
nanoparticles is that they interact favourably with the mucus covering the intestinal 
mucosa (Takeuchi et al., 2001 and Behrens et al., 2002) and then, diffuse through 
this mucus layer reaching the underlying epithelium. These interactions would 
permit a site-specific delivery of sCT for prolonged times and, consequently, a 
prolonged pharmacological response. Moreover, it could be expected that CS, 
because of its ability to interact with the tight junctions, could enhance the 
paracellular transport of the peptide released at the epithelial level. In contrast, PEG-
coated nanoparticles do not have a favourable interaction with the mucus layer 
covering the intestinal epithelium and, thus, have a limited access to the underlying 
epithelium. In addition, PEG-coated nanoparticles did not produce an enhancement 
of the epithelial permeability, which could also be responsible for the absorption of 
the peptide. These differences could justify the lack of pharmacological response 
observed for the PEG-coated nanoparticles despite their ability to enter the Caco-2 
cells monolayer.  
In summary, due to the extreme complexity inherent to the study of the 
particle uptake phenomenon and of the mechanisms of interaction with the 
epithelium (particularly for biodegradable particles), more detailed studies will have 
to be performed in order to fully understand the in vivo behaviour of these novel 
nanocarriers. Nevertheless, the results presented in this work are relevant as they 
show that particle uptake may not be the main mechanism behind the enhanced 
bioavailability of sCT in chitosan-coated nanoparticles.  
 
Conclusions 
Overall, the results of this work underline the importance of the surface 
composition of the nanoparticles in their ability to enhance the intestinal absorption 
of peptides. More specifically, the results showed that lipid nanoparticles coated 
with PEG or CS were able to enter the Caco-2 cell monolayers. However, only those 
coated with CS were able to open the tight junctions, thereby increasing the 
permeability of the model epithelium. Moreover, CS-coated nanoparticles were able 
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to enhance the oral absorption of the peptide sCT leading to a prolonged 
hypocalcemic response, whereas, PEG-coated nanoparticles were unsuccessful at 
increasing the absorption of the peptide. Consequently, the results suggest that the 
favourable interaction of the CS-coated nanoparticles with intestinal mucosa 
together with their permeation enhancing characteristics might be responsible for the 
improved oral absorption of the associated sCT. 
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Abstract 
Over the last decade we have assisted to a biotech revolution that is leading 
to the development of an important number of macromolecules with a great 
therapeutic potential. As a consequence, there is an increasing necessity to define 
specific formulation strategies for these delicate compounds. In our group, we have 
attempted to develop new nanocarriers for oral peptide administration. Among them, 
those consisting of a lipid core surrounded by a hydrophilic coating have resulted 
very promising. The lipid core was either liquid (Miglyol® 812 oil) or solid 
(tripalmitin) and the coating was a non-charged polymer such as polyethyleneglycol 
(PEG) or a positively charged polysaccharide i.e. chitosan. We first demonstrated 
that these polymer-coated nanostructures have an improved stability in the 
gastrointestinal fluids. Following this, we tested the ability of these new 
nanostructures to enhance the systemic absorption of the model peptide salmon 
calcitonin (sCT), after oral administration. The results indicated that, irrespective of 
the nature of the core, the chitosan-coated systems provided an enhanced and 
prolonged hypocalcemic response to sCT. In contrast, the PEG-coated lipid systems 
were not successful at increasing the response to sCT. The studies performed in the 
Caco-2 model cell line indicated that, irrespective of the coating, the nanostructures 
were internalized into the monolayer, however, only those coated with chitosan 
caused a significant reduction of the transepithelial resistance. Consequently, these 
results suggest that the superiority of the chitosan-coated nanostructures as 
compared to the PEG-coated nanostructures, could be related to inherent properties 
of chitosan, i.e. its favourable interaction with the mucus overlaying the intestinal 
mucosa and, possibly, its ability to open the tight junctions between epithelial cells. 
Keywords: Nanoparticles, nanocapsules, lipid-based carriers, oral peptide 
delivery, chitosan, PEG. 
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Introduction 
Overcoming the low bioavailability of drugs thathave low permeability 
through biological membranes is one of the most prominent pharmaceutical 
problems [1]. The advent of the biotech revolution has stressed even more this 
limitation as an increasing number of molecules with high therapeutic potential are 
dumped because of their poor biopharmaceutical properties [2]. Peptides and 
proteins are the molecules that best exemplify these biopharmaceutical properties: 
together with their poor permeability, thesemolecules are extremely labile to the 
action of proteolytic enzymes [3]. The combination of these two biopharmaceutical 
barriers (low permeability through the epithelia and degradation) constrainsthe oral 
bioavailability of peptides to values usually below 1%. One of the most appealing 
strategies to improve the oral absorption of these delicate macromolecules has been 
the association or inclusion of peptides in submicrometer-size carriers [4,5,6]. The 
challenge, however, has been the definition of the characteristics of the carrier that 
will lead to an optimized transport and, an adequate delivery of the associated 
peptide. Among the materials chosen for the design of these nanocarriers, the lipids 
have played an important role. 
 
From lipid excipients to nanostructured lipid carriers 
Lipids comprise a rather heterogeneous group of molecules that are 
characterized by the presence of aliphatic chains. Lipids have been used for 
pharmaceutical preparations due to their excellent biocompatibility and their wide 
spectrum of physicochemical characteristics, which make them useful for multiple 
applications [7]. To this date, waxes, mono-, di- and triglycerides, fatty acids, 
cholesterol derivatives or phospholipids are the most common classes of lipids used 
in traditional pharmaceutical formulations such as lipid emulsions, intramuscular 
depot injections, matrix tablets or suppositories. 
In the last, a better understanding of the interactions of lipids at the cellular 
level has considerably increased the interest for these materials as drug transmucosal 
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carriers. In fact, electron spin resonance and NMR studies have shown that 
monoglycerides and fatty acids interact causing a disorder in the lipid 
membranesthat is supposed to be related to their capacity to permeate the epithelia 
[8]. Moreover, some lipidshave exhibited an affinity for the SH-proteins, which are 
known to play a role in transmembrane transport and tight junction permeability [9]. 
More recently, it has also been shown that some lipids can also interact with P 
glycoprotein and cytocrome P 450, thereby facilitating intracellular drug delivery 
[10]. 
However, maybe the most unique characteristic of lipid based formulations 
is their ability to be digested in the intestine, thus producing micelles that can enter 
the organism through the intestinal lipid transport system [7]. Drugs incorporated in 
the micelles resulting from lipid digestion may be internalized through this pathway 
[11]. The absorption enhancing properties of lipid excipients have already been 
tested for oral insulin delivery [12,13]. This early works provided some proof-
ofconcept of the possibility to achieve higher oral bioavailability of peptides if 
administered with lipid promoters. 
The new challenges faced by lipid formulations have stimulated the design 
of more advanced drug delivery systems, particularly submicrometric carriers, 
whose high surface/volume ratio maximizes the interactions with the biological 
environment. Moreover, some of these nanocarriers, i.e. liposomes and solid lipid 
nanoparticles, have shown their ability to cross the intestinal epithelium, probably 
though an endocytic pathway [14,15]. 
 
Liposomes in oral peptide delivery 
The capacity of liposomes to encapsulate hydrophilic macromolecules has 
been suggested as a way to protect them in the gastrointestinalract [16]. However, in 
order to achieve this protective effect, it is critical to preserve the liposome integrity 
in this hazardous environment. Since the early works from Dapergolas et al. [17] 
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it is well known that liposomes made of phospholipids with a phase 
transition temperature above 37ºC are more stable in the GI tract than those 
composed of lipids in a liquidcrystalline state (such as natural phospholipids). 
A step further in the development of oral liposomes has been based upon 
the optimization of their surface characteristics. For example, the modification of the 
surface of liposomes with protective coatings such as mucin or PEG resulted in 
enhanced oral insulin effect compared to uncoated liposomes. In vitro experiments 
confirmed that these liposome formulations were able to protect the peptide more 
efficiently against its degradation in intestinal fluids [16]. Nevertheless, the 
beneficial effect of these coatings should not only be attributed to its protective 
capability, as a subsequent study has also shown that these polymers increased the 
residence time of the liposomes in the GI tract. More concretely, mucin-coated 
liposomes displayed an extended gastric retention and PEGcoated liposomes an 
increase in the residence time in the small intestine [18]. Liposomes coated with 
other type of mucoadhesive polymers such as Carbopol® or chitosan have also 
shown to enhance the absorption of orally administered peptides [19,20]. 
The surface charge of liposomes also seems to have an important role in the 
capacity of liposome formulations to promote the oral peptide absorption, however, 
the optimal value of that parameter remains unclear. Some papers have indicated 
that the presence of anionic lipids improves the intestinal absorption of insulin 
[21,22], while others have reported the same effect, either for insulin or calcitonin 
for cationic liposomes [16,23]. 
 
Microemulsions and nanoemulsions in oral peptide delivery 
Microemulsions and nanoemulsions are dispersed systems of two 
immiscible liquids. Microemulsions can also be defined as colloidal dispersions of 
liquids thermodynamically stabilized by a layer of surface-active molecules. 
Nanoemulsions are not thermodynamically stable, however, their coalescence can be 
hindered for prolonged periods of time if they are properly stabilized. With an 
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already marketed oral Cyclosporine A formulation (Sadimmune Neoral®), increased 
attention has been paid to the possibility of formulating peptides orally by including 
them in submicrometric emulsions. Nevertheless, up to date, the most successful 
results have been obtained with small peptides such as desmopressin [24], 
vasopressin [25] or thefibrinogen antagonist peptide SK&F 106760 [26]. This 
positive behaviour has been understood as a consequence of the lipid absorption 
promoting effect. This hypothesis has been further supported by the fact that 
composition, rather than emulsion droplet size was found to be the main factor 
responsible for the enhanced peptide absorption. Indeed, the presence of a 
polyoxyethylene derivative (Cremophor EL) was considered essential to achieve 
those high peptide oral bioavailabilities [27]. 
Despite the encouraging data obtained for Cyclosporine A and the SK&F 
106760 peptide, the success of the submicron emulsion for oral delivery of high 
molecular weight peptides remains to be a challenge. Some improvements in the 
absorption of peptides, i.e. salmon calcitonin, have been observed for submicron 
emulsions which were coated with a mucoadhesive polymer such as Carbopol® 
[24]. This improved absorption of the associated peptide was attributed to the 
enzyme inhibitory action of this polymer [28]. More recent studies [29] have 
confirmed that the presence of Carbopol® as a coating was critical for the efficacy 
of the formulation. 
 
Polymeric nanocapsules in oral peptide delivery 
Nanocapsules are carriers comprising an inner lipid reservoir and an outer 
polymeric wall. Insulin-loaded polycyanoacrylate nanocapsules have render, so far, 
some of the most outstanding results in animal models. Significant reductions in the 
glycemia of diabetic rats were produced and maintained for prolonged periods of 
time, when that nanocapsule formulation was administered orally [30]. The extent 
and duration of the pharmacological effect was explained by the penetration of the 
nanocapsules through the mucosa and the further release of the peptide from the 
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internalized formulation [31]. Unfortunately, the results obtained in the dog model, 
although positive, were not as promising as those previously reported with rats [32].  
 
New polymer-lipid nanostructures for oral peptide delivery 
Although over the last years some breakthrough technologies have led to a 
new perspective of oral peptide delivery, renewed efforts are still needed to obtain a 
clinically useful carrier system. Lipid-based carrier systems are not an exception and 
still have to face important challenges to optimize their performance. 
First, lipids are labile materials, very susceptible to enzymatic degradation 
in the intestine. As a consequence, lipid drug delivery systems are usually destroyed 
before reaching the adequate site for peptide absorption, thus loosing their ability to 
protect and enhance the transport of the peptide. Finally, it is generally accepted that 
the capacity of transport of lipid carriers, even though significant, may be 
insufficient at this stage to achieve a clinically useful effect. 
In order to advance a further step in the development of a useful peptide 
delivery system for the oral route, we have designed new carrier systems based on a 
lipid core-polymer coat structure. The polymeric coating was intended to optimize 
the interaction of the delivery system with the biological environment present in the 
gastrointestinal tract. Hence, we selected polymer coatings that were supposed to 
prevent aggregation and destruction of the delivery systems, to confer mucoadhesive 
properties to the carriers or to enhance transepithelial permeability. 
A schematic illustration of the nanostructures prepared is depicted in Figure 
1. Since the composition of the core is supposed to affect drug incorporation and 
release [33], we have proposed three different cores for the nanostructures: a solid 
lipid (tripalmitin), a liquid lipid (Miglyol® 812) or a solid-liquid lipid mixture 
(tripalmitin/Miglyol® 812). 
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Lipid core (Miglyol, tripalmitin or tripalmitin/ 
Miglyol mixtures)
Poly mer shell (PEG or chitosan)
 
Figure 1: Illustration of the proposed architecture of the designed polymer-coated 
lipid nanostructures. 
 
Regarding the polymer coating, two hydrophilic polymers have been 
selected: PEG and chitosan. The selection of PEG is based on the results of previous 
studies performed by our group, which have shown that a PEG coating around PLA 
nanoparticles greatly enhanced their stability in simulated gastrointestinal fluids [6]. 
Similarly, studies performed by Olbrich et al. have shown that a coating with 
ethylene oxide derivatives (Poloxamers) around the lipid nanoparticles protected 
them from degradation by pancreatic enzymes [34]. Moreover, it has been indicated 
that a PEG coating may favour the interaction of colloidal carriers with mucosal 
surfaces [18,35]. However, while the protective effect of PEG is well understood, its 
possible role in enhancing the interaction of nanosystems with epithelia remains 
unclear. Nevertheless, whether this improved interaction is simply a consequence of 
the enhanced stability of the nanoparticles in contact with biological fluids, or is 
additionally helped by some specific mechanisms, the clear observation is that the 
PEG-coated PLA nanoparticles are able to cross the nasal mucosa up to a more 
important extent than those non-coated [36,37]. 
On the other hand, the selection of the polysaccharide chitosan as a coating 
for transmucosal nanocarriers is justified by its interesting biopharmaceutical 
behaviour. From the point of view of drug delivery, some important features of this 
material are its mucoadhesiveness [38] and its capacity to increase the permeability 
of epithelia [39]. In addition, previous studies from our group have shown that 
chitosan-based nanosystems are able to interact with mucosal surfaces, thus 
facilitating the interaction and transport of the associated active compound across 
these surfaces. More specifically, chitosan nanoparticles were able to enhance the 
 
304 Nanocápsulas de quitosano: nuevos vehículos…. 
 
transport of insulin across the rabbit nasal mucosa up to a much greater extent than 
chitosan solutions [40]. Similarly, low molecular weight chitosan nanoparticles 
elicited an interesting capacity for the transport of antigens across the nasal mucosa 
[41]. In addition, besides their favorable behaviour for the nasal transport of 
macromolecules, chitosan nanoparticles exhibit an affinity for the ocular mucosa. 
Recent studies aimed at studying the residence time of these nanoparticles in the 
ocular mucosa, following topical administration, indicated that the interaction of 
chitosan with the cornea and conjunctiva was enhanced and prolonged when 
presented in a nanoparticulate form [42]. All these studies provided evidence of the 
benefits of chitosan nanosystems as compared to other forms of presentation of 
chitosan. 
Taking this previous information into account the aim of the present paper 
was not simply to review the state-of-the-art of the potential of lipid-based colloidal 
systems for oral peptide administration but to specifically emphasize the latest 
advances from our work regarding the design and evaluation of polymer-coated lipid 
nanosystems. 
 
Preparation and characterization of polymer-coated lipid nanostructures 
PEG-coated tripalmitin (or PEG-coated tripalmitin/Miglyol®) nanoparticles 
were prepared in a single step by a modified double emulsionsolvent evaporation 
method [43]. In this technique, hydrophilic drugs such as peptides may be 
incorporated to the nanoparticles in the inner aqueous phase. The PEG coating was 
formed due to the addition of the modified fatty acid PEG-stearate to the organic 
phase. 
On the other hand, chitosan-coated nanocarriers have been prepared 
following different procedures depending on the nature of the core. Chitosan-coated 
solid lipid nanostructures were prepared by the double emulsion-solvent evaporation 
technique, indicated above [43]. When using this procedure, chitosan can be either 
added to the external aqueous phase of the double emulsion or once the lipid cores 
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were precipitated [44]. Alternatively, chitosan-coated submicron emulsions were 
prepared according to the solvent displacement-solvent evaporation technique, as 
previously reported [45]. As in the case of the solid cores, chitosan can be added 
before or after the solvent evaporation takes place. Irrespective of the technique, a 
critical ingredient for the formation of the chitosan-coated systems was the presence 
of lecithin, which was added to the organic phase in both procedures. Indeed, an 
ionic complex between lecithin and chitosan is formed at the interface of the 
colloidal system, thus facilitating the attachment of chitosan onto the surface of the 
system. 
Lipid cores (non-coated) showed particle sizes around 200 nm upon 
preparation and strongly negative surfaces (Table 1). The coating of the tripalmitin 
cores with PEG produced a negligible effect on the particle size whereas the zeta 
potential shifted towards more neutral values [43]. As described for other PEG-
coated systems, this change is a consequence of the extension of the shear plane of 
the colloidal system [46]. The formation of a chitosan coating around the lipid cores 
led to an increase in the particle size, accompanied by an inversion of the zeta 
potential from negative to positive values (Table 1) [47]. Both, the size increase and 
the inversion of the zeta potential, support the successful formation of a chitosan 
layer surrounding the lipid cores. 
 
Table 1: Hydrodynamic diameter (analyzed by photon correlation spectroscopy) and 
zeta potential (analyzed by laser Doppler anemometry) of the studied nanostructures 
(Mean ± SD., n=3). Data from: 1Prego et al. [54] and 2García- Fuentes et al. [47]. 
 
Formulation Diameter (nm) Zeta Potential (mV) 
Miglyol® cores1 195.8 ± 1.1 -52.0 ± 1.1 
Chitosan Miglyol® nanocapsules1 266.6 ± 7.6 +34.8 ± 0.6 
Tripalmitin cores2 200.0 ± 2.3 -50.3 ± 1.8 
PEG-coated tripalmitin nanoparticles2 226.4 ± 7.5 -34.8 ± 2.8 
PEG-coated tripalmitin/ Miglyol® 
nanoparticles2 207.4 ± 19.1 -36.6 ± 2.5 
Chitosan-coated tripalmitin nanoparticles2 537 ± 16 +29.2 ± 6.2 
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The size and the morphology of the PEG- and chitosan-coated systems 
were visualized by transmission electron microscopy (Figure 2). All the 
nanostructures presented a spherical shape. In the case of PEG-coated nanoparticles, 
a difference in the staining was appreciated between the inner and the outer part of 
the nanoparticles, being this a possible indication of the core-coat structure of the 
systems. Unfortunately, this difference in staining could not be observed for 
chitosan-coated tripalmitin nanoparticles although the change in particle size was 
clearly visible in the micrographs. This dissimilarity between micrographs could be 
related not only to the different nature of the coating polymers but also to the high 
chitosan molecular weight as compared to that of PEG. This observation led us to 
suggest that the chitosan may be forming a more compact polymer layer compared 
to that of the PEG. 
 
Figure 2: Transmission electron microscopy pictures of different lipid 
nanostructures: PEG-coated tripalmitin nanoparticles (left), PEG-coated 
tripalmitin/Miglyol® nanoparticles (center) and chitosan-coated tripalmitin 
nanoparticles (right). 
 
NMR analysis has allowed us to confirm that the PEG-coated 
nanostructures are mainly composed of a triglyceride core and a small amount of 
surfactants and surface modifying molecules (i.e. lecithin, PEG-stearate) [48]. On 
the other hand, the core-coat model proposed for these structures was fully 
confirmed in the case of PEGtripalmitin nanoparticles. NMR experiments aimed to 
analyze the relaxation of the chemical groups of nanoparticle suspensions and their 
spin-population effects with the water protons confirmed the presence of PEG 
protruding towards the external phase and the presence of a solid lipid core 
comprising mainly the triglycerides. Moreover, quantitative NMR analysis has 
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confirmed the possibility of modulating the PEG coating density of these carriers by 
controlling the amount of PEGstearate added in the preparation procedure [48]. 
The NMR characterization of nanoparticles having a tripalmitin/Miglyol® 
core indicated that there were significant amounts of the oil incorporated within the 
nanoparticles matrix. Moreover, the presence of Miglyol® as separated liquid 
domains associated to the nanoparticles was confirmed by NMR relaxation analysis 
and the observed restricted diffusion dynamics of the entrapped oil. A further 
confirmation of this structure was obtained from differential scanning calorimetry 
(DSC) and x-ray diffraction spectroscopy [49]. 
 
Stability in simulated gastrointestinalfluids 
Taking into account that the designed lipid nanostructures were intended 
for oral drug delivery, the assessment of their stability in gastrointestinal fluids was 
critical. Indeed, lipid nanoparticles have shown important particle aggregation in 
gastric media and a marked degradation in simulated intestinal fluid with enzymes 
[50,51]. Interestingly, the aggregation of the lipid cores in gastric medium has been 
found to be dependent on the mechanism of particle stabilization. Thus, we 
previously prepared lipid cores that were stabilized only with lecithin (uncoated 
cores), a surfactant that confers on the system a distinctly negative charge at neutral 
pH. At low pH, the surface charge of the lipid nanostructures was significantly 
reduced due to the less important ionization of the negatively charged phospholipids, 
thus leading to the aggregation of the nanoparticles in simulated gastric medium 
(Figure 3) [43]. The importance of the pH of gastric medium in the aggregation 
processes was also assessed by incubating the formulations in an inorganic acid 
solution (pH 1.2), without enzymes. As can be appreciated in Figure 3, the addition 
of a second ionic stabilizing surfactant (sodium cholate) did not enhance the stability 
of tripalmitin cores neither in inorganic medium nor in simulated gastric medium. 
On the contrary, by coating the lipid cores with polymers with steric stabilizing 
properties such as the PEG-stearate or the poloxamer 188, completely stabilized the 
formulations in both media [43,52]. As indicated before, previous experiments 
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performed in our group with polyester nanoparticles also support the key role of 
PEG in providing enhanced stability to the nanoparticles formulations incubated in 
simulated gastric media [6]. 
 
Figure 3: Relative turbidity (expresed as the ratio between the optical density value 
after 1 h of incubation with respect to the initial value) of tripalmitin cores (control) 
and tripalmitin cores stabilized with different surfactants in an inorganic acid 
medium and in simulated gastric medium (mean ±SD, n=3). Adapted with 
permission from García-Fuentes et al. (2002) [43] 
 
The results of our experiments also showed that, as expected, the lipid cores 
undergo an important degradation in intestinal medium (Figure 4). In fact, the 
capacity of pancreatic lipase to degrade lipids is accelerated in these formulations as 
the lipid is highly dispersed and, therefore, presents an important surface area for 
interaction with enzymes. However, protection of the lipid cores by a hydrophilic 
polymer coating capable of hindering the interaction with lipolytic enzymes, such as 
that of provided by PEG-stearate or poloxamer 188, reduced significantly the 
degradation. 
 
Anexo 309 
-0.2
0
0.2
0.4
0.6
0.8
1
0 1 2 3 4
Time (h)
D
eg
ra
da
tio
n 
(fr
ac
tio
n 
of
 to
ta
l) Control Poloxamer PEG
 
Figure 4: Degradation of tripalmitin cores (control) and PEG or poloxamer-coated 
tripalmitin nanoparticles in simulated intestinal medium (mean ±SD, n=3). Graph 
from García-Fuentes et al. (2002) [43]. 
 
Although the charge and solubility of chitosan are pH-dependent due to the 
presence of amine groups, our stability studies have evidenced that it may also 
enhance the stability of lipid nanostructures in gastrointestinal fluids [47,53]. More 
specifically, the results from our studies showed that chitosancoated lipid 
nanostructures are stable in simulated gastric fluids. Moreover, chitosan also 
protected the lipid cores against enzymatic degradation in simulated intestinal 
medium [47]. 
 
Peptide loading and release 
A major goal in designing these lipid nanostructures was to achieve a 
sufficient loading of the peptide in the carriers while maintaining their active 
structure. Specific nanoparticle preparation methods were developed for this aim. In 
the case of nanocapsules, the peptide sCT was easily associated upon incorporation 
in the organic phase, using the nanoprecipitation technique. This smooth 
nanoencapsulation method resulted in high peptide encapsulation efficiencies 
(>98%) with preservation of peptide integrity [54]. On the other hand, peptides such 
as insulin or sCT were loaded in solid lipid (tripalmitin) nanoparticles using a 
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modified double emulsion method. When using this approach, the peptide was 
dissolved in the inner aqueous phase of the double emulsion. This method has 
allowed us to increase markedly the capacity of these solid lipid matrixes to 
incorporate peptides such as insulin (encapsulation efficiency>45%) [43] and sCT 
(encapsulation efficiency>90%) [47]. As in the case of the nanocapsules, no signs of 
peptide degradation were detected by reverse phase high performance liquid 
chromatography (Figure 5). 
 
Figure 5: Reverse phase high performance liquid chromatograms of salmon 
calcitonin (retention time= 18-18.5 min) in a standard buffer solution (top) or after 
being released from a PEG-coated tripalmitin nanoparticle formulation (bottom). 
 
This important association efficiency can be explained by the affinity of 
these peptides by the lipids. Indeed, it is known that phosphatidylglycerol, which 
present in our particles, shows a particularly strong interaction with this 
macromolecule [55]. On the other hand, insulin has already been shown to associate 
to lipid-based carriers such as polycyanoacrylate nanocapsules [30]. Moreover, as 
indicated in the introductory section, there is a significant number of references 
which have shown the efficient incorporation of peptides within lipid submicron 
emulsions [24,25]. Furthermore, in order to corroborate this, theoretically possible, 
interaction we have performed some adsorption experiments which have confirmed 
that our negatively charged nanostructures were able to adsorb high amounts of sCT 
following a Langmuir-type isotherm [47]. 
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The release of the peptide sCT from the lipid nanostructures was slightly 
dependent on the lipid core. In the case of solid and solid-liquid mixtures, the release 
profile of sCT followed a biphasic pattern consisting of an initial burst (20% of the 
amount encapsulated) followed by a continuous and slow release [47]. The burst 
release was attributed to the surface-associated peptide whereas the second slow 
phase would correspond to the peptide entrapped in the lipid matrix. On the other 
hand, the burst release effect was reduced when the carriers were coated with the 
polymer chitosan (10% of the amount encapsulated) [47]. This reduction in the burst 
effect has been attributed to the lower amount of peptide on the surface of the 
nanostructures. In the case of the oily nanostructures, only the chitosan-coated 
systems showed a detectable release of sCT. The release process from these systems 
followed a biphasic pattern similar to that of the chitosan-coated solid 
nanostructures, although only negligible amounts of the peptide were released after 
the initial burst. 
In conclusion, we have developed nanoencapsulation techniques that make 
feasible the association of peptides to lipid systems. By means of these techniques, 
lipid nanostructures are able to load peptides and release them in a controlled 
manner. 
 
Studies in the Caco-2 cell model 
Studies in the Caco-2 cell model were aimed at gaining information about 
the mechanism of interaction of the designed polymer-coated lipid nanostructures 
with the intestinal epithelium. 
We have previously reported a study showing the capacity of PEG-coated 
polyester nanoparticles and chitosan nanoparticles to be internalized in the Caco-2 
cell model [56]. The results from this work showed that the uptake of chitosan 
nanoparticles was higher than that of PEG-polyester nanoparticles, a result that was 
even more remarkable when both formulations were compared in the MTX-E12 
cells, a model of mucus secreting cells. Interestingly, within the range of 
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concentrations studied (31.25- 1000 µg/ml), the association of chitosan 
nanoparticles to the monolayer was saturable and temperature dependent. 
These results are different from those obtained for polymer-coated lipid 
nanostructures in the Caco-2 model cell line. Indeed, the amount of fluorescent 
particles associated to the cells was similar independently of the polymer coating 
[57]. On the other hand, when we compared the behaviour of the chitosan 
nanocapsules with that of the chitosan-coated tripalmitin nanoparticles, we observed 
an important difference in the amount of carrier associated to the cells, being it 
higher for the solid lipid cores [54,57]. However, these surprising results should be 
cautiously interpreted due to the different source of chitosan used to form the 
coating of the structures and also the fact that both systems were assayed separately. 
We have also checked the capacity of our polymercoated nanostructures to 
modify the permeability of the cell monolayers. In this sense, it is known that 
chitosan has a capacity to cause a dosedependent decrease in the transepithelial 
electric resistance (TEER) [39] while PEG is supposed to be inert in terms of 
cellular interaction. In agreement with this, we observed that PEG-coated lipid cores 
did not cause a reduction in the TEER of Caco-2 cell monolayers in the range of 
concentrations investigated (220-330 µg/cm2). In contrast, chitosan-coated lipid 
nanostructures induced a dose-dependent drop in the TEER of Caco-2 monolayers 
reaching significant reductions for the range of concentrations (83-330 µg/cm2) 
[54,57]. The values of the reduction of the TEER values were additionally supported 
by the observation of enhanced paracellular transport of the macromolecular marker 
dextran-Texas Red® (Mw = 3000 Da). However, it should be added that these 
values were, in the case of nanocapsules, close to those that compromised cell 
viability (220 µg/cm2). Therefore, it could be expected that this change in the 
epithelium permeability could only be seen when an important amount of particles 
are accumulated onto the epithelium. 
Reductions in the TEER similar to those of the chitosan-coated lipid 
nanostructures have been observed for chitosan solutions when the concentrations of 
the polymer were within the same range [58]. Interestingly, we observed that, as in 
the case of chitosan solutions, the normal TEER values were slowly recuperated 
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after the exposure to the chitosan-coated nanostructures. Indeed, values within 10% 
of the original value of TEER were achieved after 8 h of recuperation and after 24 h, 
all monolayers had returned to the initial resistance level [54,57]. 
 
In vivo efficacy of polymer-coated lipid nanosystems as oral peptide 
carriers 
Keeping in mind that the main goal of our work was to design new peptide 
carriers for oral delivery, it was important for us to assess the ability of the new 
polymer-coated nanostructures to increase the transport of peptides across the 
intestinal mucosa. For this purpose, we chose sCT as a model compound [54,57]. A 
control experiment showed that sCT in solution was unable to reduce the serum 
calcium levels. Similarly, significant reductions in serum calcium levels could not be 
achieved after the oral administration of sCT included in the control nanoemulsion 
or in the PEG-coated tripalmitin nanoparticles. However, significant hypocalcemic 
responses were observed for sCT when included in the chitosan-coated lipid 
nanostructures. More importantly, this significant reduction in the serum calcium 
levels (25-27% reduction at 1 h post-administration for both chitosan-coated lipid 
nanostructures) was maintained for at least 24 h [54,57]. Interestingly, the positive 
behaviour of these new systems should not be simply attributed to the presence of 
chitosan but to their intrinsic nanostructural composition. In fact, Takeuchi et al. 
observed that the polymer itself in solution was ineffective at improving the 
intestinal calcitonin absorption [20]. In addition, we have recently evaluated in vivo 
the efficacy of chitosan microspheres (identical dose of chitosan and sCT) and found 
that they were unsuccessful at reducing the serum calcium levels [59]. Therefore, the 
general conclusion from these studies is that the efficacy of the new nanostructures 
presented in this report can not be assigned to their individual components, but to 
the way these components are nanostructured. 
The mechanistic explanation for the positive behaviour of the chitosan-
coated lipid nanostructures as compared to that of non-coated or PEG-coated lipid 
systems is not perfectly defined yet, although some preliminary hypothesis can be 
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established from the in vitro experiments. First, the enhanced stability provided by 
the polymeric coatings seems to be a relevant issue for peptide delivery. Chitosan, a 
polymer with well defined mucoadhesive properties, not only provides better colloid 
stability but possibly enhances the interaction of the nanostructures with the mucosal 
surfaces [19,38]. At this stage, increasing evidence points to the process of 
mucoadhesion as a way of gaining better access to the underlying epithelium [56]. 
Finally, taking into account the results from the Caco-2 experiments, one could 
attribute the success of the chitosan-coated lipid nanostructures to their ability to 
reduce the TEER. However, we should underline that sCT co-administered with 
chitosan solutions that show similar reduction in the TEER do not produce any 
significant hypocalcemic effect. In addition, it should be noted that the marked 
reductions in the TEER were observed for high doses of chitosan-coated lipid 
nanostructures while doses in animal where far below this limit. In conclusion, the 
positive behaviour of chitosan-coated lipid nanostructures seems to be determined 
by a combination of functions from the carrier that may include better peptide 
protection, improved carrier stability and enhanced interaction between drug and the 
mucosal surfaces. 
Conclusions 
This article reports the design and characterization of new polymer-coated 
lipid-based nanostructures for oral drug delivery. Among the systems prepared, 
chitosan-coated lipid nanostructures have shown the capacity to improve the oral 
efficacy of sCT. The positive behaviour of this system should be most probably 
attributed to a combination of factors that contribute to the protection of the peptide 
in the gastrointestinal tract and enhances its interaction with the epithelium of the 
intestine. Among them, the mucoadhesive properties of chitosan can have a major 
role at improving theefficacy of orally administered peptides. 
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